id	sid	tid	token	lemma	pos
dti-1419	1	1	https://doi.org/10.1177/1177392819857089	https://doi.org/10.1177/1177392819857089	NOUN
dti-1419	1	2	drug	drug	NOUN
dti-1419	1	3	target	target	NOUN
dti-1419	1	4	insights	insight	NOUN
dti-1419	1	5	volume	volume	VERB
dti-1419	1	6	13	13	NUM
dti-1419	1	7	:	:	SYM
dti-1419	1	8	1–8	1–8	NUM
dti-1419	2	1	©	©	ADP
dti-1419	2	2	the	the	DET
dti-1419	2	3	author(s	author(s	PROPN
dti-1419	2	4	)	)	PUNCT
dti-1419	2	5	2019	2019	NUM
dti-1419	2	6	article	article	NOUN
dti-1419	2	7	reuse	reuse	VERB
dti-1419	2	8	guidelines	guideline	NOUN
dti-1419	2	9	:	:	PUNCT
dti-1419	2	10	sagepub.com/journals-permissions	sagepub.com/journals-permission	NOUN
dti-1419	2	11	doi	doi	NOUN
dti-1419	2	12	:	:	PUNCT
dti-1419	2	13	10.1177/1177392819857089	10.1177/1177392819857089	NUM
dti-1419	2	14	creative	creative	ADJ
dti-1419	2	15	commons	commons	PROPN
dti-1419	2	16	non	non	ADJ
dti-1419	2	17	commercial	commercial	PROPN
dti-1419	2	18	cc	cc	PROPN
dti-1419	2	19	by	by	ADP
dti-1419	2	20	-	-	PUNCT
dti-1419	2	21	nc	nc	PROPN
dti-1419	2	22	:	:	PUNCT
dti-1419	2	23	this	this	DET
dti-1419	2	24	article	article	NOUN
dti-1419	2	25	is	be	AUX
dti-1419	2	26	distributed	distribute	VERB
dti-1419	2	27	under	under	ADP
dti-1419	2	28	the	the	DET
dti-1419	2	29	terms	term	NOUN
dti-1419	2	30	of	of	ADP
dti-1419	2	31	the	the	DET
dti-1419	2	32	creative	creative	ADJ
dti-1419	2	33	commons	common	NOUN
dti-1419	2	34	attribution	attribution	NOUN
dti-1419	2	35	-	-	PUNCT
dti-1419	2	36	noncommercial	noncommercial	ADJ
dti-1419	2	37	4.0	4.0	NUM
dti-1419	2	38	license	license	NOUN
dti-1419	2	39	(	(	PUNCT
dti-1419	2	40	http://www.creativecommons.org/licenses/by-nc/4.0/	http://www.creativecommons.org/licenses/by-nc/4.0/	PROPN
dti-1419	2	41	)	)	PUNCT
dti-1419	2	42	which	which	PRON
dti-1419	2	43	permits	permit	VERB
dti-1419	2	44	non	non	ADJ
dti-1419	2	45	-	-	ADJ
dti-1419	2	46	commercial	commercial	ADJ
dti-1419	2	47	use	use	NOUN
dti-1419	2	48	,	,	PUNCT
dti-1419	2	49	reproduction	reproduction	NOUN
dti-1419	2	50	and	and	CCONJ
dti-1419	2	51	distribution	distribution	NOUN
dti-1419	2	52	of	of	ADP
dti-1419	2	53	the	the	DET
dti-1419	2	54	work	work	NOUN
dti-1419	2	55	without	without	ADP
dti-1419	2	56	further	further	ADJ
dti-1419	2	57	permission	permission	NOUN
dti-1419	2	58	provided	provide	VERB
dti-1419	2	59	the	the	DET
dti-1419	2	60	original	original	ADJ
dti-1419	2	61	work	work	NOUN
dti-1419	2	62	is	be	AUX
dti-1419	2	63	attributed	attribute	VERB
dti-1419	2	64	as	as	ADP
dti-1419	2	65	specified	specify	VERB
dti-1419	2	66	on	on	ADP
dti-1419	2	67	the	the	DET
dti-1419	2	68	sage	sage	NOUN
dti-1419	2	69	and	and	CCONJ
dti-1419	2	70	open	open	ADJ
dti-1419	2	71	access	access	NOUN
dti-1419	2	72	pages	page	NOUN
dti-1419	2	73	(	(	PUNCT
dti-1419	2	74	https://us.sagepub.com/en-us/nam/open-access-at-sage	https://us.sagepub.com/en-us/nam/open-access-at-sage	NOUN
dti-1419	2	75	)	)	PUNCT
dti-1419	2	76	.	.	PUNCT
dti-1419	3	1	introduction	introduction	NOUN
dti-1419	3	2	phenylketonuria	phenylketonuria	NOUN
dti-1419	3	3	(	(	PUNCT
dti-1419	3	4	pku	pku	PROPN
dti-1419	3	5	)	)	PUNCT
dti-1419	3	6	is	be	AUX
dti-1419	3	7	a	a	DET
dti-1419	3	8	rare	rare	ADJ
dti-1419	3	9	autosomal	autosomal	ADJ
dti-1419	3	10	recessive	recessive	ADJ
dti-1419	3	11	condition	condition	NOUN
dti-1419	3	12	affecting	affect	VERB
dti-1419	3	13	about	about	ADV
dti-1419	3	14	1	1	NUM
dti-1419	3	15	in	in	ADP
dti-1419	3	16	13	13	NUM
dti-1419	3	17	500	500	NUM
dti-1419	3	18	to	to	PART
dti-1419	3	19	19	19	NUM
dti-1419	3	20	000	000	NUM
dti-1419	3	21	people	people	NOUN
dti-1419	3	22	in	in	ADP
dti-1419	3	23	the	the	DET
dti-1419	3	24	united	united	PROPN
dti-1419	3	25	states.1	states.1	PROPN
dti-1419	3	26	phenylketonuria	phenylketonuria	NOUN
dti-1419	3	27	is	be	AUX
dti-1419	3	28	diagnosed	diagnose	VERB
dti-1419	3	29	through	through	ADP
dti-1419	3	30	detection	detection	NOUN
dti-1419	3	31	of	of	ADP
dti-1419	3	32	elevated	elevated	ADJ
dti-1419	3	33	blood	blood	NOUN
dti-1419	3	34	phenylalanine	phenylalanine	NOUN
dti-1419	3	35	concentration.2	concentration.2	PROPN
dti-1419	3	36	if	if	SCONJ
dti-1419	3	37	untreated	untreated	ADJ
dti-1419	3	38	,	,	PUNCT
dti-1419	3	39	pku	pku	PROPN
dti-1419	3	40	can	can	AUX
dti-1419	3	41	cause	cause	VERB
dti-1419	3	42	chronic	chronic	ADJ
dti-1419	3	43	intellectual	intellectual	NOUN
dti-1419	3	44	,	,	PUNCT
dti-1419	3	45	neurodevelopmental	neurodevelopmental	ADJ
dti-1419	3	46	,	,	PUNCT
dti-1419	3	47	and	and	CCONJ
dti-1419	3	48	psychiatric	psychiatric	ADJ
dti-1419	3	49	disabilities	disability	NOUN
dti-1419	3	50	.	.	PUNCT
dti-1419	4	1	excessive	excessive	ADJ
dti-1419	4	2	phenylalanine	phenylalanine	NOUN
dti-1419	4	3	is	be	AUX
dti-1419	4	4	thought	think	VERB
dti-1419	4	5	to	to	PART
dti-1419	4	6	interfere	interfere	VERB
dti-1419	4	7	with	with	ADP
dti-1419	4	8	brain	brain	NOUN
dti-1419	4	9	growth	growth	NOUN
dti-1419	4	10	,	,	PUNCT
dti-1419	4	11	myelination	myelination	NOUN
dti-1419	4	12	,	,	PUNCT
dti-1419	4	13	and	and	CCONJ
dti-1419	4	14	neurotransmitter	neurotransmitter	NOUN
dti-1419	4	15	synthesis	synthesis	NOUN
dti-1419	4	16	.	.	PUNCT
dti-1419	5	1	most	most	ADJ
dti-1419	5	2	cases	case	NOUN
dti-1419	5	3	of	of	ADP
dti-1419	5	4	pku	pku	PROPN
dti-1419	5	5	are	be	AUX
dti-1419	5	6	detected	detect	VERB
dti-1419	5	7	shortly	shortly	ADV
dti-1419	5	8	after	after	ADP
dti-1419	5	9	birth	birth	NOUN
dti-1419	5	10	by	by	ADP
dti-1419	5	11	newborn	newborn	ADJ
dti-1419	5	12	screening	screening	NOUN
dti-1419	5	13	.	.	PUNCT
dti-1419	6	1	as	as	ADP
dti-1419	6	2	a	a	DET
dti-1419	6	3	result	result	NOUN
dti-1419	6	4	,	,	PUNCT
dti-1419	6	5	the	the	DET
dti-1419	6	6	severe	severe	ADJ
dti-1419	6	7	signs	sign	NOUN
dti-1419	6	8	and	and	CCONJ
dti-1419	6	9	symptoms	symptom	NOUN
dti-1419	6	10	of	of	ADP
dti-1419	6	11	classic	classic	ADJ
dti-1419	6	12	pku	pku	NOUN
dti-1419	6	13	are	be	AUX
dti-1419	6	14	rarely	rarely	ADV
dti-1419	6	15	seen.2	seen.2	PRON
dti-1419	6	16	elevated	elevated	ADJ
dti-1419	6	17	phenylalanine	phenylalanine	NOUN
dti-1419	6	18	levels	level	NOUN
dti-1419	6	19	are	be	AUX
dti-1419	6	20	caused	cause	VERB
dti-1419	6	21	by	by	ADP
dti-1419	6	22	a	a	DET
dti-1419	6	23	deficiency	deficiency	NOUN
dti-1419	6	24	in	in	ADP
dti-1419	6	25	the	the	DET
dti-1419	6	26	enzyme	enzyme	NOUN
dti-1419	6	27	,	,	PUNCT
dti-1419	6	28	phenylalanine	phenylalanine	NOUN
dti-1419	6	29	hydroxylase	hydroxylase	NOUN
dti-1419	6	30	(	(	PUNCT
dti-1419	6	31	pah).2	pah).2	PROPN
dti-1419	6	32	the	the	DET
dti-1419	6	33	spectrum	spectrum	NOUN
dti-1419	6	34	of	of	ADP
dti-1419	6	35	severity	severity	NOUN
dti-1419	6	36	in	in	ADP
dti-1419	6	37	untreated	untreated	ADJ
dti-1419	6	38	pku	pku	PROPN
dti-1419	6	39	ranges	range	VERB
dti-1419	6	40	from	from	ADP
dti-1419	6	41	complete	complete	ADJ
dti-1419	6	42	enzyme	enzyme	NOUN
dti-1419	6	43	deficiency	deficiency	NOUN
dti-1419	6	44	or	or	CCONJ
dti-1419	6	45	classic	classic	ADJ
dti-1419	6	46	pku	pku	NOUN
dti-1419	6	47	(	(	PUNCT
dti-1419	6	48	phenylalanine	phenylalanine	NOUN
dti-1419	6	49	concentration	concentration	NOUN
dti-1419	6	50	>	>	X
dti-1419	6	51	1200	1200	NUM
dti-1419	6	52	µmol	µmol	ADP
dti-1419	6	53	/	/	SYM
dti-1419	6	54	l	l	NOUN
dti-1419	6	55	)	)	PUNCT
dti-1419	6	56	,	,	PUNCT
dti-1419	6	57	moderate	moderate	ADJ
dti-1419	6	58	pku	pku	PROPN
dti-1419	6	59	(	(	PUNCT
dti-1419	6	60	phenylalanine	phenylalanine	NOUN
dti-1419	6	61	concentration	concentration	NOUN
dti-1419	6	62	=	=	NOUN
dti-1419	6	63	900	900	NUM
dti-1419	6	64	-	-	SYM
dti-1419	6	65	1200	1200	NUM
dti-1419	6	66	µmol	µmol	NOUN
dti-1419	6	67	/	/	SYM
dti-1419	6	68	l	l	NOUN
dti-1419	6	69	)	)	PUNCT
dti-1419	6	70	,	,	PUNCT
dti-1419	7	1	mild	mild	ADJ
dti-1419	7	2	pku	pku	NOUN
dti-1419	7	3	(	(	PUNCT
dti-1419	7	4	phenylalanine	phenylalanine	NOUN
dti-1419	7	5	concentration	concentration	NOUN
dti-1419	7	6	=	=	NOUN
dti-1419	7	7	600	600	NUM
dti-1419	7	8	-	-	SYM
dti-1419	7	9	900	900	NUM
dti-1419	7	10	µmol	µmol	NOUN
dti-1419	7	11	/	/	SYM
dti-1419	7	12	l	l	NOUN
dti-1419	7	13	)	)	PUNCT
dti-1419	7	14	,	,	PUNCT
dti-1419	7	15	and	and	CCONJ
dti-1419	7	16	mild	mild	ADJ
dti-1419	7	17	hyperphenylalaninemia	hyperphenylalaninemia	NOUN
dti-1419	7	18	(	(	PUNCT
dti-1419	7	19	hpa	hpa	NOUN
dti-1419	7	20	)	)	PUNCT
dti-1419	7	21	(	(	PUNCT
dti-1419	7	22	phenylalanine	phenylalanine	NOUN
dti-1419	7	23	concentration	concentration	NOUN
dti-1419	7	24	=	=	SYM
dti-1419	7	25	360	360	NUM
dti-1419	7	26	-	-	SYM
dti-1419	7	27	600	600	NUM
dti-1419	7	28	µmol	µmol	ADV
dti-1419	7	29	/	/	SYM
dti-1419	7	30	l).3	l).3	PROPN
dti-1419	7	31	although	although	SCONJ
dti-1419	7	32	guidelines	guideline	NOUN
dti-1419	7	33	recommend	recommend	VERB
dti-1419	7	34	lifelong	lifelong	ADJ
dti-1419	7	35	treatment	treatment	NOUN
dti-1419	7	36	to	to	ADP
dti-1419	7	37	a	a	DET
dti-1419	7	38	target	target	NOUN
dti-1419	7	39	blood	blood	NOUN
dti-1419	7	40	phenylalanine	phenylalanine	NOUN
dti-1419	7	41	level	level	NOUN
dti-1419	7	42	of	of	ADP
dti-1419	7	43	120	120	NUM
dti-1419	7	44	to	to	PART
dti-1419	7	45	360	360	NUM
dti-1419	7	46	µmol	µmol	NOUN
dti-1419	7	47	/	/	SYM
dti-1419	7	48	l4,5	l4,5	NOUN
dti-1419	7	49	or	or	CCONJ
dti-1419	7	50	120	120	NUM
dti-1419	7	51	to	to	PART
dti-1419	7	52	600	600	NUM
dti-1419	7	53	µmol	µmol	ADP
dti-1419	7	54	/	/	SYM
dti-1419	7	55	l	l	NOUN
dti-1419	7	56	,	,	PUNCT
dti-1419	7	57	(	(	PUNCT
dti-1419	7	58	van	van	PROPN
dti-1419	7	59	wegberg	wegberg	PROPN
dti-1419	7	60	,	,	PUNCT
dti-1419	7	61	macdonald	macdonald	PROPN
dti-1419	7	62	and	and	CCONJ
dti-1419	7	63	ahring	ahring	NOUN
dti-1419	7	64	,	,	PUNCT
dti-1419	7	65	2017	2017	NUM
dti-1419	7	66	)	)	PUNCT
dti-1419	7	67	therapy	therapy	NOUN
dti-1419	7	68	must	must	AUX
dti-1419	7	69	be	be	AUX
dti-1419	7	70	individualized	individualize	VERB
dti-1419	7	71	to	to	ADP
dti-1419	7	72	each	each	DET
dti-1419	7	73	patient	patient	NOUN
dti-1419	7	74	.	.	PUNCT
dti-1419	8	1	management	management	NOUN
dti-1419	8	2	of	of	ADP
dti-1419	8	3	patients	patient	NOUN
dti-1419	8	4	with	with	ADP
dti-1419	8	5	hpa	hpa	NOUN
dti-1419	8	6	and	and	CCONJ
dti-1419	8	7	pku	pku	PROPN
dti-1419	8	8	should	should	AUX
dti-1419	8	9	be	be	AUX
dti-1419	8	10	provided	provide	VERB
dti-1419	8	11	by	by	ADP
dti-1419	8	12	an	an	DET
dti-1419	8	13	interdisciplinary	interdisciplinary	ADJ
dti-1419	8	14	team	team	NOUN
dti-1419	8	15	of	of	ADP
dti-1419	8	16	nutritionists	nutritionist	NOUN
dti-1419	8	17	,	,	PUNCT
dti-1419	8	18	psychologists	psychologist	NOUN
dti-1419	8	19	,	,	PUNCT
dti-1419	8	20	social	social	ADJ
dti-1419	8	21	workers	worker	NOUN
dti-1419	8	22	,	,	PUNCT
dti-1419	8	23	and	and	CCONJ
dti-1419	8	24	metabolic	metabolic	ADJ
dti-1419	8	25	specialists.2	specialists.2	ADJ
dti-1419	8	26	phenylketonuria	phenylketonuria	NOUN
dti-1419	8	27	is	be	AUX
dti-1419	8	28	a	a	DET
dti-1419	8	29	relatively	relatively	ADV
dti-1419	8	30	rare	rare	ADJ
dti-1419	8	31	disease	disease	NOUN
dti-1419	8	32	and	and	CCONJ
dti-1419	8	33	patients	patient	NOUN
dti-1419	8	34	may	may	AUX
dti-1419	8	35	require	require	VERB
dti-1419	8	36	lifelong	lifelong	ADJ
dti-1419	8	37	treatment	treatment	NOUN
dti-1419	8	38	.	.	PUNCT
dti-1419	9	1	the	the	DET
dti-1419	9	2	goal	goal	NOUN
dti-1419	9	3	of	of	ADP
dti-1419	9	4	therapy	therapy	NOUN
dti-1419	9	5	is	be	AUX
dti-1419	9	6	to	to	PART
dti-1419	9	7	lower	lower	VERB
dti-1419	9	8	blood	blood	NOUN
dti-1419	9	9	phenylalanine	phenylalanine	NOUN
dti-1419	9	10	concentrations	concentration	NOUN
dti-1419	9	11	to	to	PART
dti-1419	9	12	minimize	minimize	VERB
dti-1419	9	13	the	the	DET
dti-1419	9	14	neurocognitive	neurocognitive	ADJ
dti-1419	9	15	and	and	CCONJ
dti-1419	9	16	psychiatric	psychiatric	ADJ
dti-1419	9	17	effects	effect	NOUN
dti-1419	9	18	of	of	ADP
dti-1419	9	19	pku.4–7	pku.4–7	NOUN
dti-1419	9	20	the	the	DET
dti-1419	9	21	mainstay	mainstay	NOUN
dti-1419	9	22	of	of	ADP
dti-1419	9	23	therapy	therapy	NOUN
dti-1419	9	24	is	be	AUX
dti-1419	9	25	dietary	dietary	ADJ
dti-1419	9	26	restriction	restriction	NOUN
dti-1419	9	27	of	of	ADP
dti-1419	9	28	phenylalanine	phenylalanine	NOUN
dti-1419	9	29	and	and	CCONJ
dti-1419	9	30	supplementation	supplementation	NOUN
dti-1419	9	31	with	with	ADP
dti-1419	9	32	phenylalanine	phenylalanine	NOUN
dti-1419	9	33	-	-	PUNCT
dti-1419	9	34	free	free	ADJ
dti-1419	9	35	medical	medical	ADJ
dti-1419	9	36	foods	food	NOUN
dti-1419	9	37	to	to	PART
dti-1419	9	38	avoid	avoid	VERB
dti-1419	9	39	nutritional	nutritional	ADJ
dti-1419	9	40	deficits.4–6	deficits.4–6	PROPN
dti-1419	9	41	the	the	DET
dti-1419	9	42	medical	medical	ADJ
dti-1419	9	43	foods	food	NOUN
dti-1419	9	44	are	be	AUX
dti-1419	9	45	protein	protein	NOUN
dti-1419	9	46	substitutes	substitute	NOUN
dti-1419	9	47	that	that	PRON
dti-1419	9	48	are	be	AUX
dti-1419	9	49	phenylalanine	phenylalanine	NOUN
dti-1419	9	50	-	-	PUNCT
dti-1419	9	51	free	free	ADJ
dti-1419	9	52	and	and	CCONJ
dti-1419	9	53	fortified	fortified	ADJ
dti-1419	9	54	in	in	ADP
dti-1419	9	55	tyrosine	tyrosine	NOUN
dti-1419	9	56	and	and	CCONJ
dti-1419	9	57	may	may	AUX
dti-1419	9	58	contain	contain	VERB
dti-1419	9	59	glycomacropeptides	glycomacropeptide	NOUN
dti-1419	9	60	and	and	CCONJ
dti-1419	9	61	other	other	ADJ
dti-1419	9	62	large	large	ADJ
dti-1419	9	63	neutral	neutral	ADJ
dti-1419	9	64	amino	amino	NOUN
dti-1419	9	65	acids	acid	NOUN
dti-1419	9	66	as	as	SCONJ
dti-1419	9	67	the	the	DET
dti-1419	9	68	protein	protein	NOUN
dti-1419	9	69	source.3	source.3	NOUN
dti-1419	9	70	adherence	adherence	NOUN
dti-1419	9	71	to	to	ADP
dti-1419	9	72	the	the	DET
dti-1419	9	73	restrictive	restrictive	ADJ
dti-1419	9	74	diet	diet	NOUN
dti-1419	9	75	requires	require	VERB
dti-1419	9	76	planning	planning	NOUN
dti-1419	9	77	and	and	CCONJ
dti-1419	9	78	organization	organization	NOUN
dti-1419	9	79	,	,	PUNCT
dti-1419	9	80	and	and	CCONJ
dti-1419	9	81	can	can	AUX
dti-1419	9	82	be	be	AUX
dti-1419	9	83	challenging	challenge	VERB
dti-1419	9	84	for	for	ADP
dti-1419	9	85	patients.4	patients.4	PROPN
dti-1419	9	86	sapropterin	sapropterin	NOUN
dti-1419	9	87	was	be	AUX
dti-1419	9	88	food	food	NOUN
dti-1419	9	89	and	and	CCONJ
dti-1419	9	90	drug	drug	PROPN
dti-1419	9	91	administration	administration	PROPN
dti-1419	9	92	(	(	PUNCT
dti-1419	9	93	fda	fda	PROPN
dti-1419	9	94	)	)	PUNCT
dti-1419	9	95	–	–	PUNCT
dti-1419	9	96	approved	approve	VERB
dti-1419	9	97	on	on	ADP
dti-1419	9	98	december	december	PROPN
dti-1419	9	99	13	13	NUM
dti-1419	9	100	,	,	PUNCT
dti-1419	9	101	2007	2007	NUM
dti-1419	9	102	,	,	PUNCT
dti-1419	9	103	and	and	CCONJ
dti-1419	9	104	was	be	AUX
dti-1419	9	105	the	the	DET
dti-1419	9	106	first	first	ADJ
dti-1419	9	107	pharmacologic	pharmacologic	ADJ
dti-1419	9	108	therapy	therapy	NOUN
dti-1419	9	109	for	for	ADP
dti-1419	9	110	treatment	treatment	NOUN
dti-1419	9	111	of	of	ADP
dti-1419	9	112	pku.8	pku.8	NOUN
dti-1419	9	113	it	it	PRON
dti-1419	9	114	is	be	AUX
dti-1419	9	115	an	an	DET
dti-1419	9	116	oral	oral	ADJ
dti-1419	9	117	pah	pah	NOUN
dti-1419	9	118	cofactor	cofactor	NOUN
dti-1419	9	119	a	a	DET
dti-1419	9	120	comprehensive	comprehensive	ADJ
dti-1419	9	121	review	review	NOUN
dti-1419	9	122	of	of	ADP
dti-1419	9	123	pegvaliase	pegvaliase	NOUN
dti-1419	9	124	,	,	PUNCT
dti-1419	9	125	an	an	DET
dti-1419	9	126	enzyme	enzyme	NOUN
dti-1419	9	127	substitution	substitution	NOUN
dti-1419	9	128	therapy	therapy	NOUN
dti-1419	9	129	for	for	ADP
dti-1419	9	130	the	the	DET
dti-1419	9	131	treatment	treatment	NOUN
dti-1419	9	132	of	of	ADP
dti-1419	9	133	phenylketonuria	phenylketonuria	NOUN
dti-1419	9	134	tasmina	tasmina	PROPN
dti-1419	9	135	hydery1	hydery1	PROPN
dti-1419	9	136	and	and	CCONJ
dti-1419	9	137	valerie	valerie	PROPN
dti-1419	9	138	azzopardi	azzopardi	PROPN
dti-1419	9	139	coppenrath2	coppenrath2	PROPN
dti-1419	10	1	1department	1department	NUM
dti-1419	10	2	of	of	ADP
dti-1419	10	3	family	family	NOUN
dti-1419	10	4	medicine	medicine	NOUN
dti-1419	10	5	and	and	CCONJ
dti-1419	10	6	community	community	NOUN
dti-1419	10	7	health	health	NOUN
dti-1419	10	8	,	,	PUNCT
dti-1419	10	9	umass	umass	PROPN
dti-1419	10	10	medical	medical	PROPN
dti-1419	10	11	school	school	PROPN
dti-1419	10	12	—	—	PUNCT
dti-1419	10	13	clinical	clinical	ADJ
dti-1419	10	14	pharmacy	pharmacy	NOUN
dti-1419	10	15	services	service	NOUN
dti-1419	10	16	(	(	PUNCT
dti-1419	10	17	cps	cps	PROPN
dti-1419	10	18	)	)	PUNCT
dti-1419	10	19	,	,	PUNCT
dti-1419	10	20	shrewsbury	shrewsbury	PROPN
dti-1419	10	21	,	,	PUNCT
dti-1419	10	22	ma	ma	PROPN
dti-1419	10	23	,	,	PUNCT
dti-1419	10	24	usa	usa	PROPN
dti-1419	10	25	.	.	PROPN
dti-1419	11	1	2school	2school	NUM
dti-1419	11	2	of	of	ADP
dti-1419	11	3	pharmacy	pharmacy	NOUN
dti-1419	11	4	—	—	PUNCT
dti-1419	11	5	worcester	worcester	PROPN
dti-1419	11	6	/	/	SYM
dti-1419	11	7	manchester	manchester	PROPN
dti-1419	11	8	,	,	PUNCT
dti-1419	11	9	massachusetts	massachusetts	PROPN
dti-1419	11	10	college	college	PROPN
dti-1419	11	11	of	of	ADP
dti-1419	11	12	pharmacy	pharmacy	NOUN
dti-1419	11	13	and	and	CCONJ
dti-1419	11	14	health	health	NOUN
dti-1419	11	15	sciences	science	NOUN
dti-1419	11	16	(	(	PUNCT
dti-1419	11	17	mcphs	mcph	NOUN
dti-1419	11	18	)	)	PUNCT
dti-1419	11	19	university	university	NOUN
dti-1419	11	20	,	,	PUNCT
dti-1419	11	21	worcester	worcester	PROPN
dti-1419	11	22	,	,	PUNCT
dti-1419	11	23	ma	ma	PROPN
dti-1419	11	24	,	,	PUNCT
dti-1419	11	25	usa	usa	PROPN
dti-1419	11	26	.	.	PROPN
dti-1419	11	27	abstract	abstract	ADJ
dti-1419	11	28	objective	objective	NOUN
dti-1419	11	29	:	:	PUNCT
dti-1419	11	30	to	to	PART
dti-1419	11	31	review	review	VERB
dti-1419	11	32	the	the	DET
dti-1419	11	33	pharmacology	pharmacology	NOUN
dti-1419	11	34	,	,	PUNCT
dti-1419	11	35	pharmacokinetics	pharmacokinetic	NOUN
dti-1419	11	36	,	,	PUNCT
dti-1419	11	37	efficacy	efficacy	NOUN
dti-1419	11	38	,	,	PUNCT
dti-1419	11	39	safety	safety	NOUN
dti-1419	11	40	,	,	PUNCT
dti-1419	11	41	and	and	CCONJ
dti-1419	11	42	place	place	NOUN
dti-1419	11	43	in	in	ADP
dti-1419	11	44	therapy	therapy	NOUN
dti-1419	11	45	of	of	ADP
dti-1419	11	46	a	a	DET
dti-1419	11	47	phenylalanine	phenylalanine	NOUN
dti-1419	11	48	-	-	PUNCT
dti-1419	11	49	metabolizing	metabolize	VERB
dti-1419	11	50	enzyme	enzyme	NOUN
dti-1419	11	51	indicated	indicate	VERB
dti-1419	11	52	to	to	PART
dti-1419	11	53	reduce	reduce	VERB
dti-1419	11	54	blood	blood	NOUN
dti-1419	11	55	phenylalanine	phenylalanine	NOUN
dti-1419	11	56	concentrations	concentration	NOUN
dti-1419	11	57	,	,	PUNCT
dti-1419	11	58	pegvaliase	pegvaliase	ADJ
dti-1419	11	59	injection	injection	NOUN
dti-1419	11	60	.	.	PUNCT
dti-1419	12	1	data	datum	NOUN
dti-1419	12	2	sources	source	NOUN
dti-1419	12	3	:	:	PUNCT
dti-1419	12	4	searches	search	NOUN
dti-1419	12	5	of	of	ADP
dti-1419	12	6	medline	medline	NOUN
dti-1419	12	7	(	(	PUNCT
dti-1419	12	8	1946	1946	NUM
dti-1419	12	9	-	-	SYM
dti-1419	12	10	september	september	PROPN
dti-1419	12	11	1	1	NUM
dti-1419	12	12	,	,	PUNCT
dti-1419	12	13	2018	2018	NUM
dti-1419	12	14	)	)	PUNCT
dti-1419	12	15	were	be	AUX
dti-1419	12	16	conducted	conduct	VERB
dti-1419	12	17	using	use	VERB
dti-1419	12	18	the	the	DET
dti-1419	12	19	terms	term	NOUN
dti-1419	12	20	pegvaliase	pegvaliase	ADJ
dti-1419	12	21	and	and	CCONJ
dti-1419	12	22	phenylalanine	phenylalanine	ADJ
dti-1419	12	23	ammonia	ammonia	NOUN
dti-1419	12	24	lyase	lyase	NOUN
dti-1419	12	25	(	(	PUNCT
dti-1419	12	26	pal	pal	NOUN
dti-1419	12	27	)	)	PUNCT
dti-1419	12	28	.	.	PUNCT
dti-1419	13	1	additional	additional	ADJ
dti-1419	13	2	data	datum	NOUN
dti-1419	13	3	were	be	AUX
dti-1419	13	4	obtained	obtain	VERB
dti-1419	13	5	from	from	ADP
dti-1419	13	6	the	the	DET
dti-1419	13	7	prescribing	prescribing	NOUN
dti-1419	13	8	information	information	NOUN
dti-1419	13	9	,	,	PUNCT
dti-1419	13	10	the	the	DET
dti-1419	13	11	product	product	NOUN
dti-1419	13	12	dossier	dossier	NOUN
dti-1419	13	13	obtained	obtain	VERB
dti-1419	13	14	from	from	ADP
dti-1419	13	15	the	the	DET
dti-1419	13	16	manufacturer	manufacturer	NOUN
dti-1419	13	17	,	,	PUNCT
dti-1419	13	18	and	and	CCONJ
dti-1419	13	19	clinicaltrials.gov	clinicaltrials.gov	NOUN
dti-1419	13	20	.	.	NOUN
dti-1419	13	21	study	study	NOUN
dti-1419	13	22	selection	selection	NOUN
dti-1419	13	23	and	and	CCONJ
dti-1419	13	24	data	datum	NOUN
dti-1419	13	25	extraction	extraction	NOUN
dti-1419	13	26	:	:	PUNCT
dti-1419	13	27	all	all	DET
dti-1419	13	28	english	english	ADJ
dti-1419	13	29	language	language	NOUN
dti-1419	13	30	articles	article	NOUN
dti-1419	13	31	related	relate	VERB
dti-1419	13	32	to	to	ADP
dti-1419	13	33	pharmacology	pharmacology	NOUN
dti-1419	13	34	,	,	PUNCT
dti-1419	13	35	pharmacokinetics	pharmacokinetic	NOUN
dti-1419	13	36	,	,	PUNCT
dti-1419	13	37	efficacy	efficacy	NOUN
dti-1419	13	38	,	,	PUNCT
dti-1419	13	39	or	or	CCONJ
dti-1419	13	40	safety	safety	NOUN
dti-1419	13	41	of	of	ADP
dti-1419	13	42	the	the	DET
dti-1419	13	43	combination	combination	NOUN
dti-1419	13	44	therapy	therapy	NOUN
dti-1419	13	45	in	in	ADP
dti-1419	13	46	human	human	ADJ
dti-1419	13	47	subjects	subject	NOUN
dti-1419	13	48	were	be	AUX
dti-1419	13	49	reviewed	review	VERB
dti-1419	13	50	.	.	PUNCT
dti-1419	14	1	data	datum	NOUN
dti-1419	14	2	synthesis	synthesis	NOUN
dti-1419	14	3	:	:	PUNCT
dti-1419	14	4	pegvaliase	pegvaliase	PROPN
dti-1419	14	5	is	be	AUX
dti-1419	14	6	a	a	DET
dti-1419	14	7	pegylated	pegylated	ADJ
dti-1419	14	8	pal	pal	ADJ
dti-1419	14	9	enzyme	enzyme	NOUN
dti-1419	14	10	that	that	PRON
dti-1419	14	11	converts	convert	VERB
dti-1419	14	12	phenylalanine	phenylalanine	NOUN
dti-1419	14	13	to	to	ADP
dti-1419	14	14	ammonia	ammonia	NOUN
dti-1419	14	15	and	and	CCONJ
dti-1419	14	16	trans	trans	ADJ
dti-1419	14	17	-	-	ADJ
dti-1419	14	18	cinnamic	cinnamic	ADJ
dti-1419	14	19	acid	acid	NOUN
dti-1419	14	20	.	.	PUNCT
dti-1419	15	1	blood	blood	NOUN
dti-1419	15	2	phenylalanine	phenylalanine	NOUN
dti-1419	15	3	levels	level	NOUN
dti-1419	15	4	were	be	AUX
dti-1419	15	5	reduced	reduce	VERB
dti-1419	15	6	by	by	ADP
dti-1419	15	7	approximately	approximately	ADV
dti-1419	15	8	50	50	NUM
dti-1419	15	9	%	%	NOUN
dti-1419	15	10	to	to	PART
dti-1419	15	11	70	70	NUM
dti-1419	15	12	%	%	NOUN
dti-1419	15	13	in	in	ADP
dti-1419	15	14	patients	patient	NOUN
dti-1419	15	15	receiving	receive	VERB
dti-1419	15	16	therapeutic	therapeutic	ADJ
dti-1419	15	17	doses	dose	NOUN
dti-1419	15	18	of	of	ADP
dti-1419	15	19	pegvaliase	pegvaliase	NOUN
dti-1419	15	20	.	.	PUNCT
dti-1419	16	1	however	however	ADV
dti-1419	16	2	,	,	PUNCT
dti-1419	16	3	most	most	ADJ
dti-1419	16	4	patients	patient	NOUN
dti-1419	16	5	experienced	experience	VERB
dti-1419	16	6	adverse	adverse	ADJ
dti-1419	16	7	events	event	NOUN
dti-1419	16	8	.	.	PUNCT
dti-1419	17	1	conclusions	conclusion	NOUN
dti-1419	17	2	and	and	CCONJ
dti-1419	17	3	relevance	relevance	NOUN
dti-1419	17	4	:	:	PUNCT
dti-1419	17	5	the	the	DET
dti-1419	17	6	mainstay	mainstay	NOUN
dti-1419	17	7	of	of	ADP
dti-1419	17	8	therapy	therapy	NOUN
dti-1419	17	9	in	in	ADP
dti-1419	17	10	phenylketonuria	phenylketonuria	NOUN
dti-1419	17	11	(	(	PUNCT
dti-1419	17	12	pku	pku	PROPN
dti-1419	17	13	)	)	PUNCT
dti-1419	17	14	has	have	AUX
dti-1419	17	15	historically	historically	ADV
dti-1419	17	16	consisted	consist	VERB
dti-1419	17	17	of	of	ADP
dti-1419	17	18	dietary	dietary	ADJ
dti-1419	17	19	restriction	restriction	NOUN
dti-1419	17	20	of	of	ADP
dti-1419	17	21	phenylalanine	phenylalanine	NOUN
dti-1419	17	22	.	.	PUNCT
dti-1419	18	1	pegvaliase	pegvaliase	ADJ
dti-1419	18	2	injection	injection	NOUN
dti-1419	18	3	is	be	AUX
dti-1419	18	4	the	the	DET
dti-1419	18	5	first	first	ADJ
dti-1419	18	6	food	food	NOUN
dti-1419	18	7	and	and	CCONJ
dti-1419	18	8	drug	drug	PROPN
dti-1419	18	9	administration	administration	NOUN
dti-1419	18	10	(	(	PUNCT
dti-1419	18	11	fda)–approved	fda)–approve	VERB
dti-1419	18	12	enzyme	enzyme	NOUN
dti-1419	18	13	substitution	substitution	NOUN
dti-1419	18	14	therapy	therapy	NOUN
dti-1419	18	15	for	for	ADP
dti-1419	18	16	patients	patient	NOUN
dti-1419	18	17	with	with	ADP
dti-1419	18	18	pku	pku	PROPN
dti-1419	18	19	.	.	PUNCT
dti-1419	19	1	the	the	DET
dti-1419	19	2	therapy	therapy	NOUN
dti-1419	19	3	may	may	AUX
dti-1419	19	4	be	be	AUX
dti-1419	19	5	a	a	DET
dti-1419	19	6	viable	viable	ADJ
dti-1419	19	7	option	option	NOUN
dti-1419	19	8	for	for	ADP
dti-1419	19	9	patients	patient	NOUN
dti-1419	19	10	with	with	ADP
dti-1419	19	11	documented	document	VERB
dti-1419	19	12	blood	blood	NOUN
dti-1419	19	13	phenylalanine	phenylalanine	NOUN
dti-1419	19	14	>	>	X
dti-1419	19	15	600	600	NUM
dti-1419	19	16	µmol	µmol	ADV
dti-1419	19	17	/	/	SYM
dti-1419	19	18	l	l	NOUN
dti-1419	19	19	who	who	PRON
dti-1419	19	20	have	have	AUX
dti-1419	19	21	failed	fail	VERB
dti-1419	19	22	existing	exist	VERB
dti-1419	19	23	management	management	NOUN
dti-1419	19	24	strategies	strategy	NOUN
dti-1419	19	25	.	.	PUNCT
dti-1419	20	1	keywords	keyword	NOUN
dti-1419	20	2	:	:	PUNCT
dti-1419	20	3	palynziq	palynziq	ADJ
dti-1419	20	4	,	,	PUNCT
dti-1419	20	5	pegvaliase	pegvaliase	ADJ
dti-1419	20	6	,	,	PUNCT
dti-1419	20	7	phenylalanine	phenylalanine	ADJ
dti-1419	20	8	ammonia	ammonia	NOUN
dti-1419	20	9	lyase	lyase	NOUN
dti-1419	20	10	,	,	PUNCT
dti-1419	20	11	pegvaliase	pegvaliase	NOUN
dti-1419	20	12	-	-	PUNCT
dti-1419	20	13	pqpz	pqpz	ADJ
dti-1419	20	14	,	,	PUNCT
dti-1419	20	15	phenylketonuria	phenylketonuria	NOUN
dti-1419	20	16	,	,	PUNCT
dti-1419	20	17	pku	pku	PROPN
dti-1419	20	18	received	receive	VERB
dti-1419	20	19	:	:	PUNCT
dti-1419	20	20	may	may	AUX
dti-1419	20	21	22	22	NUM
dti-1419	20	22	,	,	PUNCT
dti-1419	20	23	2019	2019	NUM
dti-1419	20	24	.	.	PUNCT
dti-1419	21	1	accepted	accept	VERB
dti-1419	21	2	:	:	PUNCT
dti-1419	21	3	may	may	AUX
dti-1419	21	4	23	23	NUM
dti-1419	21	5	,	,	PUNCT
dti-1419	21	6	2019	2019	NUM
dti-1419	21	7	.	.	PUNCT
dti-1419	22	1	type	type	NOUN
dti-1419	22	2	:	:	PUNCT
dti-1419	22	3	review	review	NOUN
dti-1419	22	4	funding	funding	NOUN
dti-1419	22	5	:	:	PUNCT
dti-1419	22	6	the	the	DET
dti-1419	22	7	author(s	author(s	PROPN
dti-1419	22	8	)	)	PUNCT
dti-1419	22	9	received	receive	VERB
dti-1419	22	10	no	no	DET
dti-1419	22	11	financial	financial	ADJ
dti-1419	22	12	support	support	NOUN
dti-1419	22	13	for	for	ADP
dti-1419	22	14	the	the	DET
dti-1419	22	15	research	research	NOUN
dti-1419	22	16	,	,	PUNCT
dti-1419	22	17	authorship	authorship	NOUN
dti-1419	22	18	,	,	PUNCT
dti-1419	22	19	and/or	and/or	CCONJ
dti-1419	22	20	publication	publication	NOUN
dti-1419	22	21	of	of	ADP
dti-1419	22	22	this	this	DET
dti-1419	22	23	article	article	NOUN
dti-1419	22	24	.	.	PUNCT
dti-1419	23	1	declaration	declaration	NOUN
dti-1419	23	2	of	of	ADP
dti-1419	23	3	conflicting	conflicting	ADJ
dti-1419	23	4	interests	interest	NOUN
dti-1419	23	5	:	:	PUNCT
dti-1419	23	6	the	the	DET
dti-1419	23	7	author(s	author(s	NOUN
dti-1419	23	8	)	)	PUNCT
dti-1419	23	9	declared	declare	VERB
dti-1419	23	10	no	no	DET
dti-1419	23	11	potential	potential	ADJ
dti-1419	23	12	conflicts	conflict	NOUN
dti-1419	23	13	of	of	ADP
dti-1419	23	14	interest	interest	NOUN
dti-1419	23	15	with	with	ADP
dti-1419	23	16	respect	respect	NOUN
dti-1419	23	17	to	to	ADP
dti-1419	23	18	the	the	DET
dti-1419	23	19	research	research	NOUN
dti-1419	23	20	,	,	PUNCT
dti-1419	23	21	authorship	authorship	NOUN
dti-1419	23	22	,	,	PUNCT
dti-1419	23	23	and/or	and/or	CCONJ
dti-1419	23	24	publication	publication	NOUN
dti-1419	23	25	of	of	ADP
dti-1419	23	26	this	this	DET
dti-1419	23	27	article	article	NOUN
dti-1419	23	28	.	.	PUNCT
dti-1419	24	1	corresponding	correspond	VERB
dti-1419	24	2	author	author	NOUN
dti-1419	24	3	:	:	PUNCT
dti-1419	24	4	tasmina	tasmina	PROPN
dti-1419	24	5	hydery	hydery	PROPN
dti-1419	24	6	,	,	PUNCT
dti-1419	24	7	department	department	NOUN
dti-1419	24	8	of	of	ADP
dti-1419	24	9	family	family	NOUN
dti-1419	24	10	medicine	medicine	NOUN
dti-1419	24	11	and	and	CCONJ
dti-1419	24	12	community	community	NOUN
dti-1419	24	13	health	health	NOUN
dti-1419	24	14	,	,	PUNCT
dti-1419	24	15	umass	umass	PROPN
dti-1419	24	16	medical	medical	PROPN
dti-1419	24	17	school	school	PROPN
dti-1419	24	18	—	—	PUNCT
dti-1419	24	19	clinical	clinical	ADJ
dti-1419	24	20	pharmacy	pharmacy	NOUN
dti-1419	24	21	services	service	NOUN
dti-1419	24	22	(	(	PUNCT
dti-1419	24	23	cps	cps	PROPN
dti-1419	24	24	)	)	PUNCT
dti-1419	24	25	,	,	PUNCT
dti-1419	24	26	shrewsbury	shrewsbury	PROPN
dti-1419	24	27	,	,	PUNCT
dti-1419	24	28	ma	ma	PROPN
dti-1419	24	29	01545	01545	PROPN
dti-1419	24	30	,	,	PUNCT
dti-1419	24	31	usa	usa	PROPN
dti-1419	24	32	.	.	PROPN
dti-1419	24	33	email	email	NOUN
dti-1419	24	34	:	:	PUNCT
dti-1419	24	35	tasmina.hydery@umassmed.edu	tasmina.hydery@umassmed.edu	PROPN
dti-1419	24	36	857089	857089	NUM
dti-1419	24	37	dti0010.1177/1177392819857089drug	dti0010.1177/1177392819857089drug	DET
dti-1419	24	38	target	target	NOUN
dti-1419	24	39	insightshydery	insightshydery	NOUN
dti-1419	24	40	and	and	CCONJ
dti-1419	24	41	coppenrath	coppenrath	PROPN
dti-1419	24	42	review	review	PROPN
dti-1419	24	43	-	-	PUNCT
dti-1419	24	44	article2019	article2019	PROPN
dti-1419	24	45	https://uk.sagepub.com/en-gb/journals-permissions	https://uk.sagepub.com/en-gb/journals-permission	NOUN
dti-1419	24	46	mailto:tasmina.hydery@umassmed.edu	mailto:tasmina.hydery@umassmed.edu	NOUN
dti-1419	24	47	2	2	NUM
dti-1419	24	48	drug	drug	NOUN
dti-1419	24	49	target	target	NOUN
dti-1419	24	50	insights	insight	NOUN
dti-1419	24	51	indicated	indicate	VERB
dti-1419	24	52	to	to	PART
dti-1419	24	53	reduce	reduce	VERB
dti-1419	24	54	blood	blood	NOUN
dti-1419	24	55	phenylalanine	phenylalanine	NOUN
dti-1419	24	56	concentrations	concentration	NOUN
dti-1419	24	57	in	in	ADP
dti-1419	24	58	patients	patient	NOUN
dti-1419	24	59	with	with	ADP
dti-1419	24	60	hpa	hpa	NOUN
dti-1419	24	61	due	due	ADP
dti-1419	24	62	to	to	ADP
dti-1419	24	63	tetrahydrobiopterin	tetrahydrobiopterin	NOUN
dti-1419	24	64	(	(	PUNCT
dti-1419	24	65	bh4)responsive	bh4)responsive	PROPN
dti-1419	24	66	pku	pku	PROPN
dti-1419	24	67	.	.	PROPN
dti-1419	24	68	sapropterin	sapropterin	PROPN
dti-1419	24	69	is	be	AUX
dti-1419	24	70	used	use	VERB
dti-1419	24	71	in	in	ADP
dti-1419	24	72	conjunction	conjunction	NOUN
dti-1419	24	73	with	with	ADP
dti-1419	24	74	a	a	DET
dti-1419	24	75	phenylalanine	phenylalanine	NOUN
dti-1419	24	76	-	-	PUNCT
dti-1419	24	77	restricted	restrict	VERB
dti-1419	24	78	diet.9	diet.9	VERB
dti-1419	24	79	the	the	DET
dti-1419	24	80	efficacy	efficacy	NOUN
dti-1419	24	81	of	of	ADP
dti-1419	24	82	sapropterin	sapropterin	NOUN
dti-1419	24	83	is	be	AUX
dti-1419	24	84	based	base	VERB
dti-1419	24	85	on	on	ADP
dti-1419	24	86	the	the	DET
dti-1419	24	87	presence	presence	NOUN
dti-1419	24	88	of	of	ADP
dti-1419	24	89	residual	residual	ADJ
dti-1419	24	90	pah	pah	PROPN
dti-1419	24	91	enzymatic	enzymatic	ADJ
dti-1419	24	92	activity	activity	NOUN
dti-1419	24	93	.	.	PUNCT
dti-1419	25	1	approximately	approximately	ADV
dti-1419	25	2	25	25	NUM
dti-1419	25	3	%	%	NOUN
dti-1419	25	4	to	to	PART
dti-1419	25	5	50	50	NUM
dti-1419	25	6	%	%	NOUN
dti-1419	25	7	of	of	ADP
dti-1419	25	8	patients	patient	NOUN
dti-1419	25	9	with	with	ADP
dti-1419	25	10	pku	pku	PROPN
dti-1419	25	11	respond	respond	NOUN
dti-1419	25	12	to	to	PART
dti-1419	25	13	sapropterin.4	sapropterin.4	VERB
dti-1419	25	14	phase	phase	NOUN
dti-1419	25	15	3	3	NUM
dti-1419	25	16	trials	trial	NOUN
dti-1419	25	17	for	for	ADP
dti-1419	25	18	an	an	DET
dti-1419	25	19	enzyme	enzyme	NOUN
dti-1419	25	20	substitution	substitution	NOUN
dti-1419	25	21	therapy	therapy	NOUN
dti-1419	25	22	for	for	ADP
dti-1419	25	23	pku	pku	PROPN
dti-1419	25	24	began	begin	VERB
dti-1419	25	25	in	in	ADP
dti-1419	25	26	2013	2013	NUM
dti-1419	25	27	and	and	CCONJ
dti-1419	25	28	showed	show	VERB
dti-1419	25	29	promise	promise	NOUN
dti-1419	25	30	to	to	PART
dti-1419	25	31	be	be	AUX
dti-1419	25	32	effective	effective	ADJ
dti-1419	25	33	in	in	ADP
dti-1419	25	34	any	any	DET
dti-1419	25	35	patient	patient	NOUN
dti-1419	25	36	with	with	ADP
dti-1419	25	37	pku	pku	PROPN
dti-1419	25	38	regardless	regardless	ADV
dti-1419	25	39	of	of	ADP
dti-1419	25	40	residual	residual	ADJ
dti-1419	25	41	enzymatic	enzymatic	ADJ
dti-1419	25	42	activity.4	activity.4	VERB
dti-1419	25	43	pegvaliase	pegvaliase	NOUN
dti-1419	25	44	,	,	PUNCT
dti-1419	25	45	fda	fda	PROPN
dti-1419	25	46	-	-	PUNCT
dti-1419	25	47	approved	approve	VERB
dti-1419	25	48	on	on	ADP
dti-1419	25	49	may	may	PROPN
dti-1419	25	50	24	24	NUM
dti-1419	25	51	,	,	PUNCT
dti-1419	25	52	2018	2018	NUM
dti-1419	25	53	,	,	PUNCT
dti-1419	25	54	acts	act	VERB
dti-1419	25	55	as	as	ADP
dti-1419	25	56	a	a	DET
dti-1419	25	57	substitute	substitute	NOUN
dti-1419	25	58	for	for	ADP
dti-1419	25	59	the	the	DET
dti-1419	25	60	deficient	deficient	ADJ
dti-1419	25	61	pah	pah	PROPN
dti-1419	25	62	enzyme.10	enzyme.10	PROPN
dti-1419	25	63	pegvaliase	pegvaliase	PROPN
dti-1419	25	64	is	be	AUX
dti-1419	25	65	indicated	indicate	VERB
dti-1419	25	66	to	to	PART
dti-1419	25	67	reduce	reduce	VERB
dti-1419	25	68	blood	blood	NOUN
dti-1419	25	69	phenylalanine	phenylalanine	NOUN
dti-1419	25	70	concentrations	concentration	NOUN
dti-1419	25	71	in	in	ADP
dti-1419	25	72	adult	adult	NOUN
dti-1419	25	73	patients	patient	NOUN
dti-1419	25	74	with	with	ADP
dti-1419	25	75	pku	pku	PROPN
dti-1419	25	76	who	who	PRON
dti-1419	25	77	have	have	VERB
dti-1419	25	78	uncontrolled	uncontrolled	ADJ
dti-1419	25	79	blood	blood	NOUN
dti-1419	25	80	phenylalanine	phenylalanine	NOUN
dti-1419	25	81	concentrations	concentration	NOUN
dti-1419	25	82	>	>	PUNCT
dti-1419	25	83	600	600	NUM
dti-1419	25	84	µmol	µmol	ADV
dti-1419	25	85	/	/	SYM
dti-1419	25	86	l	l	NOUN
dti-1419	25	87	on	on	ADP
dti-1419	25	88	existing	exist	VERB
dti-1419	25	89	management.11,12	management.11,12	NOUN
dti-1419	25	90	adult	adult	NOUN
dti-1419	25	91	patients	patient	NOUN
dti-1419	25	92	with	with	ADP
dti-1419	25	93	pku	pku	PROPN
dti-1419	25	94	whose	whose	DET
dti-1419	25	95	phenylalanine	phenylalanine	NOUN
dti-1419	25	96	levels	level	NOUN
dti-1419	25	97	are	be	AUX
dti-1419	25	98	not	not	PART
dti-1419	25	99	appropriately	appropriately	ADV
dti-1419	25	100	managed	manage	VERB
dti-1419	25	101	may	may	AUX
dti-1419	25	102	experience	experience	VERB
dti-1419	25	103	adverse	adverse	ADJ
dti-1419	25	104	neurocognitive	neurocognitive	ADJ
dti-1419	25	105	and	and	CCONJ
dti-1419	25	106	psychiatric	psychiatric	ADJ
dti-1419	25	107	outcomes.7	outcomes.7	VERB
dti-1419	25	108	the	the	DET
dti-1419	25	109	objective	objective	NOUN
dti-1419	25	110	of	of	ADP
dti-1419	25	111	this	this	DET
dti-1419	25	112	article	article	NOUN
dti-1419	25	113	is	be	AUX
dti-1419	25	114	to	to	PART
dti-1419	25	115	review	review	VERB
dti-1419	25	116	the	the	DET
dti-1419	25	117	pharmacology	pharmacology	NOUN
dti-1419	25	118	,	,	PUNCT
dti-1419	25	119	pharmacokinetics	pharmacokinetic	NOUN
dti-1419	25	120	,	,	PUNCT
dti-1419	25	121	efficacy	efficacy	NOUN
dti-1419	25	122	,	,	PUNCT
dti-1419	25	123	safety	safety	NOUN
dti-1419	25	124	,	,	PUNCT
dti-1419	25	125	and	and	CCONJ
dti-1419	25	126	place	place	NOUN
dti-1419	25	127	in	in	ADP
dti-1419	25	128	therapy	therapy	NOUN
dti-1419	25	129	of	of	ADP
dti-1419	25	130	pegvaliase	pegvaliase	ADJ
dti-1419	25	131	injection	injection	NOUN
dti-1419	25	132	.	.	PUNCT
dti-1419	26	1	it	it	PRON
dti-1419	26	2	will	will	AUX
dti-1419	26	3	also	also	ADV
dti-1419	26	4	provide	provide	VERB
dti-1419	26	5	an	an	DET
dti-1419	26	6	overview	overview	NOUN
dti-1419	26	7	of	of	ADP
dti-1419	26	8	the	the	DET
dti-1419	26	9	role	role	NOUN
dti-1419	26	10	of	of	ADP
dti-1419	26	11	pegvaliase	pegvaliase	NOUN
dti-1419	26	12	compared	compare	VERB
dti-1419	26	13	with	with	ADP
dti-1419	26	14	current	current	ADJ
dti-1419	26	15	standard	standard	NOUN
dti-1419	26	16	of	of	ADP
dti-1419	26	17	care	care	NOUN
dti-1419	26	18	.	.	PUNCT
dti-1419	27	1	data	datum	NOUN
dti-1419	27	2	sources	source	NOUN
dti-1419	27	3	a	a	DET
dti-1419	27	4	search	search	NOUN
dti-1419	27	5	of	of	ADP
dti-1419	27	6	medline	medline	NOUN
dti-1419	27	7	(	(	PUNCT
dti-1419	27	8	1946	1946	NUM
dti-1419	27	9	-	-	SYM
dti-1419	27	10	september	september	PROPN
dti-1419	27	11	1	1	NUM
dti-1419	27	12	,	,	PUNCT
dti-1419	27	13	2018	2018	NUM
dti-1419	27	14	)	)	PUNCT
dti-1419	27	15	was	be	AUX
dti-1419	27	16	conducted	conduct	VERB
dti-1419	27	17	using	use	VERB
dti-1419	27	18	the	the	DET
dti-1419	27	19	terms	term	NOUN
dti-1419	27	20	pegvaliase	pegvaliase	ADJ
dti-1419	27	21	and	and	CCONJ
dti-1419	27	22	phenylalanine	phenylalanine	ADJ
dti-1419	27	23	ammonia	ammonia	NOUN
dti-1419	27	24	lyase	lyase	NOUN
dti-1419	27	25	(	(	PUNCT
dti-1419	27	26	pal	pal	NOUN
dti-1419	27	27	)	)	PUNCT
dti-1419	27	28	.	.	PUNCT
dti-1419	28	1	the	the	DET
dti-1419	28	2	2	2	NUM
dti-1419	28	3	terms	term	NOUN
dti-1419	28	4	were	be	AUX
dti-1419	28	5	combined	combine	VERB
dti-1419	28	6	with	with	ADP
dti-1419	28	7	the	the	DET
dti-1419	28	8	boolean	boolean	ADJ
dti-1419	28	9	operator	operator	NOUN
dti-1419	28	10	or	or	CCONJ
dti-1419	28	11	.	.	PUNCT
dti-1419	29	1	the	the	DET
dti-1419	29	2	term	term	NOUN
dti-1419	29	3	pegvaliase	pegvaliase	NOUN
dti-1419	29	4	was	be	AUX
dti-1419	29	5	also	also	ADV
dti-1419	29	6	searched	search	VERB
dti-1419	29	7	on	on	ADP
dti-1419	29	8	its	its	PRON
dti-1419	29	9	own	own	ADJ
dti-1419	29	10	.	.	PUNCT
dti-1419	30	1	all	all	DET
dti-1419	30	2	english	english	ADJ
dti-1419	30	3	language	language	NOUN
dti-1419	30	4	articles	article	NOUN
dti-1419	30	5	related	relate	VERB
dti-1419	30	6	to	to	ADP
dti-1419	30	7	pharmacology	pharmacology	NOUN
dti-1419	30	8	,	,	PUNCT
dti-1419	30	9	pharmacokinetics	pharmacokinetic	NOUN
dti-1419	30	10	,	,	PUNCT
dti-1419	30	11	efficacy	efficacy	NOUN
dti-1419	30	12	,	,	PUNCT
dti-1419	30	13	or	or	CCONJ
dti-1419	30	14	safety	safety	NOUN
dti-1419	30	15	of	of	ADP
dti-1419	30	16	the	the	DET
dti-1419	30	17	therapy	therapy	NOUN
dti-1419	30	18	in	in	ADP
dti-1419	30	19	human	human	ADJ
dti-1419	30	20	subjects	subject	NOUN
dti-1419	30	21	were	be	AUX
dti-1419	30	22	included	include	VERB
dti-1419	30	23	.	.	PUNCT
dti-1419	31	1	the	the	DET
dti-1419	31	2	references	reference	NOUN
dti-1419	31	3	of	of	ADP
dti-1419	31	4	included	include	VERB
dti-1419	31	5	articles	article	NOUN
dti-1419	31	6	were	be	AUX
dti-1419	31	7	searched	search	VERB
dti-1419	31	8	to	to	PART
dti-1419	31	9	identify	identify	VERB
dti-1419	31	10	additional	additional	ADJ
dti-1419	31	11	sources	source	NOUN
dti-1419	31	12	.	.	PUNCT
dti-1419	32	1	the	the	DET
dti-1419	32	2	product	product	NOUN
dti-1419	32	3	dossier	dossier	NOUN
dti-1419	32	4	was	be	AUX
dti-1419	32	5	obtained	obtain	VERB
dti-1419	32	6	from	from	ADP
dti-1419	32	7	the	the	DET
dti-1419	32	8	manufacturer	manufacturer	NOUN
dti-1419	32	9	,	,	PUNCT
dti-1419	32	10	and	and	CCONJ
dti-1419	32	11	additional	additional	ADJ
dti-1419	32	12	data	datum	NOUN
dti-1419	32	13	were	be	AUX
dti-1419	32	14	obtained	obtain	VERB
dti-1419	32	15	from	from	ADP
dti-1419	32	16	the	the	DET
dti-1419	32	17	prescribing	prescribing	NOUN
dti-1419	32	18	information	information	NOUN
dti-1419	32	19	and	and	CCONJ
dti-1419	32	20	clinicaltrials.gov	clinicaltrials.gov	PROPN
dti-1419	32	21	.	.	PROPN
dti-1419	32	22	data	datum	NOUN
dti-1419	32	23	synthesis	synthesis	NOUN
dti-1419	32	24	pharmacology	pharmacology	NOUN
dti-1419	32	25	pah	pah	PROPN
dti-1419	32	26	catalyzes	catalyze	VERB
dti-1419	32	27	the	the	DET
dti-1419	32	28	irreversible	irreversible	ADJ
dti-1419	32	29	conversion	conversion	NOUN
dti-1419	32	30	of	of	ADP
dti-1419	32	31	phenylalanine	phenylalanine	NOUN
dti-1419	32	32	to	to	ADP
dti-1419	32	33	tyrosine	tyrosine	NOUN
dti-1419	32	34	.	.	PUNCT
dti-1419	33	1	in	in	ADP
dti-1419	33	2	the	the	DET
dti-1419	33	3	absence	absence	NOUN
dti-1419	33	4	of	of	ADP
dti-1419	33	5	pah	pah	PROPN
dti-1419	33	6	in	in	ADP
dti-1419	33	7	pku	pku	PROPN
dti-1419	33	8	,	,	PUNCT
dti-1419	33	9	dietary	dietary	ADJ
dti-1419	33	10	phenylalanine	phenylalanine	NOUN
dti-1419	33	11	is	be	AUX
dti-1419	33	12	unable	unable	ADJ
dti-1419	33	13	to	to	PART
dti-1419	33	14	be	be	AUX
dti-1419	33	15	converted	convert	VERB
dti-1419	33	16	to	to	ADP
dti-1419	33	17	tyrosine	tyrosine	NOUN
dti-1419	33	18	and	and	CCONJ
dti-1419	33	19	undergoes	undergo	VERB
dti-1419	33	20	further	far	ADV
dti-1419	33	21	processing	process	VERB
dti-1419	33	22	to	to	ADP
dti-1419	33	23	metabolites	metabolite	NOUN
dti-1419	33	24	including	include	VERB
dti-1419	33	25	l	l	NOUN
dti-1419	33	26	-	-	NOUN
dti-1419	33	27	dopa	dopa	NOUN
dti-1419	33	28	,	,	PUNCT
dti-1419	33	29	thyroxine	thyroxine	NOUN
dti-1419	33	30	,	,	PUNCT
dti-1419	33	31	dopamine	dopamine	NOUN
dti-1419	33	32	,	,	PUNCT
dti-1419	33	33	noradrenaline	noradrenaline	NOUN
dti-1419	33	34	,	,	PUNCT
dti-1419	33	35	adrenaline	adrenaline	ADJ
dti-1419	33	36	,	,	PUNCT
dti-1419	33	37	and	and	CCONJ
dti-1419	33	38	melanin.13	melanin.13	VERB
dti-1419	33	39	there	there	PRON
dti-1419	33	40	are	be	VERB
dti-1419	33	41	2	2	NUM
dti-1419	33	42	modes	mode	NOUN
dti-1419	33	43	of	of	ADP
dti-1419	33	44	enzyme	enzyme	NOUN
dti-1419	33	45	therapy	therapy	NOUN
dti-1419	33	46	through	through	ADP
dti-1419	33	47	replacement	replacement	NOUN
dti-1419	33	48	of	of	ADP
dti-1419	33	49	the	the	DET
dti-1419	33	50	pah	pah	PROPN
dti-1419	33	51	enzyme	enzyme	NOUN
dti-1419	33	52	or	or	CCONJ
dti-1419	33	53	substitution	substitution	NOUN
dti-1419	33	54	with	with	ADP
dti-1419	33	55	another	another	DET
dti-1419	33	56	enzyme	enzyme	NOUN
dti-1419	33	57	to	to	PART
dti-1419	33	58	degrade	degrade	VERB
dti-1419	33	59	excess	excess	ADJ
dti-1419	33	60	phenylalanine.12	phenylalanine.12	NOUN
dti-1419	33	61	pegvaliase	pegvaliase	NOUN
dti-1419	33	62	follows	follow	VERB
dti-1419	33	63	the	the	DET
dti-1419	33	64	latter	latter	ADJ
dti-1419	33	65	category	category	NOUN
dti-1419	33	66	and	and	CCONJ
dti-1419	33	67	is	be	AUX
dti-1419	33	68	a	a	DET
dti-1419	33	69	pegylated	pegylated	ADJ
dti-1419	33	70	pal	pal	ADJ
dti-1419	33	71	enzyme	enzyme	NOUN
dti-1419	33	72	that	that	PRON
dti-1419	33	73	converts	convert	VERB
dti-1419	33	74	phenylalanine	phenylalanine	NOUN
dti-1419	33	75	to	to	ADP
dti-1419	33	76	ammonia	ammonia	NOUN
dti-1419	33	77	and	and	CCONJ
dti-1419	33	78	trans	trans	ADJ
dti-1419	33	79	-	-	ADJ
dti-1419	33	80	cinnamic	cinnamic	ADJ
dti-1419	33	81	acid.8	acid.8	NOUN
dti-1419	33	82	ammonia	ammonia	NOUN
dti-1419	33	83	is	be	AUX
dti-1419	33	84	metabolized	metabolize	VERB
dti-1419	33	85	by	by	ADP
dti-1419	33	86	the	the	DET
dti-1419	33	87	liver	liver	NOUN
dti-1419	33	88	.	.	PUNCT
dti-1419	34	1	trans	trans	ADJ
dti-1419	34	2	-	-	ADJ
dti-1419	34	3	cinnamic	cinnamic	ADJ
dti-1419	34	4	acid	acid	NOUN
dti-1419	34	5	and	and	CCONJ
dti-1419	34	6	its	its	PRON
dti-1419	34	7	final	final	ADJ
dti-1419	34	8	product	product	NOUN
dti-1419	34	9	,	,	PUNCT
dti-1419	34	10	benzoic	benzoic	NOUN
dti-1419	34	11	acid	acid	NOUN
dti-1419	34	12	,	,	PUNCT
dti-1419	34	13	are	be	AUX
dti-1419	34	14	conjugated	conjugate	VERB
dti-1419	34	15	with	with	ADP
dti-1419	34	16	glycine	glycine	NOUN
dti-1419	34	17	and	and	CCONJ
dti-1419	34	18	excreted	excrete	VERB
dti-1419	34	19	in	in	ADP
dti-1419	34	20	the	the	DET
dti-1419	34	21	urine.13,14	urine.13,14	ADJ
dti-1419	34	22	pharmacokinetics	pharmacokinetic	NOUN
dti-1419	34	23	due	due	ADP
dti-1419	34	24	to	to	ADP
dti-1419	34	25	the	the	DET
dti-1419	34	26	heterogeneity	heterogeneity	NOUN
dti-1419	34	27	of	of	ADP
dti-1419	34	28	immune	immune	ADJ
dti-1419	34	29	response	response	NOUN
dti-1419	34	30	in	in	ADP
dti-1419	34	31	adults	adult	NOUN
dti-1419	34	32	with	with	ADP
dti-1419	34	33	pku	pku	PROPN
dti-1419	34	34	,	,	PUNCT
dti-1419	34	35	the	the	DET
dti-1419	34	36	pharmacokinetics	pharmacokinetic	NOUN
dti-1419	34	37	of	of	ADP
dti-1419	34	38	pegvaliase	pegvaliase	NOUN
dti-1419	34	39	exhibit	exhibit	VERB
dti-1419	34	40	high	high	ADJ
dti-1419	34	41	interpatient	interpatient	NOUN
dti-1419	34	42	and	and	CCONJ
dti-1419	34	43	intrapatient	intrapatient	ADJ
dti-1419	34	44	variability	variability	NOUN
dti-1419	34	45	.	.	PUNCT
dti-1419	35	1	high	high	ADJ
dti-1419	35	2	antibody	antibody	NOUN
dti-1419	35	3	titers	titer	NOUN
dti-1419	35	4	correlated	correlate	VERB
dti-1419	35	5	with	with	ADP
dti-1419	35	6	higher	high	ADJ
dti-1419	35	7	apparent	apparent	ADJ
dti-1419	35	8	clearance	clearance	NOUN
dti-1419	35	9	.	.	PUNCT
dti-1419	36	1	the	the	DET
dti-1419	36	2	pharmacokinetic	pharmacokinetic	ADJ
dti-1419	36	3	parameters	parameter	NOUN
dti-1419	36	4	are	be	AUX
dti-1419	36	5	summarized	summarize	VERB
dti-1419	36	6	in	in	ADP
dti-1419	36	7	table	table	NOUN
dti-1419	36	8	1	1	NUM
dti-1419	36	9	.	.	PUNCT
dti-1419	37	1	clinical	clinical	ADJ
dti-1419	37	2	trials	trial	NOUN
dti-1419	37	3	phase	phase	VERB
dti-1419	37	4	1	1	NUM
dti-1419	37	5	clinical	clinical	ADJ
dti-1419	37	6	trial	trial	NOUN
dti-1419	37	7	experience	experience	NOUN
dti-1419	37	8	with	with	ADP
dti-1419	37	9	pegvaliase	pegvaliase	NOUN
dti-1419	37	10	is	be	AUX
dti-1419	37	11	summarized	summarize	VERB
dti-1419	37	12	in	in	ADP
dti-1419	37	13	table	table	NOUN
dti-1419	37	14	2	2	NUM
dti-1419	37	15	.	.	PUNCT
dti-1419	38	1	the	the	DET
dti-1419	38	2	first	first	ADJ
dti-1419	38	3	study	study	NOUN
dti-1419	38	4	of	of	ADP
dti-1419	38	5	pegvaliase	pegvaliase	NOUN
dti-1419	38	6	in	in	ADP
dti-1419	38	7	humans	human	NOUN
dti-1419	38	8	was	be	AUX
dti-1419	38	9	a	a	DET
dti-1419	38	10	phase	phase	NOUN
dti-1419	38	11	1	1	NUM
dti-1419	38	12	,	,	PUNCT
dti-1419	38	13	multicenter	multicenter	NOUN
dti-1419	38	14	,	,	PUNCT
dti-1419	38	15	open	open	ADJ
dti-1419	38	16	-	-	PUNCT
dti-1419	38	17	label	label	NOUN
dti-1419	38	18	study	study	NOUN
dti-1419	38	19	in	in	ADP
dti-1419	38	20	patients	patient	NOUN
dti-1419	38	21	over	over	ADP
dti-1419	38	22	the	the	DET
dti-1419	38	23	age	age	NOUN
dti-1419	38	24	of	of	ADP
dti-1419	38	25	18	18	NUM
dti-1419	38	26	with	with	ADP
dti-1419	38	27	a	a	DET
dti-1419	38	28	diagnosis	diagnosis	NOUN
dti-1419	38	29	of	of	ADP
dti-1419	38	30	classic	classic	ADJ
dti-1419	38	31	pku	pku	NOUN
dti-1419	38	32	(	(	PUNCT
dti-1419	38	33	phenylalanine	phenylalanine	NOUN
dti-1419	38	34	concentration	concentration	NOUN
dti-1419	38	35	>	>	X
dti-1419	38	36	1200	1200	NUM
dti-1419	38	37	µmol	µmol	ADP
dti-1419	38	38	/	/	SYM
dti-1419	38	39	l	l	NOUN
dti-1419	38	40	at	at	ADP
dti-1419	38	41	diagnosis	diagnosis	NOUN
dti-1419	38	42	)	)	PUNCT
dti-1419	38	43	and	and	CCONJ
dti-1419	38	44	had	have	VERB
dti-1419	38	45	a	a	DET
dti-1419	38	46	history	history	NOUN
dti-1419	38	47	of	of	ADP
dti-1419	38	48	poor	poor	ADJ
dti-1419	38	49	dietary	dietary	ADJ
dti-1419	38	50	compliance	compliance	NOUN
dti-1419	38	51	(	(	PUNCT
dti-1419	38	52	pal-001	pal-001	NOUN
dti-1419	38	53	,	,	PUNCT
dti-1419	38	54	nct00634660	nct00634660	NOUN
dti-1419	38	55	)	)	PUNCT
dti-1419	38	56	.	.	PUNCT
dti-1419	39	1	the	the	DET
dti-1419	39	2	average	average	ADJ
dti-1419	39	3	baseline	baseline	ADJ
dti-1419	39	4	phenylalanine	phenylalanine	NOUN
dti-1419	39	5	concentration	concentration	NOUN
dti-1419	39	6	was	be	AUX
dti-1419	39	7	1310	1310	NUM
dti-1419	39	8	µmol	µmol	NOUN
dti-1419	39	9	/	/	SYM
dti-1419	39	10	l	l	NOUN
dti-1419	39	11	,	,	PUNCT
dti-1419	39	12	and	and	CCONJ
dti-1419	39	13	the	the	DET
dti-1419	39	14	average	average	ADJ
dti-1419	39	15	body	body	NOUN
dti-1419	39	16	mass	mass	NOUN
dti-1419	39	17	index	index	NOUN
dti-1419	39	18	(	(	PUNCT
dti-1419	39	19	bmi	bmi	PROPN
dti-1419	39	20	)	)	PUNCT
dti-1419	39	21	was	be	AUX
dti-1419	39	22	26.4	26.4	NUM
dti-1419	39	23	kg	kg	NOUN
dti-1419	39	24	/	/	SYM
dti-1419	39	25	m2	m2	PROPN
dti-1419	39	26	.	.	PUNCT
dti-1419	40	1	twenty	twenty	NUM
dti-1419	40	2	-	-	PUNCT
dti-1419	40	3	five	five	NUM
dti-1419	40	4	patients	patient	NOUN
dti-1419	40	5	were	be	AUX
dti-1419	40	6	recruited	recruit	VERB
dti-1419	40	7	from	from	ADP
dti-1419	40	8	7	7	NUM
dti-1419	40	9	centers	center	NOUN
dti-1419	40	10	in	in	ADP
dti-1419	40	11	the	the	DET
dti-1419	40	12	united	united	PROPN
dti-1419	40	13	states	states	PROPN
dti-1419	40	14	.	.	PUNCT
dti-1419	41	1	patients	patient	NOUN
dti-1419	41	2	were	be	AUX
dti-1419	41	3	table	table	NOUN
dti-1419	41	4	1	1	NUM
dti-1419	41	5	.	.	PUNCT
dti-1419	42	1	summary	summary	NOUN
dti-1419	42	2	of	of	ADP
dti-1419	42	3	pharmacokinetic	pharmacokinetic	ADJ
dti-1419	42	4	parameters	parameter	NOUN
dti-1419	42	5	studied	study	VERB
dti-1419	42	6	.	.	PUNCT
dti-1419	43	1	pharmacokinetic	pharmacokinetic	ADJ
dti-1419	43	2	parameter	parameter	NOUN
dti-1419	43	3	daily	daily	ADJ
dti-1419	43	4	maintenance	maintenance	NOUN
dti-1419	43	5	dosage	dosage	NOUN
dti-1419	43	6	pegvaliase	pegvaliase	NOUN
dti-1419	43	7	20	20	NUM
dti-1419	43	8	mg	mg	NOUN
dti-1419	43	9	pegvaliase	pegvaliase	PROPN
dti-1419	43	10	40	40	NUM
dti-1419	43	11	mg	mg	NOUN
dti-1419	43	12	median	median	NOUN
dti-1419	43	13	tmax	tmax	ADP
dti-1419	43	14	8	8	NUM
dti-1419	43	15	hours	hour	NOUN
dti-1419	43	16	cmax	cmax	NOUN
dti-1419	43	17	at	at	ADP
dti-1419	43	18	steady	steady	ADJ
dti-1419	43	19	state	state	NOUN
dti-1419	43	20	(	(	PUNCT
dti-1419	43	21	mean	mean	PROPN
dti-1419	43	22	±	±	NUM
dti-1419	43	23	sd	sd	NOUN
dti-1419	43	24	)	)	PUNCT
dti-1419	43	25	14.0	14.0	NUM
dti-1419	43	26	±	±	NUM
dti-1419	43	27	16.3	16.3	NUM
dti-1419	43	28	mg	mg	PROPN
dti-1419	43	29	/	/	SYM
dti-1419	43	30	l	l	NOUN
dti-1419	43	31	16.7	16.7	NUM
dti-1419	43	32	±	±	NUM
dti-1419	43	33	19.5	19.5	NUM
dti-1419	43	34	mg	mg	PROPN
dti-1419	43	35	/	/	SYM
dti-1419	43	36	l	l	NOUN
dti-1419	43	37	apparent	apparent	ADJ
dti-1419	43	38	volume	volume	NOUN
dti-1419	43	39	of	of	ADP
dti-1419	43	40	distribution	distribution	NOUN
dti-1419	43	41	(	(	PUNCT
dti-1419	43	42	mean	mean	NOUN
dti-1419	43	43	±	±	NUM
dti-1419	43	44	sd	sd	NOUN
dti-1419	43	45	)	)	PUNCT
dti-1419	43	46	26.4	26.4	NUM
dti-1419	43	47	±	±	NUM
dti-1419	43	48	64.8	64.8	NUM
dti-1419	43	49	l	l	NOUN
dti-1419	43	50	22.2	22.2	NUM
dti-1419	43	51	±	±	NUM
dti-1419	43	52	19.7	19.7	NUM
dti-1419	43	53	l	l	NOUN
dti-1419	43	54	apparent	apparent	ADJ
dti-1419	43	55	clearance	clearance	NOUN
dti-1419	43	56	at	at	ADP
dti-1419	43	57	steady	steady	ADJ
dti-1419	43	58	state	state	NOUN
dti-1419	43	59	(	(	PUNCT
dti-1419	43	60	mean	mean	PROPN
dti-1419	43	61	±	±	NUM
dti-1419	43	62	sd	sd	NOUN
dti-1419	43	63	)	)	PUNCT
dti-1419	43	64	0.39	0.39	NUM
dti-1419	43	65	±	±	NUM
dti-1419	43	66	0.87	0.87	NUM
dti-1419	43	67	l	l	NOUN
dti-1419	43	68	/	/	SYM
dti-1419	43	69	h	h	NOUN
dti-1419	43	70	1.25	1.25	NUM
dti-1419	43	71	±	±	NUM
dti-1419	43	72	2.46	2.46	NUM
dti-1419	43	73	l	l	NOUN
dti-1419	43	74	/	/	SYM
dti-1419	43	75	h	h	NOUN
dti-1419	43	76	half	half	ADJ
dti-1419	43	77	-	-	PUNCT
dti-1419	43	78	life	life	NOUN
dti-1419	43	79	(	(	PUNCT
dti-1419	43	80	mean	mean	NOUN
dti-1419	43	81	±	±	NUM
dti-1419	43	82	sd	sd	NOUN
dti-1419	43	83	)	)	PUNCT
dti-1419	43	84	47	47	NUM
dti-1419	43	85	±	±	NUM
dti-1419	43	86	42	42	NUM
dti-1419	43	87	hours	hour	NOUN
dti-1419	43	88	60	60	NUM
dti-1419	43	89	±	±	NUM
dti-1419	43	90	45	45	NUM
dti-1419	43	91	hours	hour	NOUN
dti-1419	43	92	steady	steady	ADJ
dti-1419	43	93	state	state	NOUN
dti-1419	43	94	plasma	plasma	NOUN
dti-1419	43	95	concentrations	concentration	NOUN
dti-1419	43	96	during	during	ADP
dti-1419	43	97	maintenance	maintenance	NOUN
dti-1419	43	98	treatment	treatment	NOUN
dti-1419	43	99	(	(	PUNCT
dti-1419	43	100	mean	mean	PROPN
dti-1419	43	101	±	±	NUM
dti-1419	43	102	sd	sd	NOUN
dti-1419	43	103	)	)	PUNCT
dti-1419	43	104	11.2	11.2	NUM
dti-1419	43	105	±	±	NUM
dti-1419	43	106	9.0	9.0	NUM
dti-1419	43	107	mg	mg	PROPN
dti-1419	43	108	/	/	SYM
dti-1419	43	109	l	l	NOUN
dti-1419	43	110	10.4	10.4	NUM
dti-1419	43	111	±	±	NUM
dti-1419	43	112	12.7	12.7	NUM
dti-1419	43	113	mg	mg	PROPN
dti-1419	43	114	/	/	SYM
dti-1419	43	115	l	l	NOUN
dti-1419	43	116	metabolism	metabolism	NOUN
dti-1419	43	117	catabolic	catabolic	ADJ
dti-1419	43	118	pathways	pathway	NOUN
dti-1419	43	119	,	,	PUNCT
dti-1419	43	120	degraded	degrade	VERB
dti-1419	43	121	into	into	ADP
dti-1419	43	122	small	small	ADJ
dti-1419	43	123	peptides	peptide	NOUN
dti-1419	43	124	and	and	CCONJ
dti-1419	43	125	amino	amino	ADJ
dti-1419	43	126	acids	acid	NOUN
dti-1419	43	127	abbreviations	abbreviation	NOUN
dti-1419	43	128	:	:	PUNCT
dti-1419	43	129	cmax	cmax	NOUN
dti-1419	43	130	,	,	PUNCT
dti-1419	43	131	peak	peak	NOUN
dti-1419	43	132	concentration	concentration	NOUN
dti-1419	43	133	;	;	PUNCT
dti-1419	43	134	tmax	tmax	ADV
dti-1419	43	135	,	,	PUNCT
dti-1419	43	136	time	time	NOUN
dti-1419	43	137	to	to	PART
dti-1419	43	138	peak	peak	VERB
dti-1419	43	139	concentration	concentration	NOUN
dti-1419	43	140	.	.	PUNCT
dti-1419	44	1	hydery	hydery	NOUN
dti-1419	44	2	and	and	CCONJ
dti-1419	44	3	coppenrath	coppenrath	PROPN
dti-1419	44	4	3	3	NUM
dti-1419	44	5	excluded	exclude	VERB
dti-1419	44	6	if	if	SCONJ
dti-1419	44	7	they	they	PRON
dti-1419	44	8	had	have	VERB
dti-1419	44	9	renal	renal	ADJ
dti-1419	44	10	or	or	CCONJ
dti-1419	44	11	hepatic	hepatic	ADJ
dti-1419	44	12	dysfunction	dysfunction	NOUN
dti-1419	44	13	,	,	PUNCT
dti-1419	44	14	had	have	VERB
dti-1419	44	15	pregnancy	pregnancy	NOUN
dti-1419	44	16	or	or	CCONJ
dti-1419	44	17	potential	potential	ADJ
dti-1419	44	18	pregnancy	pregnancy	NOUN
dti-1419	44	19	,	,	PUNCT
dti-1419	44	20	or	or	CCONJ
dti-1419	44	21	used	use	VERB
dti-1419	44	22	nicotine	nicotine	NOUN
dti-1419	44	23	,	,	PUNCT
dti-1419	44	24	drugs	drug	NOUN
dti-1419	44	25	of	of	ADP
dti-1419	44	26	abuse	abuse	NOUN
dti-1419	44	27	,	,	PUNCT
dti-1419	44	28	or	or	CCONJ
dti-1419	44	29	any	any	DET
dti-1419	44	30	investigational	investigational	ADJ
dti-1419	44	31	products	product	NOUN
dti-1419	44	32	in	in	ADP
dti-1419	44	33	the	the	DET
dti-1419	44	34	30	30	NUM
dti-1419	44	35	days	day	NOUN
dti-1419	44	36	prior	prior	ADV
dti-1419	44	37	to	to	ADP
dti-1419	44	38	screening.15	screening.15	NOUN
dti-1419	44	39	twenty	twenty	NUM
dti-1419	44	40	-	-	PUNCT
dti-1419	44	41	five	five	NUM
dti-1419	44	42	patients	patient	NOUN
dti-1419	44	43	were	be	AUX
dti-1419	44	44	assigned	assign	VERB
dti-1419	44	45	to	to	ADP
dti-1419	44	46	1	1	NUM
dti-1419	44	47	of	of	ADP
dti-1419	44	48	5	5	NUM
dti-1419	44	49	dosing	dose	VERB
dti-1419	44	50	groups	group	NOUN
dti-1419	44	51	in	in	ADP
dti-1419	44	52	which	which	PRON
dti-1419	44	53	they	they	PRON
dti-1419	44	54	received	receive	VERB
dti-1419	44	55	a	a	DET
dti-1419	44	56	single	single	ADJ
dti-1419	44	57	subcutaneous	subcutaneous	ADJ
dti-1419	44	58	injection	injection	NOUN
dti-1419	44	59	of	of	ADP
dti-1419	44	60	pegvaliase	pegvaliase	NOUN
dti-1419	44	61	on	on	ADP
dti-1419	44	62	day	day	NOUN
dti-1419	44	63	1	1	NUM
dti-1419	44	64	:	:	SYM
dti-1419	44	65	0.001	0.001	NUM
dti-1419	44	66	,	,	PUNCT
dti-1419	44	67	0.003	0.003	NUM
dti-1419	44	68	,	,	PUNCT
dti-1419	44	69	0.10	0.10	NUM
dti-1419	44	70	,	,	PUNCT
dti-1419	44	71	0.03	0.03	NUM
dti-1419	44	72	,	,	PUNCT
dti-1419	44	73	and	and	CCONJ
dti-1419	44	74	0.100	0.100	NUM
dti-1419	44	75	mg	mg	PROPN
dti-1419	44	76	/	/	SYM
dti-1419	44	77	kg	kg	PROPN
dti-1419	44	78	.	.	PUNCT
dti-1419	45	1	patients	patient	NOUN
dti-1419	45	2	were	be	AUX
dti-1419	45	3	followed	follow	VERB
dti-1419	45	4	up	up	ADP
dti-1419	45	5	for	for	ADP
dti-1419	45	6	42	42	NUM
dti-1419	45	7	days	day	NOUN
dti-1419	45	8	.	.	PUNCT
dti-1419	46	1	in	in	ADP
dti-1419	46	2	the	the	DET
dti-1419	46	3	patients	patient	NOUN
dti-1419	46	4	who	who	PRON
dti-1419	46	5	received	receive	VERB
dti-1419	46	6	the	the	DET
dti-1419	46	7	0.1	0.1	NUM
dti-1419	46	8	mg	mg	PROPN
dti-1419	46	9	/	/	SYM
dti-1419	46	10	kg	kg	PROPN
dti-1419	46	11	dose	dose	NOUN
dti-1419	46	12	,	,	PUNCT
dti-1419	46	13	pegvaliase	pegvaliase	PROPN
dti-1419	46	14	significantly	significantly	ADV
dti-1419	46	15	reduced	reduce	VERB
dti-1419	46	16	phenylalanine	phenylalanine	ADJ
dti-1419	46	17	concentrations	concentration	NOUN
dti-1419	46	18	(	(	PUNCT
dti-1419	46	19	1113	1113	NUM
dti-1419	46	20	to	to	ADP
dti-1419	46	21	575	575	NUM
dti-1419	46	22	mmol	mmol	NOUN
dti-1419	46	23	/	/	SYM
dti-1419	46	24	l	l	NOUN
dti-1419	46	25	,	,	PUNCT
dti-1419	46	26	mean	mean	ADJ
dti-1419	46	27	reduction	reduction	NOUN
dti-1419	46	28	of	of	ADP
dti-1419	46	29	48.3	48.3	NUM
dti-1419	46	30	%	%	NOUN
dti-1419	46	31	)	)	PUNCT
dti-1419	46	32	on	on	ADP
dti-1419	46	33	day	day	NOUN
dti-1419	46	34	6	6	NUM
dti-1419	46	35	.	.	PUNCT
dti-1419	47	1	phenylalanine	phenylalanine	ADJ
dti-1419	47	2	concentrations	concentration	NOUN
dti-1419	47	3	increased	increase	VERB
dti-1419	47	4	from	from	ADP
dti-1419	47	5	day	day	NOUN
dti-1419	47	6	7	7	NUM
dti-1419	47	7	to	to	ADP
dti-1419	47	8	day	day	NOUN
dti-1419	47	9	21	21	NUM
dti-1419	47	10	and	and	CCONJ
dti-1419	47	11	remained	remain	VERB
dti-1419	47	12	relatively	relatively	ADV
dti-1419	47	13	consistent	consistent	ADJ
dti-1419	47	14	through	through	ADP
dti-1419	47	15	the	the	DET
dti-1419	47	16	end	end	NOUN
dti-1419	47	17	of	of	ADP
dti-1419	47	18	the	the	DET
dti-1419	47	19	study.15	study.15	NOUN
dti-1419	47	20	phase	phase	NOUN
dti-1419	47	21	2	2	NUM
dti-1419	47	22	the	the	DET
dti-1419	47	23	optimal	optimal	ADJ
dti-1419	47	24	dosing	dosing	ADJ
dti-1419	47	25	regimens	regimen	NOUN
dti-1419	47	26	were	be	AUX
dti-1419	47	27	explored	explore	VERB
dti-1419	47	28	in	in	ADP
dti-1419	47	29	3	3	NUM
dti-1419	47	30	phase	phase	NOUN
dti-1419	47	31	2	2	NUM
dti-1419	47	32	studies	study	NOUN
dti-1419	47	33	of	of	ADP
dti-1419	47	34	pegvaliase	pegvaliase	NOUN
dti-1419	47	35	.	.	PUNCT
dti-1419	48	1	pal-002	pal-002	NOUN
dti-1419	48	2	(	(	PUNCT
dti-1419	48	3	nct00925054	nct00925054	NOUN
dti-1419	48	4	)	)	PUNCT
dti-1419	48	5	was	be	AUX
dti-1419	48	6	an	an	DET
dti-1419	48	7	openlabel	openlabel	NOUN
dti-1419	48	8	,	,	PUNCT
dti-1419	48	9	multicenter	multicenter	ADJ
dti-1419	48	10	study	study	NOUN
dti-1419	48	11	of	of	ADP
dti-1419	48	12	40	40	NUM
dti-1419	48	13	adults	adult	NOUN
dti-1419	48	14	with	with	ADP
dti-1419	48	15	pku	pku	PROPN
dti-1419	48	16	.	.	PUNCT
dti-1419	49	1	patients	patient	NOUN
dti-1419	49	2	entered	enter	VERB
dti-1419	49	3	an	an	DET
dti-1419	49	4	8	8	NUM
dti-1419	49	5	-	-	PUNCT
dti-1419	49	6	week	week	NOUN
dti-1419	49	7	induction	induction	NOUN
dti-1419	49	8	phase	phase	NOUN
dti-1419	49	9	of	of	ADP
dti-1419	49	10	various	various	ADJ
dti-1419	49	11	fixed	fix	VERB
dti-1419	49	12	and	and	CCONJ
dti-1419	49	13	weight	weight	NOUN
dti-1419	49	14	-	-	PUNCT
dti-1419	49	15	based	base	VERB
dti-1419	49	16	doses	dose	NOUN
dti-1419	49	17	of	of	ADP
dti-1419	49	18	pegvaliase	pegvaliase	PROPN
dti-1419	49	19	administered	administer	VERB
dti-1419	49	20	weekly	weekly	ADV
dti-1419	49	21	,	,	PUNCT
dti-1419	49	22	followed	follow	VERB
dti-1419	49	23	by	by	ADP
dti-1419	49	24	an	an	DET
dti-1419	49	25	8	8	NUM
dti-1419	49	26	-	-	PUNCT
dti-1419	49	27	week	week	NOUN
dti-1419	49	28	titration	titration	NOUN
dti-1419	49	29	phase	phase	NOUN
dti-1419	49	30	during	during	ADP
dti-1419	49	31	which	which	PRON
dti-1419	49	32	increasing	increase	VERB
dti-1419	49	33	doses	dose	NOUN
dti-1419	49	34	of	of	ADP
dti-1419	49	35	pegvaliase	pegvaliase	NOUN
dti-1419	49	36	were	be	AUX
dti-1419	49	37	administered	administer	VERB
dti-1419	49	38	weekly	weekly	ADV
dti-1419	49	39	with	with	ADP
dti-1419	49	40	the	the	DET
dti-1419	49	41	goal	goal	NOUN
dti-1419	49	42	of	of	ADP
dti-1419	49	43	achieving	achieve	VERB
dti-1419	49	44	reduced	reduce	VERB
dti-1419	49	45	blood	blood	NOUN
dti-1419	49	46	phenylalanine	phenylalanine	NOUN
dti-1419	49	47	concentrations	concentration	NOUN
dti-1419	49	48	.	.	PUNCT
dti-1419	50	1	the	the	DET
dti-1419	50	2	doses	dose	NOUN
dti-1419	50	3	ranged	range	VERB
dti-1419	50	4	from	from	ADP
dti-1419	50	5	0.001	0.001	NUM
dti-1419	50	6	to	to	ADP
dti-1419	50	7	0.1	0.1	NUM
dti-1419	50	8	mg	mg	PROPN
dti-1419	50	9	/	/	SYM
dti-1419	50	10	kg	kg	NOUN
dti-1419	50	11	throughout	throughout	ADP
dti-1419	50	12	the	the	DET
dti-1419	50	13	study	study	NOUN
dti-1419	50	14	.	.	PUNCT
dti-1419	51	1	these	these	DET
dti-1419	51	2	doses	dose	NOUN
dti-1419	51	3	were	be	AUX
dti-1419	51	4	not	not	PART
dti-1419	51	5	sufficient	sufficient	ADJ
dti-1419	51	6	to	to	PART
dti-1419	51	7	lower	lower	VERB
dti-1419	51	8	phenylalanine	phenylalanine	ADJ
dti-1419	51	9	concentrations	concentration	NOUN
dti-1419	51	10	.	.	PUNCT
dti-1419	52	1	table	table	NOUN
dti-1419	52	2	2	2	NUM
dti-1419	52	3	.	.	PUNCT
dti-1419	53	1	summary	summary	NOUN
dti-1419	53	2	of	of	ADP
dti-1419	53	3	trials	trial	NOUN
dti-1419	53	4	of	of	ADP
dti-1419	53	5	pegvaliase	pegvaliase	NOUN
dti-1419	53	6	for	for	ADP
dti-1419	53	7	the	the	DET
dti-1419	53	8	treatment	treatment	NOUN
dti-1419	53	9	of	of	ADP
dti-1419	53	10	pku	pku	PROPN
dti-1419	53	11	in	in	ADP
dti-1419	53	12	adults	adult	NOUN
dti-1419	53	13	.	.	PUNCT
dti-1419	54	1	phase	phase	NOUN
dti-1419	54	2	identifier	identifier	NOUN
dti-1419	54	3	design	design	NOUN
dti-1419	54	4	duration	duration	NOUN
dti-1419	54	5	dosing	dose	VERB
dti-1419	54	6	n	n	PRON
dti-1419	54	7	results	result	VERB
dti-1419	54	8	1	1	NUM
dti-1419	54	9	nct00634660	nct00634660	NOUN
dti-1419	54	10	(	(	PUNCT
dti-1419	54	11	pal-001	pal-001	NOUN
dti-1419	54	12	)	)	PUNCT
dti-1419	54	13	ol	ol	ADJ
dti-1419	54	14	,	,	PUNCT
dti-1419	54	15	single	single	ADJ
dti-1419	54	16	dose	dose	NOUN
dti-1419	54	17	42	42	NUM
dti-1419	54	18	days	day	NOUN
dti-1419	54	19	0.001	0.001	NUM
dti-1419	54	20	,	,	PUNCT
dti-1419	54	21	0.003	0.003	NUM
dti-1419	54	22	,	,	PUNCT
dti-1419	54	23	0.10	0.10	NUM
dti-1419	54	24	,	,	PUNCT
dti-1419	54	25	0.03	0.03	NUM
dti-1419	54	26	,	,	PUNCT
dti-1419	54	27	and	and	CCONJ
dti-1419	54	28	0.100	0.100	NUM
dti-1419	54	29	mg	mg	PROPN
dti-1419	54	30	/	/	SYM
dti-1419	54	31	kg	kg	PROPN
dti-1419	54	32	25	25	NUM
dti-1419	54	33	48.3	48.3	NUM
dti-1419	54	34	%	%	NOUN
dti-1419	54	35	reduction	reduction	NOUN
dti-1419	54	36	in	in	ADP
dti-1419	54	37	phe	phe	NOUN
dti-1419	54	38	from	from	ADP
dti-1419	54	39	day	day	NOUN
dti-1419	54	40	4	4	NUM
dti-1419	54	41	to	to	PART
dti-1419	54	42	7	7	NUM
dti-1419	54	43	in	in	ADP
dti-1419	54	44	the	the	DET
dti-1419	54	45	highest	high	ADJ
dti-1419	54	46	dosing	dose	VERB
dti-1419	54	47	group	group	NOUN
dti-1419	54	48	2	2	NUM
dti-1419	54	49	nct00925054	nct00925054	NOUN
dti-1419	54	50	(	(	PUNCT
dti-1419	54	51	pal-002	pal-002	NOUN
dti-1419	54	52	)	)	PUNCT
dti-1419	54	53	ol	ol	ADJ
dti-1419	54	54	,	,	PUNCT
dti-1419	54	55	multiple	multiple	NOUN
dti-1419	54	56	dose	dose	VERB
dti-1419	54	57	with	with	ADP
dti-1419	54	58	induction	induction	NOUN
dti-1419	54	59	and	and	CCONJ
dti-1419	54	60	titration	titration	NOUN
dti-1419	54	61	phases	phase	NOUN
dti-1419	54	62	16	16	NUM
dti-1419	54	63	weeks	week	NOUN
dti-1419	54	64	0.001	0.001	NUM
dti-1419	54	65	-	-	SYM
dti-1419	54	66	0.1	0.1	NUM
dti-1419	54	67	mg	mg	PROPN
dti-1419	54	68	/	/	SYM
dti-1419	54	69	kg	kg	PROPN
dti-1419	54	70	given	give	VERB
dti-1419	54	71	5	5	NUM
dti-1419	54	72	d/	d/	NOUN
dti-1419	54	73	wk	wk	ADP
dti-1419	54	74	40	40	NUM
dti-1419	54	75	no	no	DET
dti-1419	54	76	significant	significant	ADJ
dti-1419	54	77	changes	change	NOUN
dti-1419	54	78	in	in	ADP
dti-1419	54	79	phe	phe	PROPN
dti-1419	54	80	5	5	NUM
dti-1419	54	81	%	%	NOUN
dti-1419	54	82	(	(	PUNCT
dti-1419	54	83	2	2	NUM
dti-1419	54	84	patients	patient	NOUN
dti-1419	54	85	)	)	PUNCT
dti-1419	54	86	discontinued	discontinue	VERB
dti-1419	54	87	due	due	ADP
dti-1419	54	88	to	to	ADP
dti-1419	54	89	aes	aes	PROPN
dti-1419	54	90	2	2	PROPN
dti-1419	54	91	nct01212744	nct01212744	ADJ
dti-1419	54	92	(	(	PUNCT
dti-1419	54	93	pal-004	pal-004	NOUN
dti-1419	54	94	)	)	PUNCT
dti-1419	54	95	ol	ol	ADJ
dti-1419	55	1	,	,	PUNCT
dti-1419	55	2	multiple	multiple	ADJ
dti-1419	55	3	dose	dose	VERB
dti-1419	55	4	13	13	NUM
dti-1419	55	5	weeks	week	NOUN
dti-1419	55	6	0.06	0.06	NUM
dti-1419	55	7	-	-	SYM
dti-1419	55	8	0.8	0.8	NUM
dti-1419	55	9	mg	mg	NUM
dti-1419	55	10	/	/	SYM
dti-1419	55	11	kg	kg	PROPN
dti-1419	55	12	/	/	SYM
dti-1419	55	13	d	d	PROPN
dti-1419	55	14	given	give	VERB
dti-1419	55	15	5	5	NUM
dti-1419	55	16	d	d	NOUN
dti-1419	55	17	/	/	SYM
dti-1419	55	18	wk	wk	PROPN
dti-1419	55	19	16	16	NUM
dti-1419	55	20	no	no	DET
dti-1419	55	21	significant	significant	ADJ
dti-1419	55	22	changes	change	NOUN
dti-1419	55	23	in	in	ADP
dti-1419	55	24	phe	phe	PROPN
dti-1419	55	25	6.25	6.25	NUM
dti-1419	55	26	%	%	NOUN
dti-1419	55	27	(	(	PUNCT
dti-1419	55	28	1	1	NUM
dti-1419	55	29	patient	patient	NOUN
dti-1419	55	30	)	)	PUNCT
dti-1419	55	31	discontinued	discontinue	VERB
dti-1419	55	32	due	due	ADP
dti-1419	55	33	to	to	ADP
dti-1419	55	34	aes	aes	PROPN
dti-1419	55	35	2	2	NUM
dti-1419	55	36	nct01560286	nct01560286	NOUN
dti-1419	55	37	(	(	PUNCT
dti-1419	55	38	165	165	NUM
dti-1419	55	39	-	-	SYM
dti-1419	55	40	205	205	NUM
dti-1419	55	41	)	)	PUNCT
dti-1419	55	42	ol	ol	ADJ
dti-1419	55	43	,	,	PUNCT
dti-1419	55	44	multiple	multiple	NOUN
dti-1419	55	45	dose	dose	VERB
dti-1419	55	46	with	with	ADP
dti-1419	55	47	induction	induction	NOUN
dti-1419	55	48	,	,	PUNCT
dti-1419	55	49	titration	titration	NOUN
dti-1419	55	50	,	,	PUNCT
dti-1419	55	51	and	and	CCONJ
dti-1419	55	52	maintenance	maintenance	NOUN
dti-1419	55	53	phases	phase	NOUN
dti-1419	55	54	24	24	NUM
dti-1419	55	55	weeks	week	NOUN
dti-1419	55	56	2.5	2.5	NUM
dti-1419	55	57	mg	mg	NOUN
dti-1419	55	58	weekly	weekly	ADJ
dti-1419	55	59	×	×	NOUN
dti-1419	55	60	4	4	NUM
dti-1419	55	61	-	-	SYM
dti-1419	55	62	8	8	NUM
dti-1419	55	63	weeks	week	NOUN
dti-1419	55	64	,	,	PUNCT
dti-1419	55	65	then	then	ADV
dti-1419	55	66	increased	increase	VERB
dti-1419	55	67	to	to	ADP
dti-1419	55	68	a	a	DET
dti-1419	55	69	maximum	maximum	NOUN
dti-1419	55	70	of	of	ADP
dti-1419	55	71	75	75	NUM
dti-1419	55	72	mg	mg	NOUN
dti-1419	55	73	daily	daily	ADJ
dti-1419	55	74	24	24	NUM
dti-1419	55	75	46	46	NUM
dti-1419	55	76	%	%	NOUN
dti-1419	55	77	reached	reach	VERB
dti-1419	55	78	maintenance	maintenance	NOUN
dti-1419	55	79	dose	dose	VERB
dti-1419	55	80	56	56	NUM
dti-1419	55	81	%	%	NOUN
dti-1419	55	82	reduction	reduction	NOUN
dti-1419	55	83	in	in	ADP
dti-1419	55	84	phe	phe	PROPN
dti-1419	55	85	54	54	NUM
dti-1419	55	86	%	%	NOUN
dti-1419	55	87	did	do	AUX
dti-1419	55	88	not	not	PART
dti-1419	55	89	reach	reach	VERB
dti-1419	55	90	maintenance	maintenance	NOUN
dti-1419	55	91	dose	dose	VERB
dti-1419	55	92	8.33	8.33	NUM
dti-1419	55	93	%	%	NOUN
dti-1419	55	94	(	(	PUNCT
dti-1419	55	95	2	2	NUM
dti-1419	55	96	patients	patient	NOUN
dti-1419	55	97	)	)	PUNCT
dti-1419	55	98	discontinued	discontinue	VERB
dti-1419	55	99	due	due	ADP
dti-1419	55	100	to	to	ADP
dti-1419	55	101	aes	aes	PROPN
dti-1419	55	102	2	2	PROPN
dti-1419	55	103	nct00924703	nct00924703	ADJ
dti-1419	55	104	(	(	PUNCT
dti-1419	55	105	pal-003	pal-003	NOUN
dti-1419	55	106	)	)	PUNCT
dti-1419	55	107	ol	ol	ADJ
dti-1419	55	108	,	,	PUNCT
dti-1419	55	109	multiple	multiple	ADJ
dti-1419	55	110	dose	dose	NOUN
dti-1419	55	111	extension	extension	NOUN
dti-1419	55	112	study	study	NOUN
dti-1419	55	113	extended	extend	VERB
dti-1419	55	114	follow	follow	NOUN
dti-1419	55	115	-	-	PUNCT
dti-1419	55	116	up	up	NOUN
dti-1419	55	117	of	of	ADP
dti-1419	55	118	phase	phase	NOUN
dti-1419	55	119	2	2	NUM
dti-1419	55	120	studies	study	NOUN
dti-1419	55	121	to	to	ADP
dti-1419	55	122	264	264	NUM
dti-1419	55	123	weeks	week	NOUN
dti-1419	55	124	continued	continue	VERB
dti-1419	55	125	or	or	CCONJ
dti-1419	55	126	increased	increase	VERB
dti-1419	55	127	from	from	ADP
dti-1419	55	128	parent	parent	NOUN
dti-1419	55	129	studies	study	NOUN
dti-1419	55	130	,	,	PUNCT
dti-1419	55	131	up	up	ADP
dti-1419	55	132	to	to	PART
dti-1419	55	133	375	375	NUM
dti-1419	55	134	mg	mg	NOUN
dti-1419	55	135	/	/	SYM
dti-1419	55	136	wk	wk	VERB
dti-1419	55	137	given	give	VERB
dti-1419	55	138	up	up	ADP
dti-1419	55	139	to	to	PART
dti-1419	55	140	7	7	NUM
dti-1419	55	141	d/	d/	NOUN
dti-1419	55	142	wk	wk	NOUN
dti-1419	55	143	68a	68a	NOUN
dti-1419	55	144	58.9	58.9	NUM
dti-1419	55	145	%	%	NOUN
dti-1419	55	146	reduction	reduction	NOUN
dti-1419	55	147	in	in	ADP
dti-1419	55	148	phe	phe	NOUN
dti-1419	55	149	at	at	ADP
dti-1419	55	150	48	48	NUM
dti-1419	55	151	weeks	week	NOUN
dti-1419	55	152	72.3	72.3	NUM
dti-1419	55	153	%	%	NOUN
dti-1419	55	154	reduction	reduction	NOUN
dti-1419	55	155	in	in	ADP
dti-1419	55	156	phe	phe	NOUN
dti-1419	55	157	at	at	ADP
dti-1419	55	158	120	120	NUM
dti-1419	55	159	weeks	week	NOUN
dti-1419	55	160	5.9	5.9	NUM
dti-1419	55	161	%	%	NOUN
dti-1419	55	162	(	(	PUNCT
dti-1419	55	163	4	4	NUM
dti-1419	55	164	patients	patient	NOUN
dti-1419	55	165	)	)	PUNCT
dti-1419	55	166	discontinued	discontinue	VERB
dti-1419	55	167	due	due	ADP
dti-1419	55	168	to	to	ADP
dti-1419	55	169	aes	aes	PROPN
dti-1419	55	170	3	3	NUM
dti-1419	55	171	nct01819727	nct01819727	X
dti-1419	55	172	(	(	PUNCT
dti-1419	55	173	prism-1	prism-1	NOUN
dti-1419	55	174	)	)	PUNCT
dti-1419	55	175	ol	ol	ADJ
dti-1419	55	176	,	,	PUNCT
dti-1419	55	177	randomized	randomize	VERB
dti-1419	55	178	multiple	multiple	ADJ
dti-1419	55	179	dose	dose	VERB
dti-1419	55	180	with	with	ADP
dti-1419	55	181	induction	induction	NOUN
dti-1419	55	182	,	,	PUNCT
dti-1419	55	183	titration	titration	NOUN
dti-1419	55	184	,	,	PUNCT
dti-1419	55	185	and	and	CCONJ
dti-1419	55	186	maintenance	maintenance	NOUN
dti-1419	55	187	phases	phase	NOUN
dti-1419	55	188	24	24	NUM
dti-1419	55	189	months	month	NOUN
dti-1419	55	190	2.5	2.5	NUM
dti-1419	55	191	mg	mg	NOUN
dti-1419	55	192	daily	daily	ADV
dti-1419	55	193	titrated	titrate	VERB
dti-1419	55	194	to	to	ADP
dti-1419	55	195	either	either	PRON
dti-1419	55	196	20	20	NUM
dti-1419	55	197	or	or	CCONJ
dti-1419	55	198	40	40	NUM
dti-1419	55	199	mg	mg	NOUN
dti-1419	55	200	daily	daily	ADJ
dti-1419	55	201	261	261	NUM
dti-1419	55	202	51.1	51.1	NUM
dti-1419	55	203	%	%	NOUN
dti-1419	55	204	reduction	reduction	NOUN
dti-1419	55	205	in	in	ADP
dti-1419	55	206	phe	phe	NOUN
dti-1419	55	207	at	at	ADP
dti-1419	55	208	12	12	NUM
dti-1419	55	209	months	month	NOUN
dti-1419	55	210	68.7	68.7	NUM
dti-1419	55	211	%	%	NOUN
dti-1419	55	212	reduction	reduction	NOUN
dti-1419	55	213	in	in	ADP
dti-1419	55	214	phe	phe	PROPN
dti-1419	55	215	at	at	ADP
dti-1419	55	216	24	24	NUM
dti-1419	55	217	months	month	NOUN
dti-1419	55	218	improvement	improvement	NOUN
dti-1419	55	219	in	in	ADP
dti-1419	55	220	mood	mood	NOUN
dti-1419	55	221	and	and	CCONJ
dti-1419	55	222	inattention	inattention	NOUN
dti-1419	55	223	scores	score	NOUN
dti-1419	55	224	11	11	NUM
dti-1419	55	225	%	%	NOUN
dti-1419	55	226	(	(	PUNCT
dti-1419	55	227	29	29	NUM
dti-1419	55	228	patients	patient	NOUN
dti-1419	55	229	)	)	PUNCT
dti-1419	55	230	discontinued	discontinue	VERB
dti-1419	55	231	due	due	ADP
dti-1419	55	232	to	to	ADP
dti-1419	55	233	aes	aes	PROPN
dti-1419	55	234	3	3	NUM
dti-1419	55	235	nct01889862	nct01889862	NOUN
dti-1419	55	236	(	(	PUNCT
dti-1419	55	237	prism-2	prism-2	PROPN
dti-1419	55	238	)	)	PUNCT
dti-1419	55	239	prism-1	prism-1	PROPN
dti-1419	55	240	extension	extension	NOUN
dti-1419	55	241	studyb	studyb	PROPN
dti-1419	55	242	part	part	NOUN
dti-1419	55	243	1	1	NUM
dti-1419	55	244	ol	ol	ADJ
dti-1419	55	245	continuation	continuation	NOUN
dti-1419	55	246	of	of	ADP
dti-1419	55	247	prism-1	prism-1	PROPN
dti-1419	55	248	20	20	NUM
dti-1419	55	249	or	or	CCONJ
dti-1419	55	250	40	40	NUM
dti-1419	55	251	mg	mg	PROPN
dti-1419	55	252	daily	daily	ADJ
dti-1419	55	253	data	datum	NOUN
dti-1419	55	254	not	not	PART
dti-1419	55	255	published	publish	VERB
dti-1419	55	256	part	part	NOUN
dti-1419	55	257	2	2	NUM
dti-1419	55	258	r	r	NOUN
dti-1419	55	259	discontinuation	discontinuation	NOUN
dti-1419	55	260	study	study	NOUN
dti-1419	55	261	8	8	NUM
dti-1419	55	262	weeks	week	NOUN
dti-1419	55	263	20	20	NUM
dti-1419	55	264	mg	mg	NOUN
dti-1419	55	265	daily	daily	ADV
dti-1419	55	266	,	,	PUNCT
dti-1419	55	267	40	40	NUM
dti-1419	55	268	mg	mg	NOUN
dti-1419	55	269	daily	daily	ADV
dti-1419	55	270	,	,	PUNCT
dti-1419	55	271	or	or	CCONJ
dti-1419	55	272	placebo	placebo	NOUN
dti-1419	55	273	86	86	NUM
dti-1419	55	274	no	no	DET
dti-1419	55	275	change	change	NOUN
dti-1419	55	276	in	in	ADP
dti-1419	55	277	phe	phe	NOUN
dti-1419	55	278	in	in	ADP
dti-1419	55	279	the	the	DET
dti-1419	55	280	groups	group	NOUN
dti-1419	55	281	that	that	PRON
dti-1419	55	282	maintained	maintain	VERB
dti-1419	55	283	doses	dose	NOUN
dti-1419	55	284	62.6	62.6	NUM
dti-1419	55	285	%	%	NOUN
dti-1419	55	286	increase	increase	NOUN
dti-1419	55	287	in	in	ADP
dti-1419	55	288	phe	phe	NOUN
dti-1419	55	289	in	in	ADP
dti-1419	55	290	placebo	placebo	NOUN
dti-1419	55	291	20	20	NUM
dti-1419	55	292	mg	mg	PROPN
dti-1419	55	293	group	group	NOUN
dti-1419	55	294	56.4	56.4	NUM
dti-1419	55	295	%	%	NOUN
dti-1419	55	296	increase	increase	NOUN
dti-1419	55	297	in	in	ADP
dti-1419	55	298	phe	phe	NOUN
dti-1419	55	299	in	in	ADP
dti-1419	55	300	placebo	placebo	NOUN
dti-1419	55	301	40	40	NUM
dti-1419	55	302	mg	mg	PROPN
dti-1419	55	303	group	group	NOUN
dti-1419	56	1	no	no	DET
dti-1419	56	2	patients	patient	NOUN
dti-1419	56	3	discontinued	discontinue	VERB
dti-1419	56	4	due	due	ADP
dti-1419	56	5	to	to	ADP
dti-1419	56	6	aes	aes	VERB
dti-1419	56	7	part	part	NOUN
dti-1419	56	8	3	3	NUM
dti-1419	56	9	ol	ol	ADJ
dti-1419	56	10	,	,	PUNCT
dti-1419	56	11	pd	pd	PROPN
dti-1419	56	12	,	,	PUNCT
dti-1419	56	13	pk	pk	NOUN
dti-1419	56	14	20	20	NUM
dti-1419	56	15	or	or	CCONJ
dti-1419	56	16	40	40	NUM
dti-1419	56	17	mg	mg	PROPN
dti-1419	56	18	daily	daily	ADJ
dti-1419	56	19	data	datum	NOUN
dti-1419	56	20	not	not	PART
dti-1419	56	21	published	publish	VERB
dti-1419	56	22	part	part	NOUN
dti-1419	56	23	4	4	NUM
dti-1419	56	24	ol	ol	ADJ
dti-1419	56	25	extension	extension	NOUN
dti-1419	56	26	ongoing	ongoing	ADJ
dti-1419	56	27	5	5	NUM
dti-1419	56	28	-	-	SYM
dti-1419	56	29	60	60	NUM
dti-1419	56	30	mg	mg	NOUN
dti-1419	56	31	daily	daily	ADJ
dti-1419	56	32	ongoing	ongoing	ADJ
dti-1419	56	33	abbreviations	abbreviation	NOUN
dti-1419	56	34	:	:	PUNCT
dti-1419	56	35	aes	aes	ADJ
dti-1419	56	36	,	,	PUNCT
dti-1419	56	37	adverse	adverse	ADJ
dti-1419	56	38	events	event	NOUN
dti-1419	56	39	;	;	PUNCT
dti-1419	56	40	ol	ol	ADJ
dti-1419	56	41	,	,	PUNCT
dti-1419	56	42	open	open	ADJ
dti-1419	56	43	label	label	NOUN
dti-1419	56	44	;	;	PUNCT
dti-1419	56	45	pd	pd	PROPN
dti-1419	56	46	,	,	PUNCT
dti-1419	56	47	pharmacodynamics	pharmacodynamic	NOUN
dti-1419	56	48	;	;	PUNCT
dti-1419	56	49	phe	phe	NOUN
dti-1419	56	50	,	,	PUNCT
dti-1419	56	51	phenylalanine	phenylalanine	NOUN
dti-1419	56	52	;	;	PUNCT
dti-1419	56	53	pk	pk	NOUN
dti-1419	56	54	,	,	PUNCT
dti-1419	56	55	pharmacokinetic	pharmacokinetic	ADJ
dti-1419	56	56	;	;	PUNCT
dti-1419	56	57	pku	pku	ADJ
dti-1419	56	58	,	,	PUNCT
dti-1419	56	59	phenylketonuria	phenylketonuria	NOUN
dti-1419	56	60	;	;	PUNCT
dti-1419	56	61	r	r	X
dti-1419	56	62	,	,	PUNCT
dti-1419	56	63	randomized	randomize	VERB
dti-1419	56	64	.	.	PUNCT
dti-1419	57	1	apatients	apatient	NOUN
dti-1419	57	2	from	from	ADP
dti-1419	57	3	the	the	DET
dti-1419	57	4	other	other	ADJ
dti-1419	57	5	phase	phase	NOUN
dti-1419	57	6	2	2	NUM
dti-1419	57	7	studies	study	NOUN
dti-1419	57	8	.	.	PUNCT
dti-1419	58	1	b12	b12	NOUN
dti-1419	58	2	patients	patient	NOUN
dti-1419	58	3	from	from	ADP
dti-1419	58	4	the	the	DET
dti-1419	58	5	phase	phase	NOUN
dti-1419	58	6	2	2	NUM
dti-1419	58	7	studies	study	NOUN
dti-1419	58	8	,	,	PUNCT
dti-1419	58	9	but	but	CCONJ
dti-1419	58	10	their	their	PRON
dti-1419	58	11	data	datum	NOUN
dti-1419	58	12	are	be	AUX
dti-1419	58	13	not	not	PART
dti-1419	58	14	reported	report	VERB
dti-1419	58	15	.	.	PUNCT
dti-1419	59	1	4	4	NUM
dti-1419	59	2	drug	drug	NOUN
dti-1419	59	3	target	target	NOUN
dti-1419	59	4	insights	insight	NOUN
dti-1419	59	5	pal-004	pal-004	NOUN
dti-1419	59	6	(	(	PUNCT
dti-1419	59	7	nct01212744	nct01212744	ADJ
dti-1419	59	8	)	)	PUNCT
dti-1419	59	9	was	be	AUX
dti-1419	59	10	an	an	DET
dti-1419	59	11	open	open	ADJ
dti-1419	59	12	-	-	PUNCT
dti-1419	59	13	label	label	NOUN
dti-1419	59	14	,	,	PUNCT
dti-1419	59	15	multicenter	multicenter	ADJ
dti-1419	59	16	study	study	NOUN
dti-1419	59	17	of	of	ADP
dti-1419	59	18	16	16	NUM
dti-1419	59	19	adults	adult	NOUN
dti-1419	59	20	with	with	ADP
dti-1419	59	21	pku	pku	PROPN
dti-1419	59	22	.	.	PUNCT
dti-1419	60	1	patients	patient	NOUN
dti-1419	60	2	were	be	AUX
dti-1419	60	3	given	give	VERB
dti-1419	60	4	doses	dose	NOUN
dti-1419	60	5	of	of	ADP
dti-1419	60	6	pegvaliase	pegvaliase	NOUN
dti-1419	60	7	5	5	NUM
dti-1419	60	8	d	d	NOUN
dti-1419	60	9	/	/	SYM
dti-1419	60	10	wk	wk	NOUN
dti-1419	60	11	which	which	PRON
dti-1419	60	12	ranged	range	VERB
dti-1419	60	13	from	from	ADP
dti-1419	60	14	0.06	0.06	NUM
dti-1419	60	15	to	to	ADP
dti-1419	60	16	0.8	0.8	NUM
dti-1419	60	17	mg	mg	PROPN
dti-1419	60	18	/	/	SYM
dti-1419	60	19	kg	kg	NOUN
dti-1419	60	20	throughout	throughout	ADP
dti-1419	60	21	the	the	DET
dti-1419	60	22	13	13	NUM
dti-1419	60	23	weeks	week	NOUN
dti-1419	60	24	of	of	ADP
dti-1419	60	25	the	the	DET
dti-1419	60	26	study	study	NOUN
dti-1419	60	27	.	.	PUNCT
dti-1419	61	1	similar	similar	ADJ
dti-1419	61	2	to	to	ADP
dti-1419	61	3	pal-002	pal-002	NOUN
dti-1419	61	4	,	,	PUNCT
dti-1419	61	5	the	the	DET
dti-1419	61	6	doses	dose	NOUN
dti-1419	61	7	studied	study	VERB
dti-1419	61	8	resulted	result	VERB
dti-1419	61	9	in	in	ADP
dti-1419	61	10	inadequate	inadequate	ADJ
dti-1419	61	11	control	control	NOUN
dti-1419	61	12	of	of	ADP
dti-1419	61	13	blood	blood	NOUN
dti-1419	61	14	phenylalanine	phenylalanine	NOUN
dti-1419	61	15	levels	level	NOUN
dti-1419	61	16	.	.	PUNCT
dti-1419	62	1	all	all	DET
dti-1419	62	2	patients	patient	NOUN
dti-1419	62	3	in	in	ADP
dti-1419	62	4	both	both	DET
dti-1419	62	5	studies	study	NOUN
dti-1419	62	6	experienced	experience	VERB
dti-1419	62	7	at	at	ADV
dti-1419	62	8	least	least	ADV
dti-1419	62	9	1	1	NUM
dti-1419	62	10	adverse	adverse	ADJ
dti-1419	62	11	event	event	NOUN
dti-1419	62	12	(	(	PUNCT
dti-1419	62	13	ae	ae	PROPN
dti-1419	62	14	)	)	PUNCT
dti-1419	62	15	.	.	PUNCT
dti-1419	63	1	the	the	DET
dti-1419	63	2	regimens	regimen	NOUN
dti-1419	63	3	used	use	VERB
dti-1419	63	4	in	in	ADP
dti-1419	63	5	pal-002	pal-002	NOUN
dti-1419	63	6	were	be	AUX
dti-1419	63	7	generally	generally	ADV
dti-1419	63	8	well	well	ADV
dti-1419	63	9	tolerated	tolerate	VERB
dti-1419	63	10	,	,	PUNCT
dti-1419	63	11	but	but	CCONJ
dti-1419	63	12	the	the	DET
dti-1419	63	13	higher	high	ADJ
dti-1419	63	14	doses	dose	NOUN
dti-1419	63	15	in	in	ADP
dti-1419	63	16	pal-004	pal-004	NOUN
dti-1419	63	17	were	be	AUX
dti-1419	63	18	associated	associate	VERB
dti-1419	63	19	with	with	ADP
dti-1419	63	20	more	more	ADV
dti-1419	63	21	frequent	frequent	ADJ
dti-1419	63	22	hypersensitivity	hypersensitivity	NOUN
dti-1419	63	23	reactions	reaction	NOUN
dti-1419	63	24	(	(	PUNCT
dti-1419	63	25	which	which	PRON
dti-1419	63	26	included	include	VERB
dti-1419	63	27	arthralgia	arthralgia	NOUN
dti-1419	63	28	,	,	PUNCT
dti-1419	63	29	arthritis	arthritis	NOUN
dti-1419	63	30	,	,	PUNCT
dti-1419	63	31	eye	eye	NOUN
dti-1419	63	32	inflammation	inflammation	NOUN
dti-1419	63	33	,	,	PUNCT
dti-1419	63	34	eye	eye	NOUN
dti-1419	63	35	irritation	irritation	NOUN
dti-1419	63	36	,	,	PUNCT
dti-1419	63	37	eye	eye	NOUN
dti-1419	63	38	pain	pain	NOUN
dti-1419	63	39	,	,	PUNCT
dti-1419	63	40	joint	joint	ADJ
dti-1419	63	41	stiffness	stiffness	NOUN
dti-1419	63	42	,	,	PUNCT
dti-1419	63	43	joint	joint	ADJ
dti-1419	63	44	swelling	swelling	NOUN
dti-1419	63	45	,	,	PUNCT
dti-1419	63	46	pyrexia	pyrexia	NOUN
dti-1419	63	47	,	,	PUNCT
dti-1419	63	48	vision	vision	NOUN
dti-1419	63	49	blurred	blur	VERB
dti-1419	63	50	,	,	PUNCT
dti-1419	63	51	and	and	CCONJ
dti-1419	63	52	polyarthritis	polyarthritis	NOUN
dti-1419	63	53	)	)	PUNCT
dti-1419	63	54	and	and	CCONJ
dti-1419	63	55	the	the	DET
dti-1419	63	56	need	need	NOUN
dti-1419	63	57	for	for	ADP
dti-1419	63	58	dose	dose	PROPN
dti-1419	63	59	reduction.16	reduction.16	PROPN
dti-1419	63	60	based	base	VERB
dti-1419	63	61	on	on	ADP
dti-1419	63	62	observations	observation	NOUN
dti-1419	63	63	made	make	VERB
dti-1419	63	64	in	in	ADP
dti-1419	63	65	pal-002	pal-002	NOUN
dti-1419	63	66	and	and	CCONJ
dti-1419	63	67	pal-004	pal-004	NOUN
dti-1419	63	68	,	,	PUNCT
dti-1419	63	69	a	a	DET
dti-1419	63	70	third	third	ADJ
dti-1419	63	71	phase	phase	NOUN
dti-1419	63	72	2	2	NUM
dti-1419	63	73	study	study	NOUN
dti-1419	63	74	,	,	PUNCT
dti-1419	63	75	165	165	NUM
dti-1419	63	76	-	-	SYM
dti-1419	63	77	205	205	NUM
dti-1419	63	78	(	(	PUNCT
dti-1419	63	79	nct01560286	nct01560286	NOUN
dti-1419	63	80	)	)	PUNCT
dti-1419	63	81	,	,	PUNCT
dti-1419	63	82	was	be	AUX
dti-1419	63	83	conducted	conduct	VERB
dti-1419	63	84	.	.	PUNCT
dti-1419	64	1	this	this	DET
dti-1419	64	2	study	study	NOUN
dti-1419	64	3	was	be	AUX
dti-1419	64	4	an	an	DET
dti-1419	64	5	open	open	ADJ
dti-1419	64	6	-	-	PUNCT
dti-1419	64	7	label	label	NOUN
dti-1419	64	8	,	,	PUNCT
dti-1419	64	9	multicenter	multicenter	ADJ
dti-1419	64	10	study	study	NOUN
dti-1419	64	11	that	that	PRON
dti-1419	64	12	was	be	AUX
dti-1419	64	13	24	24	NUM
dti-1419	64	14	weeks	week	NOUN
dti-1419	64	15	in	in	ADP
dti-1419	64	16	duration	duration	NOUN
dti-1419	64	17	.	.	PUNCT
dti-1419	65	1	patients	patient	NOUN
dti-1419	65	2	were	be	AUX
dti-1419	65	3	eligible	eligible	ADJ
dti-1419	65	4	if	if	SCONJ
dti-1419	65	5	they	they	PRON
dti-1419	65	6	had	have	VERB
dti-1419	65	7	a	a	DET
dti-1419	65	8	blood	blood	NOUN
dti-1419	65	9	phenylalanine	phenylalanine	NOUN
dti-1419	65	10	concentration	concentration	NOUN
dti-1419	65	11	of	of	ADP
dti-1419	65	12	⩾600	⩾600	PROPN
dti-1419	65	13	µmol	µmol	PROPN
dti-1419	65	14	/	/	SYM
dti-1419	65	15	l	l	NOUN
dti-1419	65	16	at	at	ADP
dti-1419	65	17	screening	screening	NOUN
dti-1419	65	18	and	and	CCONJ
dti-1419	65	19	an	an	DET
dti-1419	65	20	average	average	ADJ
dti-1419	65	21	concentration	concentration	NOUN
dti-1419	65	22	of	of	ADP
dti-1419	65	23	⩾600	⩾600	PROPN
dti-1419	65	24	µmol	µmol	PROPN
dti-1419	65	25	/	/	SYM
dti-1419	65	26	l	l	NOUN
dti-1419	65	27	in	in	ADP
dti-1419	65	28	the	the	DET
dti-1419	65	29	6	6	NUM
dti-1419	65	30	months	month	NOUN
dti-1419	65	31	prior	prior	ADV
dti-1419	65	32	to	to	ADP
dti-1419	65	33	the	the	DET
dti-1419	65	34	screening	screening	NOUN
dti-1419	65	35	,	,	PUNCT
dti-1419	65	36	and	and	CCONJ
dti-1419	65	37	no	no	DET
dti-1419	65	38	prior	prior	ADJ
dti-1419	65	39	treatment	treatment	NOUN
dti-1419	65	40	with	with	ADP
dti-1419	65	41	sapropterin	sapropterin	NOUN
dti-1419	65	42	in	in	ADP
dti-1419	65	43	the	the	DET
dti-1419	65	44	4	4	NUM
dti-1419	65	45	months	month	NOUN
dti-1419	65	46	prior	prior	ADV
dti-1419	65	47	to	to	ADP
dti-1419	65	48	screening	screen	VERB
dti-1419	65	49	.	.	PUNCT
dti-1419	66	1	patients	patient	NOUN
dti-1419	66	2	who	who	PRON
dti-1419	66	3	were	be	AUX
dti-1419	66	4	pregnant	pregnant	ADJ
dti-1419	66	5	,	,	PUNCT
dti-1419	66	6	planning	plan	VERB
dti-1419	66	7	to	to	PART
dti-1419	66	8	become	become	VERB
dti-1419	66	9	pregnant	pregnant	ADJ
dti-1419	66	10	,	,	PUNCT
dti-1419	66	11	or	or	CCONJ
dti-1419	66	12	breastfeeding	breastfeeding	NOUN
dti-1419	66	13	were	be	AUX
dti-1419	66	14	excluded	exclude	VERB
dti-1419	66	15	.	.	PUNCT
dti-1419	67	1	patients	patient	NOUN
dti-1419	67	2	entered	enter	VERB
dti-1419	67	3	a	a	DET
dti-1419	67	4	4to	4to	ADJ
dti-1419	67	5	8	8	NUM
dti-1419	67	6	-	-	PUNCT
dti-1419	67	7	week	week	NOUN
dti-1419	67	8	induction	induction	NOUN
dti-1419	67	9	phase	phase	NOUN
dti-1419	67	10	of	of	ADP
dti-1419	67	11	2.5	2.5	NUM
dti-1419	67	12	mg	mg	NOUN
dti-1419	67	13	/	/	SYM
dti-1419	67	14	wk	wk	PROPN
dti-1419	67	15	.	.	PUNCT
dti-1419	68	1	afterward	afterward	ADV
dti-1419	68	2	,	,	PUNCT
dti-1419	68	3	the	the	DET
dti-1419	68	4	dose	dose	NOUN
dti-1419	68	5	and	and	CCONJ
dti-1419	68	6	frequency	frequency	NOUN
dti-1419	68	7	could	could	AUX
dti-1419	68	8	be	be	AUX
dti-1419	68	9	increased	increase	VERB
dti-1419	68	10	over	over	ADP
dti-1419	68	11	a	a	DET
dti-1419	68	12	minimum	minimum	NOUN
dti-1419	68	13	of	of	ADP
dti-1419	68	14	4	4	NUM
dti-1419	68	15	weeks	week	NOUN
dti-1419	68	16	to	to	PART
dti-1419	68	17	attain	attain	VERB
dti-1419	68	18	a	a	DET
dti-1419	68	19	blood	blood	NOUN
dti-1419	68	20	phenylalanine	phenylalanine	NOUN
dti-1419	68	21	concentration	concentration	NOUN
dti-1419	68	22	of	of	ADP
dti-1419	68	23	⩽600	⩽600	PROPN
dti-1419	68	24	µmol	µmol	PROPN
dti-1419	68	25	/	/	SYM
dti-1419	68	26	l.	l.	PROPN
dti-1419	69	1	the	the	DET
dti-1419	69	2	authors	author	NOUN
dti-1419	69	3	defined	define	VERB
dti-1419	69	4	the	the	DET
dti-1419	69	5	“	"	PUNCT
dti-1419	69	6	maintenance	maintenance	NOUN
dti-1419	69	7	dose	dose	NOUN
dti-1419	69	8	”	"	PUNCT
dti-1419	69	9	as	as	ADP
dti-1419	69	10	the	the	DET
dti-1419	69	11	regimen	regiman	NOUN
dti-1419	69	12	that	that	PRON
dti-1419	69	13	resulted	result	VERB
dti-1419	69	14	in	in	ADP
dti-1419	69	15	target	target	NOUN
dti-1419	69	16	concentrations	concentration	NOUN
dti-1419	69	17	for	for	ADP
dti-1419	69	18	4	4	NUM
dti-1419	69	19	weeks	week	NOUN
dti-1419	69	20	without	without	ADP
dti-1419	69	21	the	the	DET
dti-1419	69	22	need	need	NOUN
dti-1419	69	23	for	for	ADP
dti-1419	69	24	dose	dose	NOUN
dti-1419	69	25	adjustments	adjustment	NOUN
dti-1419	69	26	.	.	PUNCT
dti-1419	70	1	once	once	ADV
dti-1419	70	2	the	the	DET
dti-1419	70	3	maintenance	maintenance	NOUN
dti-1419	70	4	dose	dose	NOUN
dti-1419	70	5	was	be	AUX
dti-1419	70	6	determined	determine	VERB
dti-1419	70	7	,	,	PUNCT
dti-1419	70	8	patients	patient	NOUN
dti-1419	70	9	entered	enter	VERB
dti-1419	70	10	the	the	DET
dti-1419	70	11	next	next	ADJ
dti-1419	70	12	phase	phase	NOUN
dti-1419	70	13	.	.	PUNCT
dti-1419	71	1	in	in	ADP
dti-1419	71	2	the	the	DET
dti-1419	71	3	maintenance	maintenance	NOUN
dti-1419	71	4	phase	phase	NOUN
dti-1419	71	5	,	,	PUNCT
dti-1419	71	6	the	the	DET
dti-1419	71	7	maintenance	maintenance	NOUN
dti-1419	71	8	dose	dose	NOUN
dti-1419	71	9	was	be	AUX
dti-1419	71	10	continued	continue	VERB
dti-1419	71	11	but	but	CCONJ
dti-1419	71	12	could	could	AUX
dti-1419	71	13	still	still	ADV
dti-1419	71	14	be	be	AUX
dti-1419	71	15	adjusted	adjust	VERB
dti-1419	71	16	for	for	ADP
dti-1419	71	17	safety	safety	NOUN
dti-1419	71	18	or	or	CCONJ
dti-1419	71	19	to	to	PART
dti-1419	71	20	maintain	maintain	VERB
dti-1419	71	21	concentrations	concentration	NOUN
dti-1419	71	22	below	below	ADP
dti-1419	71	23	600	600	NUM
dti-1419	71	24	µmol	µmol	ADV
dti-1419	71	25	/	/	SYM
dti-1419	71	26	l.	l.	PROPN
dti-1419	71	27	the	the	DET
dti-1419	71	28	maximum	maximum	PROPN
dti-1419	71	29	dose	dose	NOUN
dti-1419	71	30	in	in	ADP
dti-1419	71	31	the	the	DET
dti-1419	71	32	maintenance	maintenance	NOUN
dti-1419	71	33	phase	phase	NOUN
dti-1419	71	34	was	be	AUX
dti-1419	71	35	75	75	NUM
dti-1419	71	36	mg	mg	NOUN
dti-1419	71	37	/	/	SYM
dti-1419	71	38	d	d	PROPN
dti-1419	71	39	given	give	VERB
dti-1419	71	40	5	5	NUM
dti-1419	71	41	d	d	PROPN
dti-1419	71	42	/	/	SYM
dti-1419	71	43	wk	wk	PROPN
dti-1419	71	44	.	.	PUNCT
dti-1419	72	1	however	however	ADV
dti-1419	72	2	,	,	PUNCT
dti-1419	72	3	the	the	DET
dti-1419	72	4	protocol	protocol	NOUN
dti-1419	72	5	was	be	AUX
dti-1419	72	6	updated	update	VERB
dti-1419	72	7	to	to	PART
dti-1419	72	8	change	change	VERB
dti-1419	72	9	the	the	DET
dti-1419	72	10	maximum	maximum	ADJ
dti-1419	72	11	frequency	frequency	NOUN
dti-1419	72	12	to	to	ADP
dti-1419	72	13	7	7	NUM
dti-1419	72	14	d	d	PROPN
dti-1419	72	15	/	/	SYM
dti-1419	72	16	wk	wk	PROPN
dti-1419	72	17	.	.	PUNCT
dti-1419	73	1	patients	patient	NOUN
dti-1419	73	2	experiencing	experience	VERB
dti-1419	73	3	severe	severe	ADJ
dti-1419	73	4	hypersensitivity	hypersensitivity	NOUN
dti-1419	73	5	adverse	adverse	ADJ
dti-1419	73	6	events	event	NOUN
dti-1419	73	7	(	(	PUNCT
dti-1419	73	8	haes	haes	NOUN
dti-1419	73	9	)	)	PUNCT
dti-1419	73	10	had	have	VERB
dti-1419	73	11	their	their	PRON
dti-1419	73	12	dosing	dosing	NOUN
dti-1419	73	13	interrupted	interrupted	NOUN
dti-1419	73	14	or	or	CCONJ
dti-1419	73	15	adjusted	adjust	VERB
dti-1419	73	16	and	and	CCONJ
dti-1419	73	17	restarted	restart	VERB
dti-1419	73	18	at	at	ADP
dti-1419	73	19	the	the	DET
dti-1419	73	20	same	same	ADJ
dti-1419	73	21	or	or	CCONJ
dti-1419	73	22	a	a	DET
dti-1419	73	23	lower	low	ADJ
dti-1419	73	24	dose	dose	NOUN
dti-1419	73	25	.	.	PUNCT
dti-1419	74	1	another	another	DET
dti-1419	74	2	protocol	protocol	NOUN
dti-1419	74	3	change	change	NOUN
dti-1419	74	4	allowed	allow	VERB
dti-1419	74	5	patients	patient	NOUN
dti-1419	74	6	with	with	ADP
dti-1419	74	7	treatment	treatment	NOUN
dti-1419	74	8	-	-	PUNCT
dti-1419	74	9	related	relate	VERB
dti-1419	74	10	acute	acute	ADJ
dti-1419	74	11	systemic	systemic	ADJ
dti-1419	74	12	hypersensitivity	hypersensitivity	NOUN
dti-1419	74	13	events	event	NOUN
dti-1419	74	14	to	to	PART
dti-1419	74	15	permanently	permanently	ADV
dti-1419	74	16	discontinue	discontinue	VERB
dti-1419	74	17	the	the	DET
dti-1419	74	18	study	study	NOUN
dti-1419	74	19	drug	drug	NOUN
dti-1419	74	20	.	.	PUNCT
dti-1419	75	1	the	the	DET
dti-1419	75	2	investigators	investigator	NOUN
dti-1419	75	3	used	use	VERB
dti-1419	75	4	a	a	DET
dti-1419	75	5	modified	modified	ADJ
dti-1419	75	6	intention	intention	NOUN
dti-1419	75	7	-	-	PUNCT
dti-1419	75	8	to	to	AUX
dti-1419	75	9	-	-	PUNCT
dti-1419	75	10	treat	treat	VERB
dti-1419	75	11	analysis	analysis	NOUN
dti-1419	75	12	consisting	consist	VERB
dti-1419	75	13	of	of	ADP
dti-1419	75	14	participants	participant	NOUN
dti-1419	75	15	who	who	PRON
dti-1419	75	16	received	receive	VERB
dti-1419	75	17	at	at	ADV
dti-1419	75	18	least	least	ADV
dti-1419	75	19	1	1	NUM
dti-1419	75	20	dose	dose	NOUN
dti-1419	75	21	of	of	ADP
dti-1419	75	22	the	the	DET
dti-1419	75	23	study	study	NOUN
dti-1419	75	24	drug	drug	NOUN
dti-1419	75	25	and	and	CCONJ
dti-1419	75	26	had	have	VERB
dti-1419	75	27	at	at	ADV
dti-1419	75	28	least	least	ADJ
dti-1419	75	29	1	1	NUM
dti-1419	75	30	post	post	ADJ
dti-1419	75	31	-	-	ADJ
dti-1419	75	32	treatment	treatment	ADJ
dti-1419	75	33	blood	blood	NOUN
dti-1419	75	34	phenylalanine	phenylalanine	NOUN
dti-1419	75	35	level.17	level.17	PROPN
dti-1419	75	36	twenty	twenty	NUM
dti-1419	75	37	-	-	PUNCT
dti-1419	75	38	four	four	NUM
dti-1419	75	39	patients	patient	NOUN
dti-1419	75	40	enrolled	enrol	VERB
dti-1419	75	41	in	in	ADP
dti-1419	75	42	the	the	DET
dti-1419	75	43	study	study	NOUN
dti-1419	75	44	,	,	PUNCT
dti-1419	75	45	with	with	ADP
dti-1419	75	46	11	11	NUM
dti-1419	75	47	patients	patient	NOUN
dti-1419	75	48	achieving	achieve	VERB
dti-1419	75	49	maintenance	maintenance	NOUN
dti-1419	75	50	dose	dose	VERB
dti-1419	75	51	in	in	ADP
dti-1419	75	52	the	the	DET
dti-1419	75	53	first	first	ADJ
dti-1419	75	54	24	24	NUM
dti-1419	75	55	weeks	week	NOUN
dti-1419	75	56	(	(	PUNCT
dti-1419	75	57	group	group	NOUN
dti-1419	75	58	a	a	NOUN
dti-1419	75	59	)	)	PUNCT
dti-1419	75	60	and	and	CCONJ
dti-1419	75	61	13	13	NUM
dti-1419	75	62	patients	patient	NOUN
dti-1419	75	63	not	not	PART
dti-1419	75	64	achieving	achieve	VERB
dti-1419	75	65	maintenance	maintenance	NOUN
dti-1419	75	66	dose	dose	VERB
dti-1419	75	67	within	within	ADP
dti-1419	75	68	24	24	NUM
dti-1419	75	69	weeks	week	NOUN
dti-1419	75	70	(	(	PUNCT
dti-1419	75	71	group	group	NOUN
dti-1419	75	72	b	b	NOUN
dti-1419	75	73	)	)	PUNCT
dti-1419	75	74	.	.	PUNCT
dti-1419	76	1	patients	patient	NOUN
dti-1419	76	2	had	have	VERB
dti-1419	76	3	a	a	DET
dti-1419	76	4	mean	mean	ADJ
dti-1419	76	5	age	age	NOUN
dti-1419	76	6	of	of	ADP
dti-1419	76	7	approximately	approximately	ADV
dti-1419	76	8	29	29	NUM
dti-1419	76	9	years	year	NOUN
dti-1419	76	10	,	,	PUNCT
dti-1419	76	11	and	and	CCONJ
dti-1419	76	12	baseline	baseline	VERB
dti-1419	76	13	blood	blood	NOUN
dti-1419	76	14	phenylalanine	phenylalanine	NOUN
dti-1419	76	15	concentrations	concentration	NOUN
dti-1419	76	16	were	be	AUX
dti-1419	76	17	similar	similar	ADJ
dti-1419	76	18	in	in	ADP
dti-1419	76	19	both	both	DET
dti-1419	76	20	groups	group	NOUN
dti-1419	76	21	(	(	PUNCT
dti-1419	76	22	1134.8	1134.8	NUM
dti-1419	76	23	µmol	µmol	NOUN
dti-1419	76	24	/	/	SYM
dti-1419	76	25	l	l	NOUN
dti-1419	76	26	in	in	ADP
dti-1419	76	27	group	group	PROPN
dti-1419	76	28	a	a	PRON
dti-1419	76	29	vs	vs	ADP
dti-1419	76	30	1197.5	1197.5	NUM
dti-1419	76	31	µmol	µmol	NOUN
dti-1419	76	32	/	/	SYM
dti-1419	76	33	l	l	NOUN
dti-1419	76	34	in	in	ADP
dti-1419	76	35	group	group	PROPN
dti-1419	76	36	b	b	PROPN
dti-1419	76	37	)	)	PUNCT
dti-1419	76	38	.	.	PUNCT
dti-1419	77	1	however	however	ADV
dti-1419	77	2	,	,	PUNCT
dti-1419	77	3	group	group	PROPN
dti-1419	77	4	a	a	PRON
dti-1419	77	5	was	be	AUX
dti-1419	77	6	comprised	comprise	VERB
dti-1419	77	7	mostly	mostly	ADV
dti-1419	77	8	of	of	ADP
dti-1419	77	9	women	woman	NOUN
dti-1419	77	10	with	with	ADP
dti-1419	77	11	a	a	DET
dti-1419	77	12	mean	mean	ADJ
dti-1419	77	13	weight	weight	NOUN
dti-1419	77	14	of	of	ADP
dti-1419	77	15	64.6	64.6	NUM
dti-1419	77	16	kg	kg	NOUN
dti-1419	77	17	,	,	PUNCT
dti-1419	77	18	whereas	whereas	SCONJ
dti-1419	77	19	group	group	PROPN
dti-1419	77	20	b	b	PROPN
dti-1419	77	21	was	be	AUX
dti-1419	77	22	mostly	mostly	ADV
dti-1419	77	23	men	man	NOUN
dti-1419	77	24	with	with	ADP
dti-1419	77	25	a	a	DET
dti-1419	77	26	mean	mean	ADJ
dti-1419	77	27	weight	weight	NOUN
dti-1419	77	28	of	of	ADP
dti-1419	77	29	86.4	86.4	NUM
dti-1419	77	30	kg	kg	NOUN
dti-1419	77	31	.	.	PUNCT
dti-1419	78	1	baseline	baseline	PROPN
dti-1419	78	2	total	total	ADJ
dti-1419	78	3	protein	protein	NOUN
dti-1419	78	4	intake	intake	NOUN
dti-1419	78	5	and	and	CCONJ
dti-1419	78	6	dietary	dietary	ADJ
dti-1419	78	7	phenylalanine	phenylalanine	NOUN
dti-1419	78	8	intake	intake	NOUN
dti-1419	78	9	were	be	AUX
dti-1419	78	10	higher	high	ADJ
dti-1419	78	11	in	in	ADP
dti-1419	78	12	group	group	PROPN
dti-1419	78	13	b.	b.	PROPN
dti-1419	78	14	mean	mean	PROPN
dti-1419	78	15	doses	dose	NOUN
dti-1419	78	16	of	of	ADP
dti-1419	78	17	pegvaliase	pegvaliase	NOUN
dti-1419	78	18	in	in	ADP
dti-1419	78	19	the	the	DET
dti-1419	78	20	24	24	NUM
dti-1419	78	21	-	-	PUNCT
dti-1419	78	22	week	week	NOUN
dti-1419	78	23	study	study	NOUN
dti-1419	78	24	were	be	AUX
dti-1419	78	25	64.7	64.7	NUM
dti-1419	78	26	mg	mg	NOUN
dti-1419	78	27	in	in	ADP
dti-1419	78	28	group	group	PROPN
dti-1419	78	29	a	a	PROPN
dti-1419	78	30	and	and	CCONJ
dti-1419	78	31	89.4	89.4	NUM
dti-1419	78	32	mg	mg	NOUN
dti-1419	78	33	in	in	ADP
dti-1419	78	34	group	group	PROPN
dti-1419	78	35	b.	b.	PROPN
dti-1419	79	1	the	the	DET
dti-1419	79	2	group	group	NOUN
dti-1419	79	3	a	a	DET
dti-1419	79	4	patients	patient	NOUN
dti-1419	79	5	’	'	PUNCT
dti-1419	79	6	mean	mean	VERB
dti-1419	79	7	blood	blood	NOUN
dti-1419	79	8	phenylalanine	phenylalanine	NOUN
dti-1419	79	9	concentration	concentration	NOUN
dti-1419	79	10	reached	reach	VERB
dti-1419	79	11	<	<	X
dti-1419	79	12	600	600	NUM
dti-1419	79	13	µmol	µmol	ADV
dti-1419	79	14	/	/	SYM
dti-1419	79	15	l	l	NOUN
dti-1419	79	16	by	by	ADP
dti-1419	79	17	week	week	NOUN
dti-1419	79	18	11	11	NUM
dti-1419	79	19	of	of	ADP
dti-1419	79	20	the	the	DET
dti-1419	79	21	study	study	NOUN
dti-1419	79	22	.	.	PUNCT
dti-1419	80	1	the	the	DET
dti-1419	80	2	mean	mean	ADJ
dti-1419	80	3	reduction	reduction	NOUN
dti-1419	80	4	from	from	ADP
dti-1419	80	5	baseline	baseline	PROPN
dti-1419	80	6	was	be	AUX
dti-1419	80	7	627	627	NUM
dti-1419	80	8	±	±	NUM
dti-1419	80	9	432	432	NUM
dti-1419	80	10	µmol	µmol	ADV
dti-1419	80	11	/	/	SYM
dti-1419	80	12	l	l	NOUN
dti-1419	80	13	(	(	PUNCT
dti-1419	80	14	56	56	NUM
dti-1419	80	15	%	%	NOUN
dti-1419	80	16	±	±	NUM
dti-1419	80	17	36	36	NUM
dti-1419	80	18	%	%	NOUN
dti-1419	80	19	reduction	reduction	NOUN
dti-1419	80	20	)	)	PUNCT
dti-1419	80	21	.	.	PUNCT
dti-1419	81	1	furthermore	furthermore	ADV
dti-1419	81	2	,	,	PUNCT
dti-1419	81	3	all	all	DET
dti-1419	81	4	patients	patient	NOUN
dti-1419	81	5	in	in	ADP
dti-1419	81	6	group	group	PROPN
dti-1419	81	7	a	a	PRON
dti-1419	81	8	reached	reach	VERB
dti-1419	81	9	a	a	DET
dti-1419	81	10	blood	blood	NOUN
dti-1419	81	11	phenylalanine	phenylalanine	NOUN
dti-1419	81	12	concentration	concentration	NOUN
dti-1419	81	13	target	target	NOUN
dti-1419	81	14	of	of	ADP
dti-1419	81	15	<	<	X
dti-1419	81	16	120	120	NUM
dti-1419	81	17	µmol	µmol	ADV
dti-1419	81	18	/	/	SYM
dti-1419	81	19	l	l	NOUN
dti-1419	81	20	during	during	ADP
dti-1419	81	21	the	the	DET
dti-1419	81	22	24	24	NUM
dti-1419	81	23	-	-	PUNCT
dti-1419	81	24	week	week	NOUN
dti-1419	81	25	study	study	NOUN
dti-1419	81	26	.	.	PUNCT
dti-1419	82	1	group	group	PROPN
dti-1419	82	2	a	a	PRON
dti-1419	82	3	had	have	VERB
dti-1419	82	4	lower	low	ADJ
dti-1419	82	5	anti	anti	ADJ
dti-1419	82	6	-	-	ADJ
dti-1419	82	7	drug	drug	ADJ
dti-1419	82	8	antibody	antibody	NOUN
dti-1419	82	9	responses	response	NOUN
dti-1419	82	10	,	,	PUNCT
dti-1419	82	11	which	which	PRON
dti-1419	82	12	was	be	AUX
dti-1419	82	13	likely	likely	ADV
dti-1419	82	14	associated	associate	VERB
dti-1419	82	15	with	with	ADP
dti-1419	82	16	less	less	ADJ
dti-1419	82	17	immune	immune	NOUN
dti-1419	82	18	-	-	PUNCT
dti-1419	82	19	related	relate	VERB
dti-1419	82	20	clearance	clearance	NOUN
dti-1419	82	21	compared	compare	VERB
dti-1419	82	22	with	with	ADP
dti-1419	82	23	patients	patient	NOUN
dti-1419	82	24	in	in	ADP
dti-1419	82	25	group	group	PROPN
dti-1419	82	26	b	b	PROPN
dti-1419	82	27	with	with	ADP
dti-1419	82	28	higher	high	ADJ
dti-1419	82	29	anti	anti	ADJ
dti-1419	82	30	-	-	ADJ
dti-1419	82	31	drug	drug	ADJ
dti-1419	82	32	antibody	antibody	NOUN
dti-1419	82	33	responses	response	NOUN
dti-1419	82	34	.	.	PUNCT
dti-1419	83	1	ten	ten	NUM
dti-1419	83	2	of	of	ADP
dti-1419	83	3	the	the	DET
dti-1419	83	4	13	13	NUM
dti-1419	83	5	patients	patient	NOUN
dti-1419	83	6	in	in	ADP
dti-1419	83	7	group	group	PROPN
dti-1419	83	8	b	b	PROPN
dti-1419	83	9	continued	continue	VERB
dti-1419	83	10	on	on	ADP
dti-1419	83	11	to	to	ADP
dti-1419	83	12	the	the	DET
dti-1419	83	13	extension	extension	NOUN
dti-1419	83	14	study	study	NOUN
dti-1419	83	15	,	,	PUNCT
dti-1419	83	16	during	during	ADP
dti-1419	83	17	which	which	PRON
dti-1419	83	18	they	they	PRON
dti-1419	83	19	achieved	achieve	VERB
dti-1419	83	20	a	a	DET
dti-1419	83	21	blood	blood	NOUN
dti-1419	83	22	phenylalanine	phenylalanine	NOUN
dti-1419	83	23	concentration	concentration	NOUN
dti-1419	83	24	of	of	ADP
dti-1419	83	25	⩽600	⩽600	NOUN
dti-1419	83	26	µmol	µmol	ADV
dti-1419	83	27	/	/	SYM
dti-1419	83	28	l	l	NOUN
dti-1419	83	29	by	by	ADP
dti-1419	83	30	week	week	NOUN
dti-1419	83	31	48.17	48.17	NUM
dti-1419	83	32	patients	patient	NOUN
dti-1419	83	33	in	in	ADP
dti-1419	83	34	the	the	DET
dti-1419	83	35	3	3	NUM
dti-1419	83	36	phase	phase	NOUN
dti-1419	83	37	2	2	NUM
dti-1419	83	38	dosing	dosing	NOUN
dti-1419	83	39	finding	finding	NOUN
dti-1419	83	40	studies	study	NOUN
dti-1419	83	41	(	(	PUNCT
dti-1419	83	42	will	will	AUX
dti-1419	83	43	be	be	AUX
dti-1419	83	44	referred	refer	VERB
dti-1419	83	45	to	to	ADP
dti-1419	83	46	hereon	hereon	NOUN
dti-1419	83	47	in	in	ADP
dti-1419	83	48	as	as	ADP
dti-1419	83	49	“	"	PUNCT
dti-1419	83	50	parent	parent	NOUN
dti-1419	83	51	studies	study	NOUN
dti-1419	83	52	”	"	PUNCT
dti-1419	83	53	)	)	PUNCT
dti-1419	83	54	were	be	AUX
dti-1419	83	55	invited	invite	VERB
dti-1419	83	56	to	to	PART
dti-1419	83	57	continue	continue	VERB
dti-1419	83	58	on	on	ADP
dti-1419	83	59	in	in	ADP
dti-1419	83	60	an	an	DET
dti-1419	83	61	extension	extension	NOUN
dti-1419	83	62	study	study	NOUN
dti-1419	83	63	(	(	PUNCT
dti-1419	83	64	pal-003	pal-003	NOUN
dti-1419	83	65	,	,	PUNCT
dti-1419	83	66	nct00924703	nct00924703	ADJ
dti-1419	83	67	)	)	PUNCT
dti-1419	83	68	if	if	SCONJ
dti-1419	83	69	they	they	PRON
dti-1419	83	70	were	be	AUX
dti-1419	83	71	willing	willing	ADJ
dti-1419	83	72	to	to	PART
dti-1419	83	73	continue	continue	VERB
dti-1419	83	74	stable	stable	ADJ
dti-1419	83	75	protein	protein	NOUN
dti-1419	83	76	intake	intake	NOUN
dti-1419	83	77	.	.	PUNCT
dti-1419	84	1	patients	patient	NOUN
dti-1419	84	2	taking	take	VERB
dti-1419	84	3	any	any	DET
dti-1419	84	4	other	other	ADJ
dti-1419	84	5	injectable	injectable	ADJ
dti-1419	84	6	drug	drug	NOUN
dti-1419	84	7	containing	contain	VERB
dti-1419	84	8	polyethylene	polyethylene	NOUN
dti-1419	84	9	glycol	glycol	NOUN
dti-1419	84	10	(	(	PUNCT
dti-1419	84	11	peg	peg	NOUN
dti-1419	84	12	)	)	PUNCT
dti-1419	84	13	and	and	CCONJ
dti-1419	84	14	patients	patient	NOUN
dti-1419	84	15	with	with	ADP
dti-1419	84	16	a	a	DET
dti-1419	84	17	history	history	NOUN
dti-1419	84	18	of	of	ADP
dti-1419	84	19	systemic	systemic	ADJ
dti-1419	84	20	hypersensitivity	hypersensitivity	NOUN
dti-1419	84	21	events	event	NOUN
dti-1419	84	22	to	to	ADP
dti-1419	84	23	a	a	DET
dti-1419	84	24	peg	peg	NOUN
dti-1419	84	25	-	-	PUNCT
dti-1419	84	26	containing	contain	VERB
dti-1419	84	27	product	product	NOUN
dti-1419	84	28	were	be	AUX
dti-1419	84	29	excluded	exclude	VERB
dti-1419	84	30	.	.	PUNCT
dti-1419	85	1	however	however	ADV
dti-1419	85	2	,	,	PUNCT
dti-1419	85	3	patients	patient	NOUN
dti-1419	85	4	with	with	ADP
dti-1419	85	5	a	a	DET
dti-1419	85	6	previous	previous	ADJ
dti-1419	85	7	reaction	reaction	NOUN
dti-1419	85	8	to	to	ADP
dti-1419	85	9	pegvaliase	pegvaliase	PROPN
dti-1419	85	10	could	could	AUX
dti-1419	85	11	be	be	AUX
dti-1419	85	12	eligible	eligible	ADJ
dti-1419	85	13	for	for	ADP
dti-1419	85	14	the	the	DET
dti-1419	85	15	study	study	NOUN
dti-1419	85	16	on	on	ADP
dti-1419	85	17	a	a	DET
dti-1419	85	18	case	case	NOUN
dti-1419	85	19	by	by	ADP
dti-1419	85	20	case	case	NOUN
dti-1419	85	21	basis	basis	NOUN
dti-1419	85	22	.	.	PUNCT
dti-1419	86	1	doses	dose	NOUN
dti-1419	86	2	for	for	ADP
dti-1419	86	3	individuals	individual	NOUN
dti-1419	86	4	were	be	AUX
dti-1419	86	5	either	either	CCONJ
dti-1419	86	6	continued	continue	VERB
dti-1419	86	7	from	from	ADP
dti-1419	86	8	the	the	DET
dti-1419	86	9	parent	parent	NOUN
dti-1419	86	10	study	study	NOUN
dti-1419	86	11	or	or	CCONJ
dti-1419	86	12	increased	increase	VERB
dti-1419	86	13	and	and	CCONJ
dti-1419	86	14	were	be	AUX
dti-1419	86	15	adjusted	adjust	VERB
dti-1419	86	16	throughout	throughout	ADP
dti-1419	86	17	the	the	DET
dti-1419	86	18	study	study	NOUN
dti-1419	86	19	to	to	PART
dti-1419	86	20	attain	attain	VERB
dti-1419	86	21	or	or	CCONJ
dti-1419	86	22	maintain	maintain	VERB
dti-1419	86	23	phenylalanine	phenylalanine	ADJ
dti-1419	86	24	concentrations	concentration	NOUN
dti-1419	86	25	between	between	ADP
dti-1419	86	26	60	60	NUM
dti-1419	86	27	and	and	CCONJ
dti-1419	86	28	600	600	NUM
dti-1419	86	29	µmol	µmol	ADV
dti-1419	86	30	/	/	SYM
dti-1419	86	31	l.	l.	NOUN
dti-1419	86	32	in	in	ADP
dti-1419	86	33	addition	addition	NOUN
dti-1419	86	34	,	,	PUNCT
dti-1419	86	35	doses	dose	NOUN
dti-1419	86	36	could	could	AUX
dti-1419	86	37	be	be	AUX
dti-1419	86	38	adjusted	adjust	VERB
dti-1419	86	39	to	to	PART
dti-1419	86	40	manage	manage	VERB
dti-1419	86	41	aes	aes	PROPN
dti-1419	86	42	.	.	PUNCT
dti-1419	86	43	initially	initially	ADV
dti-1419	86	44	,	,	PUNCT
dti-1419	86	45	dosing	dosing	NOUN
dti-1419	86	46	ranged	range	VERB
dti-1419	86	47	from	from	ADP
dti-1419	86	48	2.5	2.5	NUM
dti-1419	86	49	to	to	PART
dti-1419	86	50	375	375	NUM
dti-1419	86	51	mg	mg	NOUN
dti-1419	86	52	/	/	SYM
dti-1419	86	53	wk	wk	NOUN
dti-1419	86	54	or	or	CCONJ
dti-1419	86	55	0.001	0.001	NUM
dti-1419	86	56	to	to	PART
dti-1419	86	57	5	5	NUM
dti-1419	86	58	mg	mg	PROPN
dti-1419	86	59	/	/	SYM
dti-1419	86	60	kg	kg	PROPN
dti-1419	86	61	/	/	SYM
dti-1419	86	62	wk	wk	PROPN
dti-1419	86	63	,	,	PUNCT
dti-1419	86	64	but	but	CCONJ
dti-1419	86	65	a	a	DET
dti-1419	86	66	protocol	protocol	NOUN
dti-1419	86	67	changed	change	VERB
dti-1419	86	68	limited	limited	ADJ
dti-1419	86	69	weekly	weekly	NOUN
dti-1419	86	70	dosing	dose	VERB
dti-1419	86	71	to	to	ADP
dti-1419	86	72	375	375	NUM
dti-1419	86	73	mg	mg	NUM
dti-1419	86	74	/	/	SYM
dti-1419	86	75	wk	wk	PROPN
dti-1419	86	76	.	.	PUNCT
dti-1419	87	1	the	the	DET
dti-1419	87	2	authors	author	NOUN
dti-1419	87	3	used	use	VERB
dti-1419	87	4	a	a	DET
dti-1419	87	5	modified	modify	VERB
dti-1419	87	6	intention	intention	NOUN
dti-1419	87	7	-	-	PUNCT
dti-1419	87	8	totreat	totreat	NOUN
dti-1419	87	9	analysis	analysis	NOUN
dti-1419	87	10	for	for	ADP
dti-1419	87	11	efficacy	efficacy	NOUN
dti-1419	87	12	which	which	PRON
dti-1419	87	13	included	include	VERB
dti-1419	87	14	all	all	DET
dti-1419	87	15	patients	patient	NOUN
dti-1419	87	16	who	who	PRON
dti-1419	87	17	received	receive	VERB
dti-1419	87	18	1	1	NUM
dti-1419	87	19	dose	dose	NOUN
dti-1419	87	20	of	of	ADP
dti-1419	87	21	pegvaliase	pegvaliase	PROPN
dti-1419	87	22	and	and	CCONJ
dti-1419	87	23	had	have	VERB
dti-1419	87	24	at	at	ADV
dti-1419	87	25	least	least	ADJ
dti-1419	87	26	1	1	NUM
dti-1419	87	27	phenylalanine	phenylalanine	NOUN
dti-1419	87	28	concentration	concentration	NOUN
dti-1419	87	29	measurement	measurement	NOUN
dti-1419	87	30	taken	take	VERB
dti-1419	87	31	after	after	ADP
dti-1419	87	32	treatment.17	treatment.17	PROPN
dti-1419	87	33	sixty	sixty	NUM
dti-1419	87	34	-	-	PUNCT
dti-1419	87	35	eight	eight	NUM
dti-1419	87	36	of	of	ADP
dti-1419	87	37	the	the	DET
dti-1419	87	38	80	80	NUM
dti-1419	87	39	participants	participant	NOUN
dti-1419	87	40	in	in	ADP
dti-1419	87	41	the	the	DET
dti-1419	87	42	parent	parent	NOUN
dti-1419	87	43	studies	study	NOUN
dti-1419	87	44	enrolled	enrol	VERB
dti-1419	87	45	in	in	ADP
dti-1419	87	46	the	the	DET
dti-1419	87	47	extension	extension	NOUN
dti-1419	87	48	study	study	NOUN
dti-1419	87	49	.	.	PUNCT
dti-1419	88	1	the	the	DET
dti-1419	88	2	baseline	baseline	ADJ
dti-1419	88	3	phenylalanine	phenylalanine	NOUN
dti-1419	88	4	concentration	concentration	NOUN
dti-1419	88	5	was	be	AUX
dti-1419	88	6	1022.4	1022.4	NUM
dti-1419	88	7	µmol	µmol	NOUN
dti-1419	88	8	/	/	SYM
dti-1419	88	9	l.	l.	NOUN
dti-1419	88	10	the	the	DET
dti-1419	88	11	mean	mean	ADJ
dti-1419	88	12	daily	daily	PROPN
dti-1419	88	13	dose	dose	NOUN
dti-1419	88	14	of	of	ADP
dti-1419	88	15	pegvaliase	pegvaliase	PROPN
dti-1419	88	16	in	in	ADP
dti-1419	88	17	the	the	DET
dti-1419	88	18	parent	parent	NOUN
dti-1419	88	19	studies	study	NOUN
dti-1419	88	20	was	be	AUX
dti-1419	89	1	5.3	5.3	NUM
dti-1419	89	2	mg	mg	NOUN
dti-1419	89	3	/	/	SYM
dti-1419	89	4	d	d	PROPN
dti-1419	89	5	(	(	PUNCT
dti-1419	89	6	sd	sd	NOUN
dti-1419	89	7	=	=	SYM
dti-1419	89	8	6.8	6.8	NUM
dti-1419	89	9	mg	mg	PROPN
dti-1419	89	10	/	/	SYM
dti-1419	89	11	d	d	NOUN
dti-1419	89	12	)	)	PUNCT
dti-1419	89	13	,	,	PUNCT
dti-1419	89	14	and	and	CCONJ
dti-1419	89	15	this	this	PRON
dti-1419	89	16	increased	increase	VERB
dti-1419	89	17	to	to	ADP
dti-1419	89	18	26.2	26.2	NUM
dti-1419	89	19	mg	mg	NOUN
dti-1419	89	20	/	/	SYM
dti-1419	89	21	d	d	PROPN
dti-1419	89	22	(	(	PUNCT
dti-1419	89	23	sd	sd	NOUN
dti-1419	89	24	=	=	SYM
dti-1419	89	25	17.9	17.9	NUM
dti-1419	89	26	mg	mg	NUM
dti-1419	89	27	/	/	SYM
dti-1419	89	28	d	d	NOUN
dti-1419	89	29	)	)	PUNCT
dti-1419	89	30	in	in	ADP
dti-1419	89	31	the	the	DET
dti-1419	89	32	extension	extension	NOUN
dti-1419	89	33	study	study	NOUN
dti-1419	89	34	.	.	PUNCT
dti-1419	90	1	doses	dose	NOUN
dti-1419	90	2	remained	remain	VERB
dti-1419	90	3	relatively	relatively	ADV
dti-1419	90	4	stable	stable	ADJ
dti-1419	90	5	from	from	ADP
dti-1419	90	6	week	week	NOUN
dti-1419	90	7	48	48	NUM
dti-1419	90	8	to	to	ADP
dti-1419	90	9	week	week	NOUN
dti-1419	90	10	120	120	NUM
dti-1419	90	11	of	of	ADP
dti-1419	90	12	the	the	DET
dti-1419	90	13	study	study	NOUN
dti-1419	90	14	.	.	PUNCT
dti-1419	91	1	the	the	DET
dti-1419	91	2	average	average	ADJ
dti-1419	91	3	duration	duration	NOUN
dti-1419	91	4	of	of	ADP
dti-1419	91	5	treatment	treatment	NOUN
dti-1419	91	6	in	in	ADP
dti-1419	91	7	all	all	PRON
dti-1419	91	8	of	of	ADP
dti-1419	91	9	the	the	DET
dti-1419	91	10	phase	phase	NOUN
dti-1419	91	11	2	2	NUM
dti-1419	91	12	studies	study	NOUN
dti-1419	91	13	was	be	AUX
dti-1419	91	14	approximately	approximately	ADV
dti-1419	91	15	3.4	3.4	NUM
dti-1419	91	16	years	year	NOUN
dti-1419	91	17	.	.	PUNCT
dti-1419	92	1	mean	mean	VERB
dti-1419	92	2	phenylalanine	phenylalanine	ADJ
dti-1419	92	3	concentrations	concentration	NOUN
dti-1419	92	4	decreased	decrease	VERB
dti-1419	92	5	throughout	throughout	ADP
dti-1419	92	6	the	the	DET
dti-1419	92	7	study	study	NOUN
dti-1419	92	8	by	by	ADP
dti-1419	92	9	more	more	ADJ
dti-1419	92	10	than	than	ADP
dti-1419	92	11	half	half	NOUN
dti-1419	92	12	(	(	PUNCT
dti-1419	92	13	58.9	58.9	NUM
dti-1419	92	14	%	%	NOUN
dti-1419	92	15	)	)	PUNCT
dti-1419	92	16	at	at	ADP
dti-1419	92	17	week	week	NOUN
dti-1419	92	18	48	48	NUM
dti-1419	92	19	of	of	ADP
dti-1419	92	20	treatment	treatment	NOUN
dti-1419	92	21	and	and	CCONJ
dti-1419	92	22	by	by	ADP
dti-1419	92	23	72	72	NUM
dti-1419	92	24	%	%	NOUN
dti-1419	92	25	at	at	ADP
dti-1419	92	26	week	week	NOUN
dti-1419	92	27	120	120	NUM
dti-1419	92	28	(	(	PUNCT
dti-1419	92	29	1022.4	1022.4	NUM
dti-1419	92	30	µmol	µmol	NOUN
dti-1419	92	31	/	/	SYM
dti-1419	92	32	l	l	NOUN
dti-1419	92	33	at	at	ADP
dti-1419	92	34	baseline	baseline	NOUN
dti-1419	92	35	,	,	PUNCT
dti-1419	92	36	541.6	541.6	NUM
dti-1419	92	37	µmol	µmol	NOUN
dti-1419	92	38	/	/	SYM
dti-1419	92	39	l	l	NOUN
dti-1419	92	40	at	at	ADP
dti-1419	92	41	week	week	NOUN
dti-1419	92	42	48	48	NUM
dti-1419	92	43	,	,	PUNCT
dti-1419	92	44	and	and	CCONJ
dti-1419	92	45	372	372	NUM
dti-1419	92	46	µmol	µmol	NOUN
dti-1419	92	47	/	/	SYM
dti-1419	92	48	l	l	NOUN
dti-1419	92	49	at	at	ADP
dti-1419	92	50	week	week	NOUN
dti-1419	92	51	120).17	120).17	NUM
dti-1419	92	52	approximately	approximately	ADV
dti-1419	92	53	one	one	NUM
dti-1419	92	54	-	-	PUNCT
dti-1419	92	55	third	third	NOUN
dti-1419	92	56	of	of	ADP
dti-1419	92	57	patients	patient	NOUN
dti-1419	92	58	(	(	PUNCT
dti-1419	92	59	36.8	36.8	NUM
dti-1419	92	60	%	%	NOUN
dti-1419	92	61	)	)	PUNCT
dti-1419	92	62	had	have	VERB
dti-1419	92	63	their	their	PRON
dti-1419	92	64	pegvaliase	pegvaliase	NOUN
dti-1419	92	65	dosing	dose	VERB
dti-1419	92	66	reduced	reduce	VERB
dti-1419	92	67	or	or	CCONJ
dti-1419	92	68	held	hold	VERB
dti-1419	92	69	during	during	ADP
dti-1419	92	70	the	the	DET
dti-1419	92	71	study	study	NOUN
dti-1419	92	72	.	.	PUNCT
dti-1419	93	1	a	a	DET
dti-1419	93	2	small	small	ADJ
dti-1419	93	3	number	number	NOUN
dti-1419	93	4	of	of	ADP
dti-1419	93	5	patients	patient	NOUN
dti-1419	93	6	(	(	PUNCT
dti-1419	93	7	n	n	NOUN
dti-1419	93	8	=	=	SYM
dti-1419	93	9	4	4	NUM
dti-1419	93	10	,	,	PUNCT
dti-1419	93	11	5.9	5.9	NUM
dti-1419	93	12	%	%	NOUN
dti-1419	93	13	)	)	PUNCT
dti-1419	93	14	discontinued	discontinue	VERB
dti-1419	93	15	the	the	DET
dti-1419	93	16	study	study	NOUN
dti-1419	93	17	due	due	ADP
dti-1419	93	18	to	to	ADP
dti-1419	93	19	aes	aes	PROPN
dti-1419	93	20	.	.	PUNCT
dti-1419	94	1	all	all	DET
dti-1419	94	2	4	4	NUM
dti-1419	94	3	patients	patient	NOUN
dti-1419	94	4	reported	report	VERB
dti-1419	94	5	resolution	resolution	NOUN
dti-1419	94	6	of	of	ADP
dti-1419	94	7	the	the	DET
dti-1419	94	8	aes	aes	NOUN
dti-1419	94	9	after	after	ADP
dti-1419	94	10	discontinuing	discontinue	VERB
dti-1419	94	11	treatment	treatment	NOUN
dti-1419	94	12	.	.	PUNCT
dti-1419	95	1	hypersensitivity	hypersensitivity	NOUN
dti-1419	95	2	adverse	adverse	ADJ
dti-1419	95	3	events	event	NOUN
dti-1419	95	4	were	be	AUX
dti-1419	95	5	highest	high	ADJ
dti-1419	95	6	during	during	ADP
dti-1419	95	7	early	early	ADJ
dti-1419	95	8	treatment	treatment	NOUN
dti-1419	95	9	in	in	ADP
dti-1419	95	10	phase	phase	NOUN
dti-1419	95	11	2	2	NUM
dti-1419	95	12	studies	study	NOUN
dti-1419	95	13	and	and	CCONJ
dti-1419	95	14	correlated	correlate	VERB
dti-1419	95	15	with	with	ADP
dti-1419	95	16	the	the	DET
dti-1419	95	17	timing	timing	NOUN
dti-1419	95	18	of	of	ADP
dti-1419	95	19	highest	high	ADJ
dti-1419	95	20	igm	igm	NOUN
dti-1419	95	21	,	,	PUNCT
dti-1419	95	22	peg	peg	NOUN
dti-1419	95	23	igm	igm	PROPN
dti-1419	95	24	,	,	PUNCT
dti-1419	95	25	and	and	CCONJ
dti-1419	95	26	peg	peg	NOUN
dti-1419	95	27	igg	igg	PROPN
dti-1419	95	28	antibodies.17	antibodies.17	PROPN
dti-1419	95	29	phase	phase	NOUN
dti-1419	95	30	3	3	NUM
dti-1419	95	31	pegvaliase	pegvaliase	NOUN
dti-1419	95	32	was	be	AUX
dti-1419	95	33	evaluated	evaluate	VERB
dti-1419	95	34	in	in	ADP
dti-1419	95	35	a	a	DET
dti-1419	95	36	phase	phase	NOUN
dti-1419	95	37	3	3	NUM
dti-1419	95	38	study	study	NOUN
dti-1419	95	39	,	,	PUNCT
dti-1419	95	40	prism-1	prism-1	PROPN
dti-1419	95	41	(	(	PUNCT
dti-1419	95	42	nct01819727	nct01819727	NOUN
dti-1419	95	43	)	)	PUNCT
dti-1419	95	44	.	.	PUNCT
dti-1419	96	1	in	in	ADP
dti-1419	96	2	this	this	DET
dti-1419	96	3	multicenter	multicenter	NOUN
dti-1419	96	4	,	,	PUNCT
dti-1419	96	5	open	open	ADJ
dti-1419	96	6	-	-	PUNCT
dti-1419	96	7	label	label	NOUN
dti-1419	96	8	study	study	NOUN
dti-1419	96	9	,	,	PUNCT
dti-1419	96	10	patients	patient	NOUN
dti-1419	96	11	hydery	hydery	NOUN
dti-1419	96	12	and	and	CCONJ
dti-1419	96	13	coppenrath	coppenrath	PROPN
dti-1419	96	14	5	5	NUM
dti-1419	96	15	naïve	naïve	ADJ
dti-1419	96	16	to	to	ADP
dti-1419	96	17	pegvaliase	pegvaliase	PROPN
dti-1419	96	18	were	be	AUX
dti-1419	96	19	randomized	randomize	VERB
dti-1419	96	20	to	to	PART
dti-1419	96	21	receive	receive	VERB
dti-1419	96	22	1	1	NUM
dti-1419	96	23	of	of	ADP
dti-1419	96	24	2	2	NUM
dti-1419	96	25	regimens	regimen	NOUN
dti-1419	96	26	of	of	ADP
dti-1419	96	27	pegvaliase	pegvaliase	NOUN
dti-1419	96	28	.	.	PUNCT
dti-1419	97	1	patients	patient	NOUN
dti-1419	97	2	with	with	ADP
dti-1419	97	3	a	a	DET
dti-1419	97	4	blood	blood	NOUN
dti-1419	97	5	phenylalanine	phenylalanine	NOUN
dti-1419	97	6	concentration	concentration	NOUN
dti-1419	97	7	of	of	ADP
dti-1419	97	8	600	600	NUM
dti-1419	97	9	µmol	µmol	NOUN
dti-1419	97	10	/	/	SYM
dti-1419	97	11	l	l	NOUN
dti-1419	97	12	or	or	CCONJ
dti-1419	97	13	higher	high	ADJ
dti-1419	97	14	for	for	ADP
dti-1419	97	15	at	at	ADV
dti-1419	97	16	least	least	ADV
dti-1419	97	17	6	6	NUM
dti-1419	97	18	months	month	NOUN
dti-1419	97	19	prior	prior	ADV
dti-1419	97	20	to	to	ADP
dti-1419	97	21	the	the	DET
dti-1419	97	22	study	study	NOUN
dti-1419	97	23	were	be	AUX
dti-1419	97	24	eligible	eligible	ADJ
dti-1419	97	25	.	.	PUNCT
dti-1419	98	1	it	it	PRON
dti-1419	98	2	is	be	AUX
dti-1419	98	3	unclear	unclear	ADJ
dti-1419	98	4	if	if	SCONJ
dti-1419	98	5	allocation	allocation	NOUN
dti-1419	98	6	to	to	ADP
dti-1419	98	7	treatment	treatment	NOUN
dti-1419	98	8	groups	group	NOUN
dti-1419	98	9	was	be	AUX
dti-1419	98	10	concealed	conceal	VERB
dti-1419	98	11	.	.	PUNCT
dti-1419	99	1	both	both	DET
dti-1419	99	2	groups	group	NOUN
dti-1419	99	3	received	receive	VERB
dti-1419	99	4	2.5	2.5	NUM
dti-1419	99	5	mg	mg	ADP
dti-1419	99	6	once	once	ADV
dti-1419	99	7	per	per	ADP
dti-1419	99	8	week	week	NOUN
dti-1419	99	9	of	of	ADP
dti-1419	99	10	pegvaliase	pegvaliase	NOUN
dti-1419	99	11	subcutaneously	subcutaneously	ADV
dti-1419	99	12	for	for	ADP
dti-1419	99	13	4	4	NUM
dti-1419	99	14	weeks	week	NOUN
dti-1419	99	15	during	during	ADP
dti-1419	99	16	the	the	DET
dti-1419	99	17	induction	induction	NOUN
dti-1419	99	18	period	period	NOUN
dti-1419	99	19	.	.	PUNCT
dti-1419	100	1	dosing	dosing	NOUN
dti-1419	100	2	and	and	CCONJ
dti-1419	100	3	frequency	frequency	NOUN
dti-1419	100	4	were	be	AUX
dti-1419	100	5	increased	increase	VERB
dti-1419	100	6	gradually	gradually	ADV
dti-1419	100	7	to	to	ADP
dti-1419	100	8	either	either	PRON
dti-1419	100	9	20	20	NUM
dti-1419	100	10	mg	mg	NUM
dti-1419	100	11	/	/	SYM
dti-1419	100	12	d	d	PROPN
dti-1419	100	13	or	or	CCONJ
dti-1419	100	14	to	to	ADP
dti-1419	100	15	40	40	NUM
dti-1419	100	16	mg	mg	PROPN
dti-1419	100	17	/	/	SYM
dti-1419	100	18	d.	d.	PROPN
dti-1419	100	19	titration	titration	PROPN
dti-1419	100	20	was	be	AUX
dti-1419	100	21	performed	perform	VERB
dti-1419	100	22	over	over	ADP
dti-1419	100	23	a	a	DET
dti-1419	100	24	period	period	NOUN
dti-1419	100	25	of	of	ADP
dti-1419	100	26	5	5	NUM
dti-1419	100	27	to	to	PART
dti-1419	100	28	30	30	NUM
dti-1419	100	29	weeks	week	NOUN
dti-1419	100	30	.	.	PUNCT
dti-1419	101	1	the	the	DET
dti-1419	101	2	schedule	schedule	NOUN
dti-1419	101	3	was	be	AUX
dti-1419	101	4	described	describe	VERB
dti-1419	101	5	for	for	ADP
dti-1419	101	6	the	the	DET
dti-1419	101	7	20	20	NUM
dti-1419	101	8	mg	mg	PROPN
dti-1419	101	9	/	/	SYM
dti-1419	101	10	d	d	PROPN
dti-1419	101	11	group	group	NOUN
dti-1419	101	12	:	:	PUNCT
dti-1419	101	13	2.5	2.5	NUM
dti-1419	101	14	mg	mg	NOUN
dti-1419	101	15	twice	twice	ADV
dti-1419	101	16	weekly	weekly	ADJ
dti-1419	101	17	,	,	PUNCT
dti-1419	101	18	10	10	NUM
dti-1419	101	19	mg	mg	NOUN
dti-1419	101	20	weekly	weekly	ADJ
dti-1419	101	21	,	,	PUNCT
dti-1419	101	22	10	10	NUM
dti-1419	101	23	mg	mg	NOUN
dti-1419	101	24	twice	twice	ADV
dti-1419	101	25	weekly	weekly	ADJ
dti-1419	101	26	,	,	PUNCT
dti-1419	101	27	10	10	NUM
dti-1419	101	28	mg	mg	NUM
dti-1419	101	29	4	4	NUM
dti-1419	101	30	times	time	NOUN
dti-1419	101	31	weekly	weekly	ADJ
dti-1419	101	32	,	,	PUNCT
dti-1419	101	33	10	10	NUM
dti-1419	101	34	mg	mg	NOUN
dti-1419	101	35	daily	daily	ADV
dti-1419	101	36	,	,	PUNCT
dti-1419	101	37	and	and	CCONJ
dti-1419	101	38	then	then	ADV
dti-1419	101	39	20	20	NUM
dti-1419	101	40	mg	mg	NOUN
dti-1419	101	41	daily	daily	ADV
dti-1419	101	42	.	.	PUNCT
dti-1419	102	1	doses	dose	NOUN
dti-1419	102	2	were	be	AUX
dti-1419	102	3	continued	continue	VERB
dti-1419	102	4	in	in	ADP
dti-1419	102	5	the	the	DET
dti-1419	102	6	maintenance	maintenance	NOUN
dti-1419	102	7	phase	phase	NOUN
dti-1419	102	8	,	,	PUNCT
dti-1419	102	9	which	which	PRON
dti-1419	102	10	ranged	range	VERB
dti-1419	102	11	from	from	ADP
dti-1419	102	12	24	24	NUM
dti-1419	102	13	to	to	PART
dti-1419	102	14	36	36	NUM
dti-1419	102	15	weeks	week	NOUN
dti-1419	102	16	in	in	ADP
dti-1419	102	17	duration	duration	NOUN
dti-1419	102	18	.	.	PUNCT
dti-1419	103	1	phenylalanine	phenylalanine	NOUN
dti-1419	103	2	levels	level	NOUN
dti-1419	103	3	,	,	PUNCT
dti-1419	103	4	safety	safety	NOUN
dti-1419	103	5	,	,	PUNCT
dti-1419	103	6	immunogenicity	immunogenicity	NOUN
dti-1419	103	7	,	,	PUNCT
dti-1419	103	8	and	and	CCONJ
dti-1419	103	9	neuropsychiatric	neuropsychiatric	ADJ
dti-1419	103	10	symptoms	symptom	NOUN
dti-1419	103	11	were	be	AUX
dti-1419	103	12	assessed	assess	VERB
dti-1419	103	13	by	by	ADP
dti-1419	103	14	trained	train	VERB
dti-1419	103	15	study	study	NOUN
dti-1419	103	16	staff	staff	NOUN
dti-1419	103	17	at	at	ADP
dti-1419	103	18	each	each	DET
dti-1419	103	19	site	site	NOUN
dti-1419	103	20	using	use	VERB
dti-1419	103	21	tools	tool	NOUN
dti-1419	103	22	validated	validate	VERB
dti-1419	103	23	for	for	ADP
dti-1419	103	24	use	use	NOUN
dti-1419	103	25	in	in	ADP
dti-1419	103	26	pku.18	pku.18	ADJ
dti-1419	103	27	prism-1	prism-1	PROPN
dti-1419	103	28	included	include	VERB
dti-1419	103	29	261	261	NUM
dti-1419	103	30	patients	patient	NOUN
dti-1419	103	31	:	:	PUNCT
dti-1419	103	32	131	131	NUM
dti-1419	103	33	in	in	ADP
dti-1419	103	34	the	the	DET
dti-1419	103	35	20	20	NUM
dti-1419	103	36	mg	mg	PROPN
dti-1419	103	37	/	/	SYM
dti-1419	103	38	d	d	PROPN
dti-1419	103	39	group	group	NOUN
dti-1419	103	40	and	and	CCONJ
dti-1419	103	41	130	130	NUM
dti-1419	103	42	in	in	ADP
dti-1419	103	43	the	the	DET
dti-1419	103	44	40	40	NUM
dti-1419	103	45	mg	mg	PROPN
dti-1419	103	46	/	/	SYM
dti-1419	103	47	d	d	PROPN
dti-1419	103	48	group	group	NOUN
dti-1419	103	49	.	.	PUNCT
dti-1419	104	1	patients	patient	NOUN
dti-1419	104	2	had	have	VERB
dti-1419	104	3	a	a	DET
dti-1419	104	4	mean	mean	ADJ
dti-1419	104	5	age	age	NOUN
dti-1419	104	6	of	of	ADP
dti-1419	104	7	approximately	approximately	ADV
dti-1419	104	8	30	30	NUM
dti-1419	104	9	years	year	NOUN
dti-1419	104	10	at	at	ADP
dti-1419	104	11	baseline	baseline	NOUN
dti-1419	104	12	and	and	CCONJ
dti-1419	104	13	were	be	AUX
dti-1419	104	14	mostly	mostly	ADV
dti-1419	104	15	white	white	ADJ
dti-1419	104	16	,	,	PUNCT
dti-1419	104	17	and	and	CCONJ
dti-1419	104	18	approximately	approximately	ADV
dti-1419	104	19	half	half	NOUN
dti-1419	104	20	of	of	ADP
dti-1419	104	21	them	they	PRON
dti-1419	104	22	were	be	AUX
dti-1419	104	23	women	woman	NOUN
dti-1419	104	24	.	.	PUNCT
dti-1419	105	1	mean	mean	VERB
dti-1419	105	2	phenylalanine	phenylalanine	ADJ
dti-1419	105	3	levels	level	NOUN
dti-1419	105	4	at	at	ADP
dti-1419	105	5	baseline	baseline	PROPN
dti-1419	105	6	were	be	AUX
dti-1419	105	7	1232.7	1232.7	NUM
dti-1419	105	8	µmol	µmol	ADV
dti-1419	105	9	/	/	SYM
dti-1419	105	10	l.	l.	NOUN
dti-1419	105	11	the	the	DET
dti-1419	105	12	mean	mean	ADJ
dti-1419	105	13	number	number	NOUN
dti-1419	105	14	of	of	ADP
dti-1419	105	15	weeks	week	NOUN
dti-1419	105	16	to	to	PART
dti-1419	105	17	reach	reach	VERB
dti-1419	105	18	maintenance	maintenance	NOUN
dti-1419	105	19	doses	dose	NOUN
dti-1419	105	20	was	be	AUX
dti-1419	105	21	11.5	11.5	NUM
dti-1419	105	22	and	and	CCONJ
dti-1419	105	23	14	14	NUM
dti-1419	105	24	in	in	ADP
dti-1419	105	25	the	the	DET
dti-1419	105	26	20	20	NUM
dti-1419	105	27	mg	mg	PROPN
dti-1419	105	28	/	/	SYM
dti-1419	105	29	d	d	PROPN
dti-1419	105	30	and	and	CCONJ
dti-1419	105	31	40	40	NUM
dti-1419	105	32	mg	mg	NUM
dti-1419	105	33	/	/	SYM
dti-1419	105	34	d	d	NOUN
dti-1419	105	35	groups	group	NOUN
dti-1419	105	36	,	,	PUNCT
dti-1419	105	37	respectively.18	respectively.18	X
dti-1419	105	38	mean	mean	VERB
dti-1419	105	39	phenylalanine	phenylalanine	NOUN
dti-1419	105	40	concentrations	concentration	NOUN
dti-1419	105	41	decreased	decrease	VERB
dti-1419	105	42	by	by	ADP
dti-1419	105	43	51.1	51.1	NUM
dti-1419	105	44	%	%	NOUN
dti-1419	105	45	from	from	ADP
dti-1419	105	46	baseline	baseline	NOUN
dti-1419	105	47	to	to	ADP
dti-1419	105	48	564.5	564.5	NUM
dti-1419	105	49	µmol	µmol	NOUN
dti-1419	105	50	/	/	SYM
dti-1419	105	51	l	l	NOUN
dti-1419	105	52	at	at	ADP
dti-1419	105	53	12	12	NUM
dti-1419	105	54	months	month	NOUN
dti-1419	105	55	of	of	ADP
dti-1419	105	56	follow	follow	NOUN
dti-1419	105	57	-	-	PUNCT
dti-1419	105	58	up	up	NOUN
dti-1419	105	59	,	,	PUNCT
dti-1419	105	60	and	and	CCONJ
dti-1419	105	61	by	by	ADP
dti-1419	105	62	68.7	68.7	NUM
dti-1419	105	63	%	%	NOUN
dti-1419	105	64	from	from	ADP
dti-1419	105	65	baseline	baseline	NOUN
dti-1419	105	66	to	to	ADP
dti-1419	105	67	311.4	311.4	NUM
dti-1419	105	68	µmol	µmol	NOUN
dti-1419	105	69	/	/	SYM
dti-1419	105	70	l	l	NOUN
dti-1419	105	71	at	at	ADP
dti-1419	105	72	24	24	NUM
dti-1419	105	73	months	month	NOUN
dti-1419	105	74	of	of	ADP
dti-1419	105	75	follow	follow	NOUN
dti-1419	105	76	-	-	PUNCT
dti-1419	105	77	up	up	NOUN
dti-1419	105	78	.	.	PUNCT
dti-1419	106	1	inattention	inattention	NOUN
dti-1419	106	2	and	and	CCONJ
dti-1419	106	3	mood	mood	NOUN
dti-1419	106	4	scores	score	NOUN
dti-1419	106	5	improved	improve	VERB
dti-1419	106	6	while	while	SCONJ
dti-1419	106	7	on	on	ADP
dti-1419	106	8	treatment	treatment	NOUN
dti-1419	106	9	with	with	ADP
dti-1419	106	10	pegvaliase	pegvaliase	NOUN
dti-1419	106	11	and	and	CCONJ
dti-1419	106	12	correlated	correlate	VERB
dti-1419	106	13	with	with	ADP
dti-1419	106	14	a	a	DET
dti-1419	106	15	decrease	decrease	NOUN
dti-1419	106	16	in	in	ADP
dti-1419	106	17	phenylalanine	phenylalanine	ADJ
dti-1419	106	18	levels	level	NOUN
dti-1419	106	19	.	.	PUNCT
dti-1419	107	1	similar	similar	ADJ
dti-1419	107	2	to	to	ADP
dti-1419	107	3	previous	previous	ADJ
dti-1419	107	4	studies	study	NOUN
dti-1419	107	5	,	,	PUNCT
dti-1419	107	6	all	all	DET
dti-1419	107	7	patients	patient	NOUN
dti-1419	107	8	experienced	experience	VERB
dti-1419	107	9	at	at	ADV
dti-1419	107	10	least	least	ADV
dti-1419	107	11	1	1	NUM
dti-1419	107	12	ae	ae	PROPN
dti-1419	107	13	.	.	PUNCT
dti-1419	108	1	however	however	ADV
dti-1419	108	2	,	,	PUNCT
dti-1419	108	3	in	in	ADP
dti-1419	108	4	this	this	DET
dti-1419	108	5	study	study	NOUN
dti-1419	108	6	,	,	PUNCT
dti-1419	108	7	99	99	NUM
dti-1419	108	8	%	%	NOUN
dti-1419	108	9	of	of	ADP
dti-1419	108	10	events	event	NOUN
dti-1419	108	11	were	be	AUX
dti-1419	108	12	mild	mild	ADJ
dti-1419	108	13	to	to	PART
dti-1419	108	14	moderate	moderate	VERB
dti-1419	108	15	in	in	ADP
dti-1419	108	16	nature	nature	NOUN
dti-1419	108	17	,	,	PUNCT
dti-1419	108	18	and	and	CCONJ
dti-1419	108	19	96	96	NUM
dti-1419	108	20	%	%	NOUN
dti-1419	108	21	resolved	resolve	VERB
dti-1419	108	22	without	without	ADP
dti-1419	108	23	dose	dose	NOUN
dti-1419	108	24	reduction	reduction	NOUN
dti-1419	108	25	or	or	CCONJ
dti-1419	108	26	interruption	interruption	NOUN
dti-1419	108	27	.	.	PUNCT
dti-1419	109	1	this	this	PRON
dti-1419	109	2	represents	represent	VERB
dti-1419	109	3	an	an	DET
dti-1419	109	4	improvement	improvement	NOUN
dti-1419	109	5	in	in	ADP
dti-1419	109	6	the	the	DET
dti-1419	109	7	safety	safety	NOUN
dti-1419	109	8	profile	profile	NOUN
dti-1419	109	9	compared	compare	VERB
dti-1419	109	10	with	with	ADP
dti-1419	109	11	previous	previous	ADJ
dti-1419	109	12	regimens	regimen	NOUN
dti-1419	109	13	studied	study	VERB
dti-1419	109	14	.	.	PUNCT
dti-1419	110	1	the	the	DET
dti-1419	110	2	most	most	ADV
dti-1419	110	3	common	common	ADJ
dti-1419	110	4	aes	aes	PROPN
dti-1419	110	5	were	be	AUX
dti-1419	110	6	arthralgia	arthralgia	NOUN
dti-1419	110	7	(	(	PUNCT
dti-1419	110	8	70.5	70.5	NUM
dti-1419	110	9	%	%	NOUN
dti-1419	110	10	)	)	PUNCT
dti-1419	110	11	,	,	PUNCT
dti-1419	110	12	injection	injection	NOUN
dti-1419	110	13	site	site	NOUN
dti-1419	110	14	reactions	reaction	NOUN
dti-1419	110	15	(	(	PUNCT
dti-1419	110	16	62.1	62.1	NUM
dti-1419	110	17	%	%	NOUN
dti-1419	110	18	)	)	PUNCT
dti-1419	110	19	,	,	PUNCT
dti-1419	110	20	injection	injection	NOUN
dti-1419	110	21	site	site	NOUN
dti-1419	110	22	erythema	erythema	NOUN
dti-1419	110	23	(	(	PUNCT
dti-1419	110	24	47.9	47.9	NUM
dti-1419	110	25	%	%	NOUN
dti-1419	110	26	)	)	PUNCT
dti-1419	110	27	,	,	PUNCT
dti-1419	110	28	and	and	CCONJ
dti-1419	110	29	headache	headache	NOUN
dti-1419	110	30	(	(	PUNCT
dti-1419	110	31	47.1	47.1	NUM
dti-1419	110	32	%	%	NOUN
dti-1419	110	33	)	)	PUNCT
dti-1419	110	34	.	.	PUNCT
dti-1419	111	1	of	of	ADP
dti-1419	111	2	the	the	DET
dti-1419	111	3	aes	aes	NOUN
dti-1419	111	4	leading	lead	VERB
dti-1419	111	5	to	to	ADP
dti-1419	111	6	discontinuation	discontinuation	NOUN
dti-1419	111	7	,	,	PUNCT
dti-1419	111	8	2.7	2.7	NUM
dti-1419	111	9	%	%	NOUN
dti-1419	111	10	were	be	AUX
dti-1419	111	11	anaphylaxis	anaphylaxis	ADJ
dti-1419	111	12	,	,	PUNCT
dti-1419	111	13	2.7	2.7	NUM
dti-1419	111	14	%	%	NOUN
dti-1419	111	15	were	be	AUX
dti-1419	111	16	arthralgia	arthralgia	NOUN
dti-1419	111	17	,	,	PUNCT
dti-1419	111	18	1.1	1.1	NUM
dti-1419	111	19	%	%	NOUN
dti-1419	111	20	were	be	AUX
dti-1419	111	21	injection	injection	NOUN
dti-1419	111	22	site	site	NOUN
dti-1419	111	23	reactions	reaction	NOUN
dti-1419	111	24	,	,	PUNCT
dti-1419	111	25	and	and	CCONJ
dti-1419	111	26	0.8	0.8	NUM
dti-1419	111	27	%	%	NOUN
dti-1419	111	28	were	be	AUX
dti-1419	111	29	generalized	generalized	ADJ
dti-1419	111	30	rash	rash	NOUN
dti-1419	111	31	.	.	PUNCT
dti-1419	112	1	twelve	twelve	NUM
dti-1419	112	2	patients	patient	NOUN
dti-1419	112	3	(	(	PUNCT
dti-1419	112	4	4.6	4.6	NUM
dti-1419	112	5	%	%	NOUN
dti-1419	112	6	)	)	PUNCT
dti-1419	112	7	experienced	experience	VERB
dti-1419	112	8	1	1	NUM
dti-1419	112	9	or	or	CCONJ
dti-1419	112	10	more	more	ADV
dti-1419	112	11	acute	acute	ADJ
dti-1419	112	12	systemic	systemic	ADJ
dti-1419	112	13	haes	haes	NOUN
dti-1419	112	14	which	which	PRON
dti-1419	112	15	were	be	AUX
dti-1419	112	16	independently	independently	ADV
dti-1419	112	17	adjudicated	adjudicate	VERB
dti-1419	112	18	by	by	ADP
dti-1419	112	19	an	an	DET
dti-1419	112	20	allergist	allergist	NOUN
dti-1419	112	21	/	/	SYM
dti-1419	112	22	immunologist	immunologist	NOUN
dti-1419	112	23	.	.	PUNCT
dti-1419	113	1	the	the	DET
dti-1419	113	2	median	median	ADJ
dti-1419	113	3	time	time	NOUN
dti-1419	113	4	after	after	SCONJ
dti-1419	113	5	pegvaliase	pegvaliase	PROPN
dti-1419	113	6	administration	administration	PROPN
dti-1419	113	7	to	to	PART
dti-1419	113	8	acute	acute	VERB
dti-1419	113	9	systemic	systemic	ADJ
dti-1419	113	10	hae	hae	NOUN
dti-1419	113	11	was	be	AUX
dti-1419	113	12	1.8	1.8	NUM
dti-1419	113	13	minutes	minute	NOUN
dti-1419	113	14	,	,	PUNCT
dti-1419	113	15	and	and	CCONJ
dti-1419	113	16	all	all	PRON
dti-1419	113	17	occurred	occur	VERB
dti-1419	113	18	within	within	ADP
dti-1419	113	19	the	the	DET
dti-1419	113	20	first	first	ADJ
dti-1419	113	21	50	50	NUM
dti-1419	113	22	days	day	NOUN
dti-1419	113	23	of	of	ADP
dti-1419	113	24	dosing	dosing	NOUN
dti-1419	113	25	and	and	CCONJ
dti-1419	113	26	were	be	AUX
dti-1419	113	27	resolved	resolve	VERB
dti-1419	113	28	quickly.18	quickly.18	ADJ
dti-1419	113	29	patients	patient	NOUN
dti-1419	113	30	enrolled	enrol	VERB
dti-1419	113	31	in	in	ADP
dti-1419	113	32	prism-1	prism-1	PROPN
dti-1419	113	33	could	could	AUX
dti-1419	113	34	continue	continue	VERB
dti-1419	113	35	to	to	ADP
dti-1419	113	36	prism-2	prism-2	NUM
dti-1419	113	37	(	(	PUNCT
dti-1419	113	38	nct01889862	nct01889862	ADV
dti-1419	113	39	)	)	PUNCT
dti-1419	113	40	,	,	PUNCT
dti-1419	113	41	a	a	DET
dti-1419	113	42	study	study	NOUN
dti-1419	113	43	to	to	PART
dti-1419	113	44	evaluate	evaluate	VERB
dti-1419	113	45	the	the	DET
dti-1419	113	46	safety	safety	NOUN
dti-1419	113	47	and	and	CCONJ
dti-1419	113	48	efficacy	efficacy	NOUN
dti-1419	113	49	of	of	ADP
dti-1419	113	50	long	long	ADJ
dti-1419	113	51	-	-	PUNCT
dti-1419	113	52	term	term	NOUN
dti-1419	113	53	treatment	treatment	NOUN
dti-1419	113	54	.	.	PUNCT
dti-1419	114	1	patients	patient	NOUN
dti-1419	114	2	reaching	reach	VERB
dti-1419	114	3	maintenance	maintenance	NOUN
dti-1419	114	4	dosing	dose	VERB
dti-1419	114	5	in	in	ADP
dti-1419	114	6	prism-1	prism-1	PROPN
dti-1419	114	7	entered	enter	VERB
dti-1419	114	8	part	part	NOUN
dti-1419	114	9	1	1	NUM
dti-1419	114	10	of	of	ADP
dti-1419	114	11	prism-2	prism-2	NOUN
dti-1419	114	12	,	,	PUNCT
dti-1419	114	13	and	and	CCONJ
dti-1419	114	14	continued	continue	VERB
dti-1419	114	15	their	their	PRON
dti-1419	114	16	assigned	assign	VERB
dti-1419	114	17	doses	dose	NOUN
dti-1419	114	18	,	,	PUNCT
dti-1419	114	19	either	either	CCONJ
dti-1419	114	20	20	20	NUM
dti-1419	114	21	mg	mg	NOUN
dti-1419	114	22	or	or	CCONJ
dti-1419	114	23	40	40	NUM
dti-1419	114	24	mg	mg	NOUN
dti-1419	114	25	daily	daily	ADV
dti-1419	114	26	.	.	PUNCT
dti-1419	115	1	part	part	NOUN
dti-1419	115	2	2	2	NUM
dti-1419	115	3	was	be	AUX
dti-1419	115	4	a	a	DET
dti-1419	115	5	randomized	randomized	ADJ
dti-1419	115	6	,	,	PUNCT
dti-1419	115	7	double	double	ADJ
dti-1419	115	8	-	-	PUNCT
dti-1419	115	9	blinded	blind	VERB
dti-1419	115	10	,	,	PUNCT
dti-1419	115	11	placebo	placebo	NOUN
dti-1419	115	12	-	-	PUNCT
dti-1419	115	13	controlled	control	VERB
dti-1419	115	14	discontinuation	discontinuation	NOUN
dti-1419	115	15	study	study	NOUN
dti-1419	115	16	which	which	PRON
dti-1419	115	17	will	will	AUX
dti-1419	115	18	be	be	AUX
dti-1419	115	19	described	describe	VERB
dti-1419	115	20	below	below	ADV
dti-1419	115	21	.	.	PUNCT
dti-1419	116	1	part	part	NOUN
dti-1419	116	2	3	3	NUM
dti-1419	116	3	was	be	AUX
dti-1419	116	4	an	an	DET
dti-1419	116	5	open	open	ADJ
dti-1419	116	6	-	-	PUNCT
dti-1419	116	7	label	label	NOUN
dti-1419	116	8	pharmacodynamics	pharmacodynamic	NOUN
dti-1419	116	9	and	and	CCONJ
dti-1419	116	10	pharmacokinetic	pharmacokinetic	ADJ
dti-1419	116	11	study	study	NOUN
dti-1419	116	12	,	,	PUNCT
dti-1419	116	13	and	and	CCONJ
dti-1419	116	14	part	part	NOUN
dti-1419	116	15	4	4	NUM
dti-1419	116	16	is	be	AUX
dti-1419	116	17	an	an	DET
dti-1419	116	18	open	open	ADJ
dti-1419	116	19	-	-	PUNCT
dti-1419	116	20	label	label	NOUN
dti-1419	116	21	extension	extension	NOUN
dti-1419	116	22	study	study	NOUN
dti-1419	116	23	which	which	PRON
dti-1419	116	24	is	be	AUX
dti-1419	116	25	ongoing	ongoing	ADJ
dti-1419	116	26	.	.	PUNCT
dti-1419	117	1	patients	patient	NOUN
dti-1419	117	2	who	who	PRON
dti-1419	117	3	did	do	AUX
dti-1419	117	4	not	not	PART
dti-1419	117	5	reach	reach	VERB
dti-1419	117	6	maintenance	maintenance	NOUN
dti-1419	117	7	dosing	dose	VERB
dti-1419	117	8	in	in	ADP
dti-1419	117	9	prism-1	prism-1	PROPN
dti-1419	117	10	could	could	AUX
dti-1419	117	11	enter	enter	VERB
dti-1419	117	12	directly	directly	ADV
dti-1419	117	13	in	in	ADP
dti-1419	117	14	to	to	PART
dti-1419	117	15	part	part	NOUN
dti-1419	117	16	4	4	NUM
dti-1419	117	17	of	of	ADP
dti-1419	117	18	prism-2	prism-2	NOUN
dti-1419	117	19	,	,	PUNCT
dti-1419	117	20	in	in	ADP
dti-1419	117	21	which	which	PRON
dti-1419	117	22	the	the	DET
dti-1419	117	23	open	open	ADJ
dti-1419	117	24	-	-	PUNCT
dti-1419	117	25	label	label	NOUN
dti-1419	117	26	dosing	dosing	NOUN
dti-1419	117	27	ranges	range	NOUN
dti-1419	117	28	from	from	ADP
dti-1419	117	29	5	5	NUM
dti-1419	117	30	to	to	PART
dti-1419	117	31	60	60	NUM
dti-1419	117	32	mg	mg	NOUN
dti-1419	117	33	daily.18	daily.18	VERB
dti-1419	117	34	eighty	eighty	NUM
dti-1419	117	35	-	-	PUNCT
dti-1419	117	36	six	six	NUM
dti-1419	117	37	patients	patient	NOUN
dti-1419	117	38	who	who	PRON
dti-1419	117	39	received	receive	VERB
dti-1419	117	40	pegvaliase	pegvaliase	NOUN
dti-1419	117	41	in	in	ADP
dti-1419	117	42	prism-2	prism-2	NUM
dti-1419	117	43	part	part	NOUN
dti-1419	117	44	1	1	NUM
dti-1419	117	45	enrolled	enrol	VERB
dti-1419	117	46	in	in	ADP
dti-1419	117	47	the	the	DET
dti-1419	117	48	double	double	ADJ
dti-1419	117	49	-	-	PUNCT
dti-1419	117	50	blinded	blind	VERB
dti-1419	117	51	prism-2	prism-2	NUM
dti-1419	117	52	part	part	NOUN
dti-1419	117	53	2	2	NUM
dti-1419	117	54	discontinuation	discontinuation	NOUN
dti-1419	117	55	trial	trial	NOUN
dti-1419	117	56	.	.	PUNCT
dti-1419	118	1	an	an	DET
dti-1419	118	2	additional	additional	ADJ
dti-1419	118	3	9	9	NUM
dti-1419	118	4	patients	patient	NOUN
dti-1419	118	5	were	be	AUX
dti-1419	118	6	enrolled	enrol	VERB
dti-1419	118	7	but	but	CCONJ
dti-1419	118	8	were	be	AUX
dti-1419	118	9	not	not	PART
dti-1419	118	10	included	include	VERB
dti-1419	118	11	in	in	ADP
dti-1419	118	12	the	the	DET
dti-1419	118	13	efficacy	efficacy	NOUN
dti-1419	118	14	analysis	analysis	NOUN
dti-1419	118	15	.	.	PUNCT
dti-1419	119	1	patients	patient	NOUN
dti-1419	119	2	were	be	AUX
dti-1419	119	3	randomized	randomize	VERB
dti-1419	119	4	via	via	ADP
dti-1419	119	5	concealed	conceal	VERB
dti-1419	119	6	allocation	allocation	NOUN
dti-1419	119	7	to	to	PART
dti-1419	119	8	receive	receive	VERB
dti-1419	119	9	either	either	CCONJ
dti-1419	119	10	their	their	PRON
dti-1419	119	11	current	current	ADJ
dti-1419	119	12	pegvaliase	pegvaliase	NOUN
dti-1419	119	13	dose	dose	PROPN
dti-1419	119	14	(	(	PUNCT
dti-1419	119	15	either	either	CCONJ
dti-1419	119	16	20	20	NUM
dti-1419	119	17	or	or	CCONJ
dti-1419	119	18	40	40	NUM
dti-1419	119	19	mg	mg	NUM
dti-1419	119	20	/	/	SYM
dti-1419	119	21	d	d	NOUN
dti-1419	119	22	)	)	PUNCT
dti-1419	119	23	or	or	CCONJ
dti-1419	119	24	matched	match	VERB
dti-1419	119	25	placebo	placebo	NOUN
dti-1419	119	26	containing	contain	VERB
dti-1419	119	27	either	either	CCONJ
dti-1419	119	28	20	20	NUM
dti-1419	119	29	mg	mg	NOUN
dti-1419	119	30	or	or	CCONJ
dti-1419	119	31	40	40	NUM
dti-1419	119	32	mg	mg	NOUN
dti-1419	119	33	of	of	ADP
dti-1419	119	34	dextran	dextran	NOUN
dti-1419	119	35	40	40	NUM
dti-1419	119	36	(	(	PUNCT
dti-1419	119	37	22	22	NUM
dti-1419	119	38	%	%	NOUN
dti-1419	119	39	dextran	dextran	NOUN
dti-1419	119	40	40	40	NUM
dti-1419	119	41	)	)	PUNCT
dti-1419	119	42	.	.	PUNCT
dti-1419	120	1	the	the	DET
dti-1419	120	2	study	study	NOUN
dti-1419	120	3	drugs	drug	NOUN
dti-1419	120	4	were	be	AUX
dti-1419	120	5	self	self	NOUN
dti-1419	120	6	-	-	PUNCT
dti-1419	120	7	administered	administer	VERB
dti-1419	120	8	daily	daily	ADV
dti-1419	120	9	for	for	ADP
dti-1419	120	10	8	8	NUM
dti-1419	120	11	weeks	week	NOUN
dti-1419	120	12	,	,	PUNCT
dti-1419	120	13	rotating	rotate	VERB
dti-1419	120	14	subcutaneous	subcutaneous	ADJ
dti-1419	120	15	injection	injection	NOUN
dti-1419	120	16	sites.19	sites.19	NOUN
dti-1419	120	17	the	the	DET
dti-1419	120	18	pooled	pooled	ADJ
dti-1419	120	19	active	active	ADJ
dti-1419	120	20	pegvaliase	pegvaliase	PROPN
dti-1419	120	21	group	group	NOUN
dti-1419	120	22	phenylalanine	phenylalanine	NOUN
dti-1419	120	23	concentrations	concentration	NOUN
dti-1419	120	24	remained	remain	VERB
dti-1419	120	25	stable	stable	ADJ
dti-1419	120	26	from	from	ADP
dti-1419	120	27	baseline	baseline	NOUN
dti-1419	120	28	to	to	ADP
dti-1419	120	29	week	week	NOUN
dti-1419	120	30	8	8	NUM
dti-1419	120	31	(	(	PUNCT
dti-1419	120	32	503.9559	503.9559	NUM
dti-1419	120	33	µmol	µmol	NOUN
dti-1419	120	34	/	/	SYM
dti-1419	120	35	l	l	NOUN
dti-1419	120	36	)	)	PUNCT
dti-1419	120	37	,	,	PUNCT
dti-1419	120	38	while	while	SCONJ
dti-1419	120	39	levels	level	NOUN
dti-1419	120	40	in	in	ADP
dti-1419	120	41	both	both	DET
dti-1419	120	42	placebo	placebo	NOUN
dti-1419	120	43	groups	group	NOUN
dti-1419	120	44	increased	increase	VERB
dti-1419	120	45	(	(	PUNCT
dti-1419	120	46	563.9	563.9	NUM
dti-1419	120	47	-	-	PUNCT
dti-1419	120	48	1509	1509	NUM
dti-1419	120	49	µmol	µmol	NOUN
dti-1419	120	50	/	/	SYM
dti-1419	120	51	l	l	NOUN
dti-1419	120	52	in	in	ADP
dti-1419	120	53	the	the	DET
dti-1419	120	54	placebo	placebo	NOUN
dti-1419	120	55	20	20	NUM
dti-1419	120	56	mg	mg	PROPN
dti-1419	120	57	group	group	NOUN
dti-1419	120	58	and	and	CCONJ
dti-1419	120	59	508.21164.4	508.21164.4	NUM
dti-1419	120	60	µmol	µmol	NOUN
dti-1419	120	61	/	/	SYM
dti-1419	120	62	l	l	NOUN
dti-1419	120	63	in	in	ADP
dti-1419	120	64	the	the	DET
dti-1419	120	65	placebo	placebo	NOUN
dti-1419	120	66	40	40	NUM
dti-1419	120	67	mg	mg	PROPN
dti-1419	120	68	group	group	NOUN
dti-1419	120	69	)	)	PUNCT
dti-1419	120	70	.	.	PUNCT
dti-1419	121	1	however	however	ADV
dti-1419	121	2	,	,	PUNCT
dti-1419	121	3	no	no	DET
dti-1419	121	4	significant	significant	ADJ
dti-1419	121	5	changes	change	NOUN
dti-1419	121	6	in	in	ADP
dti-1419	121	7	mood	mood	NOUN
dti-1419	121	8	or	or	CCONJ
dti-1419	121	9	inattention	inattention	NOUN
dti-1419	121	10	were	be	AUX
dti-1419	121	11	observed	observe	VERB
dti-1419	121	12	,	,	PUNCT
dti-1419	121	13	perhaps	perhaps	ADV
dti-1419	121	14	due	due	ADP
dti-1419	121	15	to	to	ADP
dti-1419	121	16	the	the	DET
dti-1419	121	17	short	short	ADJ
dti-1419	121	18	duration	duration	NOUN
dti-1419	121	19	of	of	ADP
dti-1419	121	20	the	the	DET
dti-1419	121	21	trial	trial	NOUN
dti-1419	121	22	or	or	CCONJ
dti-1419	121	23	to	to	ADP
dti-1419	121	24	the	the	DET
dti-1419	121	25	tools	tool	NOUN
dti-1419	121	26	used	use	VERB
dti-1419	121	27	to	to	PART
dti-1419	121	28	measure	measure	VERB
dti-1419	121	29	these	these	DET
dti-1419	121	30	symptoms	symptom	NOUN
dti-1419	121	31	in	in	ADP
dti-1419	121	32	the	the	DET
dti-1419	121	33	trial.19	trial.19	ADJ
dti-1419	121	34	patients	patient	NOUN
dti-1419	121	35	in	in	ADP
dti-1419	121	36	prism-1	prism-1	PROPN
dti-1419	121	37	demonstrated	demonstrate	VERB
dti-1419	121	38	improvements	improvement	NOUN
dti-1419	121	39	in	in	ADP
dti-1419	121	40	attention	attention	NOUN
dti-1419	121	41	deficit	deficit	NOUN
dti-1419	121	42	hyperactivity	hyperactivity	NOUN
dti-1419	121	43	disorder	disorder	NOUN
dti-1419	121	44	(	(	PUNCT
dti-1419	121	45	adhd	adhd	NOUN
dti-1419	121	46	)	)	PUNCT
dti-1419	121	47	scores	score	NOUN
dti-1419	121	48	at	at	ADP
dti-1419	121	49	3	3	NUM
dti-1419	121	50	months	month	NOUN
dti-1419	121	51	of	of	ADP
dti-1419	121	52	treatment.16	treatment.16	PROPN
dti-1419	121	53	overall	overall	ADJ
dti-1419	121	54	,	,	PUNCT
dti-1419	121	55	clinical	clinical	ADJ
dti-1419	121	56	trial	trial	NOUN
dti-1419	121	57	experience	experience	NOUN
dti-1419	121	58	from	from	ADP
dti-1419	121	59	phase	phase	NOUN
dti-1419	121	60	1	1	NUM
dti-1419	121	61	to	to	PART
dti-1419	121	62	phase	phase	NOUN
dti-1419	121	63	3	3	NUM
dti-1419	121	64	suggests	suggest	VERB
dti-1419	121	65	substantial	substantial	ADJ
dti-1419	121	66	reductions	reduction	NOUN
dti-1419	121	67	in	in	ADP
dti-1419	121	68	blood	blood	NOUN
dti-1419	121	69	phenylalanine	phenylalanine	NOUN
dti-1419	121	70	concentrations	concentration	NOUN
dti-1419	121	71	and	and	CCONJ
dti-1419	121	72	improvement	improvement	NOUN
dti-1419	121	73	in	in	ADP
dti-1419	121	74	inattention	inattention	NOUN
dti-1419	121	75	and	and	CCONJ
dti-1419	121	76	mood	mood	NOUN
dti-1419	121	77	symptoms	symptom	NOUN
dti-1419	121	78	with	with	ADP
dti-1419	121	79	the	the	DET
dti-1419	121	80	use	use	NOUN
dti-1419	121	81	of	of	ADP
dti-1419	121	82	pegvaliase	pegvaliase	NOUN
dti-1419	121	83	.	.	PUNCT
dti-1419	122	1	however	however	ADV
dti-1419	122	2	,	,	PUNCT
dti-1419	122	3	these	these	DET
dti-1419	122	4	benefits	benefit	NOUN
dti-1419	122	5	must	must	AUX
dti-1419	122	6	be	be	AUX
dti-1419	122	7	weighed	weigh	VERB
dti-1419	122	8	against	against	ADP
dti-1419	122	9	the	the	DET
dti-1419	122	10	risk	risk	NOUN
dti-1419	122	11	of	of	ADP
dti-1419	122	12	common	common	ADJ
dti-1419	122	13	and	and	CCONJ
dti-1419	122	14	sometimes	sometimes	ADV
dti-1419	122	15	serious	serious	ADJ
dti-1419	122	16	aes	aes	PROPN
dti-1419	122	17	.	.	PUNCT
dti-1419	123	1	dosing	dosing	NOUN
dti-1419	123	2	and	and	CCONJ
dti-1419	123	3	administration	administration	NOUN
dti-1419	123	4	the	the	DET
dti-1419	123	5	package	package	NOUN
dti-1419	123	6	insert	insert	NOUN
dti-1419	123	7	for	for	ADP
dti-1419	123	8	palynziq	palynziq	ADJ
dti-1419	123	9	recommends	recommend	NOUN
dti-1419	123	10	to	to	PART
dti-1419	123	11	obtain	obtain	VERB
dti-1419	123	12	baseline	baseline	ADJ
dti-1419	123	13	blood	blood	NOUN
dti-1419	123	14	phenylalanine	phenylalanine	NOUN
dti-1419	123	15	concentrations	concentration	NOUN
dti-1419	123	16	prior	prior	ADV
dti-1419	123	17	to	to	ADP
dti-1419	123	18	treatment	treatment	NOUN
dti-1419	123	19	initiation.11	initiation.11	ADP
dti-1419	123	20	the	the	DET
dti-1419	123	21	induction	induction	NOUN
dti-1419	123	22	dosage	dosage	NOUN
dti-1419	123	23	for	for	ADP
dti-1419	123	24	pegvaliase	pegvaliase	NOUN
dti-1419	123	25	is	be	AUX
dti-1419	123	26	2.5	2.5	NUM
dti-1419	123	27	mg	mg	NOUN
dti-1419	123	28	subcutaneously	subcutaneously	ADV
dti-1419	123	29	once	once	ADV
dti-1419	123	30	weekly	weekly	ADJ
dti-1419	123	31	for	for	ADP
dti-1419	123	32	4	4	NUM
dti-1419	123	33	weeks	week	NOUN
dti-1419	123	34	under	under	ADP
dti-1419	123	35	the	the	DET
dti-1419	123	36	supervision	supervision	NOUN
dti-1419	123	37	of	of	ADP
dti-1419	123	38	a	a	DET
dti-1419	123	39	health	health	NOUN
dti-1419	123	40	care	care	NOUN
dti-1419	123	41	provider	provider	NOUN
dti-1419	123	42	.	.	PUNCT
dti-1419	124	1	the	the	DET
dti-1419	124	2	dosage	dosage	NOUN
dti-1419	124	3	should	should	AUX
dti-1419	124	4	be	be	AUX
dti-1419	124	5	titrated	titrate	VERB
dti-1419	124	6	based	base	VERB
dti-1419	124	7	on	on	ADP
dti-1419	124	8	tolerability	tolerability	NOUN
dti-1419	124	9	over	over	ADP
dti-1419	124	10	at	at	ADV
dti-1419	124	11	least	least	ADV
dti-1419	124	12	5	5	NUM
dti-1419	124	13	weeks	week	NOUN
dti-1419	124	14	to	to	PART
dti-1419	124	15	achieve	achieve	VERB
dti-1419	124	16	a	a	DET
dti-1419	124	17	dosage	dosage	NOUN
dti-1419	124	18	of	of	ADP
dti-1419	124	19	20	20	NUM
dti-1419	124	20	mg	mg	NOUN
dti-1419	124	21	subcutaneously	subcutaneously	ADV
dti-1419	124	22	once	once	ADV
dti-1419	124	23	daily	daily	ADV
dti-1419	124	24	.	.	PUNCT
dti-1419	125	1	therapeutic	therapeutic	ADJ
dti-1419	125	2	response	response	NOUN
dti-1419	125	3	may	may	AUX
dti-1419	125	4	not	not	PART
dti-1419	125	5	be	be	AUX
dti-1419	125	6	achieved	achieve	VERB
dti-1419	125	7	until	until	SCONJ
dti-1419	125	8	the	the	DET
dti-1419	125	9	patient	patient	NOUN
dti-1419	125	10	is	be	AUX
dti-1419	125	11	titrated	titrate	VERB
dti-1419	125	12	to	to	ADP
dti-1419	125	13	an	an	DET
dti-1419	125	14	effective	effective	ADJ
dti-1419	125	15	maintenance	maintenance	NOUN
dti-1419	125	16	dose	dose	NOUN
dti-1419	125	17	.	.	PUNCT
dti-1419	126	1	during	during	ADP
dti-1419	126	2	treatment	treatment	NOUN
dti-1419	126	3	,	,	PUNCT
dti-1419	126	4	patient	patient	ADJ
dti-1419	126	5	tolerability	tolerability	NOUN
dti-1419	126	6	,	,	PUNCT
dti-1419	126	7	blood	blood	NOUN
dti-1419	126	8	phenylalanine	phenylalanine	NOUN
dti-1419	126	9	concentrations	concentration	NOUN
dti-1419	126	10	,	,	PUNCT
dti-1419	126	11	dietary	dietary	ADJ
dti-1419	126	12	protein	protein	NOUN
dti-1419	126	13	,	,	PUNCT
dti-1419	126	14	and	and	CCONJ
dti-1419	126	15	phenylalanine	phenylalanine	NOUN
dti-1419	126	16	intake	intake	NOUN
dti-1419	126	17	should	should	AUX
dti-1419	126	18	be	be	AUX
dti-1419	126	19	monitored	monitor	VERB
dti-1419	126	20	.	.	PUNCT
dti-1419	127	1	studies	study	NOUN
dti-1419	127	2	in	in	ADP
dti-1419	127	3	adult	adult	NOUN
dti-1419	127	4	pku	pku	NOUN
dti-1419	127	5	patients	patient	NOUN
dti-1419	127	6	have	have	AUX
dti-1419	127	7	shown	show	VERB
dti-1419	127	8	a	a	DET
dti-1419	127	9	variation	variation	NOUN
dti-1419	127	10	in	in	ADP
dti-1419	127	11	phenylalanine	phenylalanine	ADJ
dti-1419	127	12	levels	level	NOUN
dti-1419	127	13	can	can	AUX
dti-1419	127	14	be	be	AUX
dti-1419	127	15	observed	observe	VERB
dti-1419	127	16	without	without	ADP
dti-1419	127	17	any	any	DET
dti-1419	127	18	change	change	NOUN
dti-1419	127	19	in	in	ADP
dti-1419	127	20	treatment.20	treatment.20	PROPN
dti-1419	127	21	in	in	ADP
dti-1419	127	22	clinical	clinical	ADJ
dti-1419	127	23	trials	trial	NOUN
dti-1419	127	24	,	,	PUNCT
dti-1419	127	25	the	the	DET
dti-1419	127	26	response	response	NOUN
dti-1419	127	27	to	to	ADP
dti-1419	127	28	sapropterin	sapropterin	ADJ
dti-1419	127	29	treatment	treatment	NOUN
dti-1419	127	30	was	be	AUX
dti-1419	127	31	defined	define	VERB
dti-1419	127	32	as	as	ADP
dti-1419	127	33	a	a	DET
dti-1419	127	34	30	30	NUM
dti-1419	127	35	%	%	NOUN
dti-1419	127	36	reduction	reduction	NOUN
dti-1419	127	37	in	in	ADP
dti-1419	127	38	blood	blood	NOUN
dti-1419	127	39	phenylalanine	phenylalanine	NOUN
dti-1419	127	40	concentration	concentration	NOUN
dti-1419	127	41	from	from	ADP
dti-1419	127	42	baseline.21	baseline.21	PROPN
dti-1419	127	43	in	in	ADP
dti-1419	127	44	contrast	contrast	NOUN
dti-1419	127	45	,	,	PUNCT
dti-1419	127	46	therapeutic	therapeutic	ADJ
dti-1419	127	47	response	response	NOUN
dti-1419	127	48	with	with	ADP
dti-1419	127	49	pegvaliase	pegvaliase	PROPN
dti-1419	127	50	was	be	AUX
dti-1419	127	51	based	base	VERB
dti-1419	127	52	on	on	ADP
dti-1419	127	53	a	a	DET
dti-1419	127	54	20	20	NUM
dti-1419	127	55	%	%	NOUN
dti-1419	127	56	reduction	reduction	NOUN
dti-1419	127	57	in	in	ADP
dti-1419	127	58	blood	blood	NOUN
dti-1419	127	59	phenylalanine	phenylalanine	NOUN
dti-1419	127	60	concentration	concentration	NOUN
dti-1419	127	61	from	from	ADP
dti-1419	127	62	baseline	baseline	NOUN
dti-1419	127	63	or	or	CCONJ
dti-1419	127	64	a	a	DET
dti-1419	127	65	blood	blood	NOUN
dti-1419	127	66	phenylalanine	phenylalanine	NOUN
dti-1419	127	67	concentration	concentration	NOUN
dti-1419	127	68	⩽600	⩽600	NOUN
dti-1419	127	69	µmol	µmol	ADV
dti-1419	127	70	/	/	SYM
dti-1419	127	71	l	l	NOUN
dti-1419	127	72	after	after	ADP
dti-1419	127	73	24	24	NUM
dti-1419	127	74	weeks	week	NOUN
dti-1419	127	75	.	.	PUNCT
dti-1419	128	1	if	if	SCONJ
dti-1419	128	2	not	not	PART
dti-1419	128	3	achieved	achieve	VERB
dti-1419	128	4	,	,	PUNCT
dti-1419	128	5	increasing	increase	VERB
dti-1419	128	6	the	the	DET
dti-1419	128	7	pegvaliase	pegvaliase	NOUN
dti-1419	128	8	dose	dose	VERB
dti-1419	128	9	to	to	ADP
dti-1419	128	10	a	a	DET
dti-1419	128	11	maximum	maximum	ADJ
dti-1419	128	12	dosage	dosage	NOUN
dti-1419	128	13	of	of	ADP
dti-1419	128	14	40	40	NUM
dti-1419	128	15	mg	mg	NOUN
dti-1419	128	16	subcutaneously	subcutaneously	ADV
dti-1419	128	17	once	once	ADV
dti-1419	128	18	daily	daily	ADV
dti-1419	128	19	can	can	AUX
dti-1419	128	20	be	be	AUX
dti-1419	128	21	considered	consider	VERB
dti-1419	128	22	.	.	PUNCT
dti-1419	129	1	if	if	SCONJ
dti-1419	129	2	therapeutic	therapeutic	ADJ
dti-1419	129	3	response	response	NOUN
dti-1419	129	4	has	have	AUX
dti-1419	129	5	not	not	PART
dti-1419	129	6	been	be	AUX
dti-1419	129	7	achieved	achieve	VERB
dti-1419	129	8	after	after	ADP
dti-1419	129	9	16	16	NUM
dti-1419	129	10	weeks	week	NOUN
dti-1419	129	11	on	on	ADP
dti-1419	129	12	the	the	DET
dti-1419	129	13	maximum	maximum	ADJ
dti-1419	129	14	dosage	dosage	NOUN
dti-1419	129	15	,	,	PUNCT
dti-1419	129	16	discontinuation	discontinuation	NOUN
dti-1419	129	17	of	of	ADP
dti-1419	129	18	pegvaliase	pegvaliase	NOUN
dti-1419	129	19	is	be	AUX
dti-1419	129	20	recommended	recommend	VERB
dti-1419	129	21	.	.	PUNCT
dti-1419	130	1	if	if	SCONJ
dti-1419	130	2	6	6	NUM
dti-1419	130	3	drug	drug	NOUN
dti-1419	130	4	target	target	NOUN
dti-1419	130	5	insights	insight	NOUN
dti-1419	130	6	patients	patient	NOUN
dti-1419	130	7	experience	experience	VERB
dti-1419	130	8	blood	blood	NOUN
dti-1419	130	9	phenylalanine	phenylalanine	NOUN
dti-1419	130	10	concentrations	concentration	NOUN
dti-1419	130	11	<	<	X
dti-1419	130	12	30	30	NUM
dti-1419	130	13	µmol	µmol	ADV
dti-1419	130	14	/	/	SYM
dti-1419	130	15	l	l	NOUN
dti-1419	130	16	during	during	ADP
dti-1419	130	17	titration	titration	NOUN
dti-1419	130	18	and	and	CCONJ
dti-1419	130	19	maintenance	maintenance	NOUN
dti-1419	130	20	,	,	PUNCT
dti-1419	130	21	the	the	DET
dti-1419	130	22	dosage	dosage	NOUN
dti-1419	130	23	of	of	ADP
dti-1419	130	24	pegvaliase	pegvaliase	NOUN
dti-1419	130	25	may	may	AUX
dti-1419	130	26	be	be	AUX
dti-1419	130	27	reduced	reduce	VERB
dti-1419	130	28	or	or	CCONJ
dti-1419	130	29	the	the	DET
dti-1419	130	30	dietary	dietary	ADJ
dti-1419	130	31	protein	protein	NOUN
dti-1419	130	32	and	and	CCONJ
dti-1419	130	33	phenylalanine	phenylalanine	NOUN
dti-1419	130	34	intake	intake	NOUN
dti-1419	130	35	may	may	AUX
dti-1419	130	36	be	be	AUX
dti-1419	130	37	modified.11	modified.11	VERB
dti-1419	130	38	for	for	ADP
dti-1419	130	39	hypersensitivity	hypersensitivity	NOUN
dti-1419	130	40	reactions	reaction	NOUN
dti-1419	130	41	,	,	PUNCT
dti-1419	130	42	premedication	premedication	NOUN
dti-1419	130	43	can	can	AUX
dti-1419	130	44	be	be	AUX
dti-1419	130	45	considered	consider	VERB
dti-1419	130	46	with	with	ADP
dti-1419	130	47	an	an	DET
dti-1419	130	48	h1	h1	NOUN
dti-1419	130	49	-	-	PUNCT
dti-1419	130	50	receptor	receptor	NOUN
dti-1419	130	51	antagonist	antagonist	NOUN
dti-1419	130	52	,	,	PUNCT
dti-1419	130	53	h2	h2	NOUN
dti-1419	130	54	-	-	PUNCT
dti-1419	130	55	receptor	receptor	NOUN
dti-1419	130	56	antagonist	antagonist	NOUN
dti-1419	130	57	,	,	PUNCT
dti-1419	130	58	and/or	and/or	CCONJ
dti-1419	130	59	antipyretic	antipyretic	ADJ
dti-1419	130	60	prior	prior	ADV
dti-1419	130	61	to	to	ADP
dti-1419	130	62	administration	administration	NOUN
dti-1419	130	63	based	base	VERB
dti-1419	130	64	on	on	ADP
dti-1419	130	65	tolerability	tolerability	NOUN
dti-1419	130	66	.	.	PUNCT
dti-1419	131	1	patients	patient	NOUN
dti-1419	131	2	should	should	AUX
dti-1419	131	3	be	be	AUX
dti-1419	131	4	observed	observe	VERB
dti-1419	131	5	during	during	ADP
dti-1419	131	6	and	and	CCONJ
dti-1419	131	7	for	for	ADP
dti-1419	131	8	at	at	ADV
dti-1419	131	9	least	least	ADV
dti-1419	131	10	60	60	NUM
dti-1419	131	11	minutes	minute	NOUN
dti-1419	131	12	after	after	ADP
dti-1419	131	13	receiving	receive	VERB
dti-1419	131	14	pegvaliase	pegvaliase	ADJ
dti-1419	131	15	injection	injection	NOUN
dti-1419	131	16	.	.	PUNCT
dti-1419	132	1	patients	patient	NOUN
dti-1419	132	2	should	should	AUX
dti-1419	132	3	also	also	ADV
dti-1419	132	4	be	be	AUX
dti-1419	132	5	trained	train	VERB
dti-1419	132	6	on	on	ADP
dti-1419	132	7	recognition	recognition	NOUN
dti-1419	132	8	of	of	ADP
dti-1419	132	9	signs	sign	NOUN
dti-1419	132	10	and	and	CCONJ
dti-1419	132	11	symptoms	symptom	NOUN
dti-1419	132	12	of	of	ADP
dti-1419	132	13	anaphylaxis	anaphylaxis	ADJ
dti-1419	132	14	,	,	PUNCT
dti-1419	132	15	how	how	SCONJ
dti-1419	132	16	to	to	PART
dti-1419	132	17	administer	administer	VERB
dti-1419	132	18	injectable	injectable	ADJ
dti-1419	132	19	epinephrine	epinephrine	NOUN
dti-1419	132	20	,	,	PUNCT
dti-1419	132	21	and	and	CCONJ
dti-1419	132	22	how	how	SCONJ
dti-1419	132	23	to	to	PART
dti-1419	132	24	seek	seek	VERB
dti-1419	132	25	emergency	emergency	NOUN
dti-1419	132	26	care	care	NOUN
dti-1419	132	27	,	,	PUNCT
dti-1419	132	28	if	if	SCONJ
dti-1419	132	29	needed	need	VERB
dti-1419	132	30	.	.	PUNCT
dti-1419	133	1	if	if	SCONJ
dti-1419	133	2	the	the	DET
dti-1419	133	3	decision	decision	NOUN
dti-1419	133	4	is	be	AUX
dti-1419	133	5	made	make	VERB
dti-1419	133	6	to	to	PART
dti-1419	133	7	readminister	readminister	VERB
dti-1419	133	8	pegvaliase	pegvaliase	NOUN
dti-1419	133	9	after	after	ADP
dti-1419	133	10	an	an	DET
dti-1419	133	11	episode	episode	NOUN
dti-1419	133	12	of	of	ADP
dti-1419	133	13	anaphylaxis	anaphylaxis	ADJ
dti-1419	133	14	,	,	PUNCT
dti-1419	133	15	the	the	DET
dti-1419	133	16	subsequent	subsequent	ADJ
dti-1419	133	17	dose	dose	NOUN
dti-1419	133	18	should	should	AUX
dti-1419	133	19	be	be	AUX
dti-1419	133	20	administered	administer	VERB
dti-1419	133	21	under	under	ADP
dti-1419	133	22	the	the	DET
dti-1419	133	23	supervision	supervision	NOUN
dti-1419	133	24	of	of	ADP
dti-1419	133	25	a	a	DET
dti-1419	133	26	health	health	NOUN
dti-1419	133	27	care	care	NOUN
dti-1419	133	28	provider	provider	NOUN
dti-1419	133	29	after	after	ADP
dti-1419	133	30	titrating	titrate	VERB
dti-1419	133	31	based	base	VERB
dti-1419	133	32	on	on	ADP
dti-1419	133	33	patient	patient	ADJ
dti-1419	133	34	tolerability	tolerability	NOUN
dti-1419	133	35	and	and	CCONJ
dti-1419	133	36	therapeutic	therapeutic	ADJ
dti-1419	133	37	response.11	response.11	NOUN
dti-1419	133	38	due	due	ADP
dti-1419	133	39	to	to	ADP
dti-1419	133	40	the	the	DET
dti-1419	133	41	risks	risk	NOUN
dti-1419	133	42	of	of	ADP
dti-1419	133	43	anaphylaxis	anaphylaxis	ADJ
dti-1419	133	44	,	,	PUNCT
dti-1419	133	45	pegvaliase	pegvaliase	PROPN
dti-1419	133	46	is	be	AUX
dti-1419	133	47	only	only	ADV
dti-1419	133	48	available	available	ADJ
dti-1419	133	49	through	through	ADP
dti-1419	133	50	a	a	DET
dti-1419	133	51	risk	risk	NOUN
dti-1419	133	52	evaluation	evaluation	NOUN
dti-1419	133	53	and	and	CCONJ
dti-1419	133	54	mitigation	mitigation	NOUN
dti-1419	133	55	strategies	strategy	NOUN
dti-1419	133	56	(	(	PUNCT
dti-1419	133	57	rems	rem	NOUN
dti-1419	133	58	)	)	PUNCT
dti-1419	133	59	program	program	NOUN
dti-1419	133	60	which	which	PRON
dti-1419	133	61	includes	include	VERB
dti-1419	133	62	prescriber	prescriber	NOUN
dti-1419	133	63	and	and	CCONJ
dti-1419	133	64	pharmacy	pharmacy	NOUN
dti-1419	133	65	certification	certification	NOUN
dti-1419	133	66	requirements	requirement	NOUN
dti-1419	133	67	and	and	CCONJ
dti-1419	133	68	patient	patient	ADJ
dti-1419	133	69	educational	educational	ADJ
dti-1419	133	70	enrollment	enrollment	NOUN
dti-1419	133	71	.	.	PUNCT
dti-1419	134	1	in	in	ADP
dti-1419	134	2	clinical	clinical	ADJ
dti-1419	134	3	trials	trial	NOUN
dti-1419	134	4	,	,	PUNCT
dti-1419	134	5	most	most	ADJ
dti-1419	134	6	patients	patient	NOUN
dti-1419	134	7	developed	develop	VERB
dti-1419	134	8	anti	anti	ADJ
dti-1419	134	9	-	-	ADJ
dti-1419	134	10	peg	peg	ADJ
dti-1419	134	11	igm	igm	NOUN
dti-1419	134	12	and	and	CCONJ
dti-1419	134	13	igg	igg	PROPN
dti-1419	134	14	antibodies	antibodie	VERB
dti-1419	134	15	after	after	ADP
dti-1419	134	16	treatment	treatment	NOUN
dti-1419	134	17	.	.	PUNCT
dti-1419	135	1	the	the	DET
dti-1419	135	2	clinical	clinical	ADJ
dti-1419	135	3	effects	effect	NOUN
dti-1419	135	4	of	of	ADP
dti-1419	135	5	concomitant	concomitant	ADJ
dti-1419	135	6	treatment	treatment	NOUN
dti-1419	135	7	with	with	ADP
dti-1419	135	8	other	other	ADJ
dti-1419	135	9	pegylated	pegylated	ADJ
dti-1419	135	10	products	product	NOUN
dti-1419	135	11	are	be	AUX
dti-1419	135	12	unknown	unknown	ADJ
dti-1419	135	13	.	.	PUNCT
dti-1419	136	1	therefore	therefore	ADV
dti-1419	136	2	,	,	PUNCT
dti-1419	136	3	if	if	SCONJ
dti-1419	136	4	patients	patient	NOUN
dti-1419	136	5	are	be	AUX
dti-1419	136	6	treated	treat	VERB
dti-1419	136	7	in	in	ADP
dti-1419	136	8	combination	combination	NOUN
dti-1419	136	9	with	with	ADP
dti-1419	136	10	other	other	ADJ
dti-1419	136	11	pegylated	pegylated	ADJ
dti-1419	136	12	products	product	NOUN
dti-1419	136	13	,	,	PUNCT
dti-1419	136	14	further	far	ADV
dti-1419	136	15	monitoring	monitoring	NOUN
dti-1419	136	16	for	for	ADP
dti-1419	136	17	hypersensitivity	hypersensitivity	NOUN
dti-1419	136	18	reactions	reaction	NOUN
dti-1419	136	19	and	and	CCONJ
dti-1419	136	20	anaphylaxis	anaphylaxis	NOUN
dti-1419	136	21	is	be	AUX
dti-1419	136	22	recommended.11	recommended.11	ADJ
dti-1419	136	23	relevance	relevance	NOUN
dti-1419	136	24	to	to	ADP
dti-1419	136	25	patient	patient	NOUN
dti-1419	136	26	care	care	NOUN
dti-1419	136	27	and	and	CCONJ
dti-1419	136	28	clinical	clinical	ADJ
dti-1419	136	29	practice	practice	NOUN
dti-1419	136	30	the	the	DET
dti-1419	136	31	risk	risk	NOUN
dti-1419	136	32	of	of	ADP
dti-1419	136	33	adverse	adverse	ADJ
dti-1419	136	34	outcomes	outcome	NOUN
dti-1419	136	35	in	in	ADP
dti-1419	136	36	pku	pku	PROPN
dti-1419	136	37	is	be	AUX
dti-1419	136	38	related	relate	VERB
dti-1419	136	39	to	to	ADP
dti-1419	136	40	disease	disease	NOUN
dti-1419	136	41	severity	severity	NOUN
dti-1419	136	42	,	,	PUNCT
dti-1419	136	43	blood	blood	NOUN
dti-1419	136	44	phenylalanine	phenylalanine	NOUN
dti-1419	136	45	concentration	concentration	NOUN
dti-1419	136	46	,	,	PUNCT
dti-1419	136	47	and	and	CCONJ
dti-1419	136	48	adherence	adherence	NOUN
dti-1419	136	49	to	to	ADP
dti-1419	136	50	treatment.4	treatment.4	NUM
dti-1419	136	51	the	the	DET
dti-1419	136	52	assessment	assessment	NOUN
dti-1419	136	53	of	of	ADP
dti-1419	136	54	blood	blood	NOUN
dti-1419	136	55	phenylalanine	phenylalanine	NOUN
dti-1419	136	56	concentrations	concentration	NOUN
dti-1419	136	57	may	may	AUX
dti-1419	136	58	also	also	ADV
dti-1419	136	59	be	be	AUX
dti-1419	136	60	indicative	indicative	ADJ
dti-1419	136	61	of	of	ADP
dti-1419	136	62	patient	patient	ADJ
dti-1419	136	63	adherence	adherence	NOUN
dti-1419	136	64	to	to	ADP
dti-1419	136	65	therapy.22	therapy.22	VERB
dti-1419	136	66	poor	poor	ADJ
dti-1419	136	67	adherence	adherence	NOUN
dti-1419	136	68	can	can	AUX
dti-1419	136	69	manifest	manifest	VERB
dti-1419	136	70	as	as	ADP
dti-1419	136	71	failure	failure	NOUN
dti-1419	136	72	to	to	PART
dti-1419	136	73	take	take	VERB
dti-1419	136	74	medical	medical	ADJ
dti-1419	136	75	foods	food	NOUN
dti-1419	136	76	or	or	CCONJ
dti-1419	136	77	prescribed	prescribed	ADJ
dti-1419	136	78	medications	medication	NOUN
dti-1419	136	79	,	,	PUNCT
dti-1419	136	80	and	and	CCONJ
dti-1419	136	81	missing	miss	VERB
dti-1419	136	82	regular	regular	ADJ
dti-1419	136	83	clinic	clinic	NOUN
dti-1419	136	84	appointments	appointment	NOUN
dti-1419	136	85	or	or	CCONJ
dti-1419	136	86	blood	blood	NOUN
dti-1419	136	87	phenylalanine	phenylalanine	NOUN
dti-1419	136	88	testing.23	testing.23	PROPN
dti-1419	136	89	a	a	DET
dti-1419	136	90	presentation	presentation	NOUN
dti-1419	136	91	released	release	VERB
dti-1419	136	92	by	by	ADP
dti-1419	136	93	biomarin	biomarin	NOUN
dti-1419	136	94	pharmaceuticals	pharmaceutical	NOUN
dti-1419	136	95	suggests	suggest	VERB
dti-1419	136	96	there	there	PRON
dti-1419	136	97	are	be	VERB
dti-1419	136	98	125	125	NUM
dti-1419	136	99	pku	pku	NOUN
dti-1419	136	100	clinics	clinic	NOUN
dti-1419	136	101	in	in	ADP
dti-1419	136	102	the	the	DET
dti-1419	136	103	united	united	PROPN
dti-1419	136	104	states	states	PROPN
dti-1419	136	105	currently	currently	ADV
dti-1419	136	106	managing	manage	VERB
dti-1419	136	107	patients	patient	NOUN
dti-1419	136	108	through	through	ADP
dti-1419	136	109	dietary	dietary	ADJ
dti-1419	136	110	counseling	counseling	NOUN
dti-1419	136	111	and/or	and/or	CCONJ
dti-1419	136	112	sapropterin.24	sapropterin.24	VERB
dti-1419	136	113	a	a	DET
dti-1419	136	114	study	study	NOUN
dti-1419	136	115	of	of	ADP
dti-1419	136	116	45	45	NUM
dti-1419	136	117	pku	pku	ADJ
dti-1419	136	118	clinics	clinic	NOUN
dti-1419	136	119	showed	show	VERB
dti-1419	136	120	that	that	SCONJ
dti-1419	136	121	non	non	ADJ
dti-1419	136	122	-	-	NOUN
dti-1419	136	123	adherence	adherence	NOUN
dti-1419	136	124	to	to	ADP
dti-1419	136	125	clinic	clinic	NOUN
dti-1419	136	126	-	-	PUNCT
dti-1419	136	127	recommended	recommend	VERB
dti-1419	136	128	target	target	NOUN
dti-1419	136	129	phenylalanine	phenylalanine	NOUN
dti-1419	136	130	concentrations	concentration	NOUN
dti-1419	136	131	increased	increase	VERB
dti-1419	136	132	with	with	ADP
dti-1419	136	133	age	age	NOUN
dti-1419	136	134	.	.	PUNCT
dti-1419	137	1	most	most	ADJ
dti-1419	137	2	adults	adult	NOUN
dti-1419	137	3	had	have	VERB
dti-1419	137	4	blood	blood	NOUN
dti-1419	137	5	phenylalanine	phenylalanine	NOUN
dti-1419	137	6	concentrations	concentration	NOUN
dti-1419	137	7	>	>	X
dti-1419	137	8	360	360	NUM
dti-1419	137	9	µmol	µmol	ADP
dti-1419	137	10	/	/	SYM
dti-1419	137	11	l	l	NOUN
dti-1419	137	12	with	with	ADP
dti-1419	137	13	15	15	NUM
dti-1419	137	14	%	%	NOUN
dti-1419	137	15	of	of	ADP
dti-1419	137	16	patients	patient	NOUN
dti-1419	137	17	aged	age	VERB
dti-1419	137	18	18	18	NUM
dti-1419	137	19	to	to	PART
dti-1419	137	20	29	29	NUM
dti-1419	137	21	years	year	NOUN
dti-1419	137	22	and	and	CCONJ
dti-1419	137	23	20	20	NUM
dti-1419	137	24	%	%	NOUN
dti-1419	137	25	of	of	ADP
dti-1419	137	26	patients	patient	NOUN
dti-1419	137	27	aged	age	VERB
dti-1419	137	28	30	30	NUM
dti-1419	137	29	+	+	NUM
dti-1419	137	30	years	year	NOUN
dti-1419	137	31	reported	report	VERB
dti-1419	137	32	to	to	PART
dti-1419	137	33	have	have	VERB
dti-1419	137	34	concentrations	concentration	NOUN
dti-1419	137	35	>	>	PUNCT
dti-1419	137	36	1200	1200	NUM
dti-1419	137	37	µmol	µmol	PART
dti-1419	137	38	/	/	SYM
dti-1419	137	39	l.23	l.23	NOUN
dti-1419	137	40	given	give	VERB
dti-1419	137	41	that	that	SCONJ
dti-1419	137	42	pku	pku	PROPN
dti-1419	137	43	can	can	AUX
dti-1419	137	44	cause	cause	VERB
dti-1419	137	45	neurocognitive	neurocognitive	ADJ
dti-1419	137	46	and	and	CCONJ
dti-1419	137	47	psychiatric	psychiatric	ADJ
dti-1419	137	48	symptoms	symptom	NOUN
dti-1419	137	49	,	,	PUNCT
dti-1419	137	50	there	there	PRON
dti-1419	137	51	may	may	AUX
dti-1419	137	52	be	be	AUX
dti-1419	137	53	an	an	DET
dti-1419	137	54	unmet	unmet	NOUN
dti-1419	137	55	need	need	NOUN
dti-1419	137	56	for	for	ADP
dti-1419	137	57	additional	additional	ADJ
dti-1419	137	58	therapeutic	therapeutic	ADJ
dti-1419	137	59	approaches	approach	NOUN
dti-1419	137	60	in	in	ADP
dti-1419	137	61	adults	adult	NOUN
dti-1419	137	62	with	with	ADP
dti-1419	137	63	uncontrolled	uncontrolled	ADJ
dti-1419	137	64	disease	disease	NOUN
dti-1419	137	65	.	.	PUNCT
dti-1419	138	1	dietary	dietary	ADJ
dti-1419	138	2	treatment	treatment	NOUN
dti-1419	138	3	consists	consist	VERB
dti-1419	138	4	of	of	ADP
dti-1419	138	5	dietary	dietary	ADJ
dti-1419	138	6	restriction	restriction	NOUN
dti-1419	138	7	of	of	ADP
dti-1419	138	8	phenylalanine	phenylalanine	NOUN
dti-1419	138	9	,	,	PUNCT
dti-1419	138	10	phenylalanine	phenylalanine	NOUN
dti-1419	138	11	-	-	PUNCT
dti-1419	138	12	free	free	ADJ
dti-1419	138	13	protein	protein	NOUN
dti-1419	138	14	substitutes	substitute	NOUN
dti-1419	138	15	(	(	PUNCT
dti-1419	138	16	l	l	ADJ
dti-1419	138	17	-	-	ADJ
dti-1419	138	18	amino	amino	ADJ
dti-1419	138	19	acid	acid	NOUN
dti-1419	138	20	mixtures	mixture	NOUN
dti-1419	138	21	)	)	PUNCT
dti-1419	138	22	,	,	PUNCT
dti-1419	138	23	and	and	CCONJ
dti-1419	138	24	modified	modify	VERB
dti-1419	138	25	low	low	ADJ
dti-1419	138	26	-	-	PUNCT
dti-1419	138	27	protein	protein	NOUN
dti-1419	138	28	foods.4,6	foods.4,6	PROPN
dti-1419	138	29	patients	patient	NOUN
dti-1419	138	30	with	with	ADP
dti-1419	138	31	residual	residual	ADJ
dti-1419	138	32	enzymatic	enzymatic	ADJ
dti-1419	138	33	activity	activity	NOUN
dti-1419	138	34	of	of	ADP
dti-1419	138	35	pah	pah	PROPN
dti-1419	138	36	may	may	AUX
dti-1419	138	37	respond	respond	VERB
dti-1419	138	38	to	to	ADP
dti-1419	138	39	sapropterin	sapropterin	NOUN
dti-1419	138	40	which	which	PRON
dti-1419	138	41	increases	increase	VERB
dti-1419	138	42	metabolism	metabolism	NOUN
dti-1419	138	43	of	of	ADP
dti-1419	138	44	phenylalanine	phenylalanine	NOUN
dti-1419	138	45	to	to	ADP
dti-1419	138	46	tyrosine	tyrosine	NOUN
dti-1419	138	47	.	.	PUNCT
dti-1419	139	1	safety	safety	NOUN
dti-1419	139	2	and	and	CCONJ
dti-1419	139	3	efficacy	efficacy	NOUN
dti-1419	139	4	of	of	ADP
dti-1419	139	5	sapropterin	sapropterin	NOUN
dti-1419	139	6	have	have	AUX
dti-1419	139	7	been	be	AUX
dti-1419	139	8	established	establish	VERB
dti-1419	139	9	in	in	ADP
dti-1419	139	10	pediatric	pediatric	ADJ
dti-1419	139	11	patients	patient	NOUN
dti-1419	139	12	as	as	ADV
dti-1419	139	13	young	young	ADJ
dti-1419	139	14	as	as	ADP
dti-1419	139	15	1	1	NUM
dti-1419	139	16	month	month	NOUN
dti-1419	139	17	of	of	ADP
dti-1419	139	18	age.21	age.21	PROPN
dti-1419	139	19	prior	prior	ADV
dti-1419	139	20	to	to	ADP
dti-1419	139	21	routine	routine	ADJ
dti-1419	139	22	treatment	treatment	NOUN
dti-1419	139	23	with	with	ADP
dti-1419	139	24	sapropterin	sapropterin	NOUN
dti-1419	139	25	,	,	PUNCT
dti-1419	139	26	a	a	DET
dti-1419	139	27	test	test	NOUN
dti-1419	139	28	should	should	AUX
dti-1419	139	29	be	be	AUX
dti-1419	139	30	conducted	conduct	VERB
dti-1419	139	31	to	to	PART
dti-1419	139	32	determine	determine	VERB
dti-1419	139	33	if	if	SCONJ
dti-1419	139	34	the	the	DET
dti-1419	139	35	patient	patient	NOUN
dti-1419	139	36	is	be	AUX
dti-1419	139	37	sapropterin	sapropterin	NOUN
dti-1419	139	38	-	-	PUNCT
dti-1419	139	39	responsive	responsive	ADJ
dti-1419	139	40	,	,	PUNCT
dti-1419	139	41	defined	define	VERB
dti-1419	139	42	as	as	ADP
dti-1419	139	43	a	a	DET
dti-1419	139	44	rapid	rapid	ADJ
dti-1419	139	45	decline	decline	NOUN
dti-1419	139	46	in	in	ADP
dti-1419	139	47	phenylalanine	phenylalanine	NOUN
dti-1419	139	48	or	or	CCONJ
dti-1419	139	49	increase	increase	VERB
dti-1419	139	50	in	in	ADP
dti-1419	139	51	phenylalanine	phenylalanine	ADJ
dti-1419	139	52	tolerance	tolerance	NOUN
dti-1419	139	53	.	.	PUNCT
dti-1419	140	1	sapropterin	sapropterin	PROPN
dti-1419	140	2	can	can	AUX
dti-1419	140	3	provide	provide	VERB
dti-1419	140	4	better	well	ADJ
dti-1419	140	5	phenylalanine	phenylalanine	NOUN
dti-1419	140	6	control	control	NOUN
dti-1419	140	7	and	and	CCONJ
dti-1419	140	8	increase	increase	VERB
dti-1419	140	9	dietary	dietary	ADJ
dti-1419	140	10	phenylalanine	phenylalanine	NOUN
dti-1419	140	11	tolerance.25	tolerance.25	NOUN
dti-1419	140	12	clinical	clinical	ADJ
dti-1419	140	13	guidelines	guideline	NOUN
dti-1419	140	14	have	have	AUX
dti-1419	140	15	recently	recently	ADV
dti-1419	140	16	been	be	AUX
dti-1419	140	17	updated	update	VERB
dti-1419	140	18	on	on	ADP
dti-1419	140	19	to	to	PART
dti-1419	140	20	address	address	VERB
dti-1419	140	21	the	the	DET
dti-1419	140	22	role	role	NOUN
dti-1419	140	23	of	of	ADP
dti-1419	140	24	pegvaliase	pegvaliase	NOUN
dti-1419	140	25	in	in	ADP
dti-1419	140	26	management	management	NOUN
dti-1419	140	27	of	of	ADP
dti-1419	140	28	pku	pku	PROPN
dti-1419	140	29	.	.	PUNCT
dti-1419	141	1	the	the	DET
dti-1419	141	2	goal	goal	NOUN
dti-1419	141	3	of	of	ADP
dti-1419	141	4	pegvaliase	pegvaliase	ADJ
dti-1419	141	5	treatment	treatment	NOUN
dti-1419	141	6	is	be	AUX
dti-1419	141	7	to	to	PART
dti-1419	141	8	provide	provide	VERB
dti-1419	141	9	maintenance	maintenance	NOUN
dti-1419	141	10	of	of	ADP
dti-1419	141	11	blood	blood	NOUN
dti-1419	141	12	phenylalanine	phenylalanine	NOUN
dti-1419	141	13	concentrations	concentration	NOUN
dti-1419	141	14	while	while	SCONJ
dti-1419	141	15	normalizing	normalize	VERB
dti-1419	141	16	diet	diet	NOUN
dti-1419	141	17	.	.	PUNCT
dti-1419	142	1	pegvaliase	pegvaliase	PROPN
dti-1419	142	2	can	can	AUX
dti-1419	142	3	be	be	AUX
dti-1419	142	4	considered	consider	VERB
dti-1419	142	5	for	for	SCONJ
dti-1419	142	6	all	all	DET
dti-1419	142	7	adult	adult	NOUN
dti-1419	142	8	patients	patient	NOUN
dti-1419	142	9	with	with	ADP
dti-1419	142	10	pku	pku	PROPN
dti-1419	142	11	who	who	PRON
dti-1419	142	12	can	can	AUX
dti-1419	142	13	adhere	adhere	VERB
dti-1419	142	14	to	to	ADP
dti-1419	142	15	therapy	therapy	NOUN
dti-1419	142	16	,	,	PUNCT
dti-1419	142	17	including	include	VERB
dti-1419	142	18	requirement	requirement	NOUN
dti-1419	142	19	for	for	ADP
dti-1419	142	20	monitoring	monitoring	NOUN
dti-1419	142	21	of	of	ADP
dti-1419	142	22	aes.26	aes.26	ADJ
dti-1419	142	23	no	no	DET
dti-1419	142	24	head	head	NOUN
dti-1419	142	25	-	-	PUNCT
dti-1419	142	26	to	to	ADP
dti-1419	142	27	-	-	PUNCT
dti-1419	142	28	head	head	NOUN
dti-1419	142	29	trials	trial	NOUN
dti-1419	142	30	were	be	AUX
dti-1419	142	31	conducted	conduct	VERB
dti-1419	142	32	comparing	compare	VERB
dti-1419	142	33	the	the	DET
dti-1419	142	34	safety	safety	NOUN
dti-1419	142	35	and	and	CCONJ
dti-1419	142	36	efficacy	efficacy	NOUN
dti-1419	142	37	of	of	ADP
dti-1419	142	38	sapropterin	sapropterin	NOUN
dti-1419	142	39	with	with	ADP
dti-1419	142	40	pegvaliase	pegvaliase	NOUN
dti-1419	142	41	.	.	PUNCT
dti-1419	143	1	given	give	VERB
dti-1419	143	2	patients	patient	NOUN
dti-1419	143	3	in	in	ADP
dti-1419	143	4	the	the	DET
dti-1419	143	5	clinical	clinical	ADJ
dti-1419	143	6	trials	trial	NOUN
dti-1419	143	7	were	be	AUX
dti-1419	143	8	unable	unable	ADJ
dti-1419	143	9	to	to	PART
dti-1419	143	10	continue	continue	VERB
dti-1419	143	11	sapropterin	sapropterin	NOUN
dti-1419	143	12	in	in	ADP
dti-1419	143	13	the	the	DET
dti-1419	143	14	pegvaliase	pegvaliase	PROPN
dti-1419	143	15	trials	trial	NOUN
dti-1419	143	16	,	,	PUNCT
dti-1419	143	17	it	it	PRON
dti-1419	143	18	is	be	AUX
dti-1419	143	19	unclear	unclear	ADJ
dti-1419	143	20	whether	whether	SCONJ
dti-1419	143	21	the	the	DET
dti-1419	143	22	combination	combination	NOUN
dti-1419	143	23	is	be	AUX
dti-1419	143	24	statistically	statistically	ADV
dti-1419	143	25	and	and	CCONJ
dti-1419	143	26	clinically	clinically	ADV
dti-1419	143	27	more	more	ADV
dti-1419	143	28	beneficial	beneficial	ADJ
dti-1419	143	29	than	than	ADP
dti-1419	143	30	either	either	DET
dti-1419	143	31	treatment	treatment	NOUN
dti-1419	143	32	alone	alone	ADV
dti-1419	143	33	.	.	PUNCT
dti-1419	144	1	although	although	SCONJ
dti-1419	144	2	the	the	DET
dti-1419	144	3	package	package	NOUN
dti-1419	144	4	insert	insert	NOUN
dti-1419	144	5	for	for	ADP
dti-1419	144	6	pegvaliase	pegvaliase	NOUN
dti-1419	144	7	does	do	AUX
dti-1419	144	8	not	not	PART
dti-1419	144	9	specify	specify	VERB
dti-1419	144	10	use	use	NOUN
dti-1419	144	11	to	to	PART
dti-1419	144	12	be	be	AUX
dti-1419	144	13	in	in	ADP
dti-1419	144	14	conjunction	conjunction	NOUN
dti-1419	144	15	with	with	ADP
dti-1419	144	16	a	a	DET
dti-1419	144	17	phenylalanine	phenylalanine	NOUN
dti-1419	144	18	-	-	PUNCT
dti-1419	144	19	restricted	restrict	VERB
dti-1419	144	20	diet	diet	NOUN
dti-1419	144	21	,	,	PUNCT
dti-1419	144	22	it	it	PRON
dti-1419	144	23	is	be	AUX
dti-1419	144	24	indicated	indicate	VERB
dti-1419	144	25	in	in	ADP
dti-1419	144	26	patients	patient	NOUN
dti-1419	144	27	with	with	ADP
dti-1419	144	28	uncontrolled	uncontrolled	ADJ
dti-1419	144	29	blood	blood	NOUN
dti-1419	144	30	phenylalanine	phenylalanine	NOUN
dti-1419	144	31	concentrations	concentration	NOUN
dti-1419	144	32	“	"	PUNCT
dti-1419	144	33	on	on	ADP
dti-1419	144	34	existing	exist	VERB
dti-1419	144	35	management”11	management”11	PROPN
dti-1419	144	36	which	which	PRON
dti-1419	144	37	can	can	AUX
dti-1419	144	38	be	be	AUX
dti-1419	144	39	inferred	infer	VERB
dti-1419	144	40	as	as	ADP
dti-1419	144	41	guideline	guideline	NOUN
dti-1419	144	42	-	-	PUNCT
dti-1419	144	43	recommended	recommend	VERB
dti-1419	144	44	dietary	dietary	ADJ
dti-1419	144	45	therapy	therapy	NOUN
dti-1419	144	46	and/or	and/or	CCONJ
dti-1419	144	47	sapropterin	sapropterin	NOUN
dti-1419	144	48	pharmacotherapy	pharmacotherapy	NOUN
dti-1419	144	49	.	.	PUNCT
dti-1419	145	1	furthermore	furthermore	ADV
dti-1419	145	2	,	,	PUNCT
dti-1419	145	3	in	in	ADP
dti-1419	145	4	pegvaliase	pegvaliase	ADJ
dti-1419	145	5	clinical	clinical	ADJ
dti-1419	145	6	trials	trial	NOUN
dti-1419	145	7	,	,	PUNCT
dti-1419	145	8	patients	patient	NOUN
dti-1419	145	9	were	be	AUX
dti-1419	145	10	stable	stable	ADJ
dti-1419	145	11	in	in	ADP
dti-1419	145	12	protein	protein	NOUN
dti-1419	145	13	intake	intake	NOUN
dti-1419	145	14	and	and	CCONJ
dti-1419	145	15	in	in	ADP
dti-1419	145	16	many	many	ADJ
dti-1419	145	17	instances	instance	NOUN
dti-1419	145	18	received	receive	VERB
dti-1419	145	19	counseling	counseling	NOUN
dti-1419	145	20	from	from	ADP
dti-1419	145	21	a	a	DET
dti-1419	145	22	dietician.15–19	dietician.15–19	NOUN
dti-1419	145	23	however	however	ADV
dti-1419	145	24	,	,	PUNCT
dti-1419	145	25	while	while	SCONJ
dti-1419	145	26	thomas	thomas	PROPN
dti-1419	145	27	et	et	PROPN
dti-1419	145	28	 	 	SPACE
dti-1419	145	29	al	al	PROPN
dti-1419	145	30	observed	observe	VERB
dti-1419	145	31	stable	stable	ADJ
dti-1419	145	32	total	total	ADJ
dti-1419	145	33	dietary	dietary	ADJ
dti-1419	145	34	protein	protein	NOUN
dti-1419	145	35	intake	intake	NOUN
dti-1419	145	36	,	,	PUNCT
dti-1419	145	37	there	there	PRON
dti-1419	145	38	was	be	VERB
dti-1419	145	39	a	a	DET
dti-1419	145	40	decrease	decrease	NOUN
dti-1419	145	41	in	in	ADP
dti-1419	145	42	medical	medical	ADJ
dti-1419	145	43	food	food	NOUN
dti-1419	145	44	protein	protein	NOUN
dti-1419	145	45	(	(	PUNCT
dti-1419	145	46	from	from	ADP
dti-1419	145	47	26.3	26.3	NUM
dti-1419	145	48	to	to	ADP
dti-1419	145	49	18.4	18.4	NUM
dti-1419	145	50	g	g	NOUN
dti-1419	145	51	/	/	SYM
dti-1419	145	52	d	d	NOUN
dti-1419	145	53	)	)	PUNCT
dti-1419	145	54	and	and	CCONJ
dti-1419	145	55	an	an	DET
dti-1419	145	56	increase	increase	NOUN
dti-1419	145	57	in	in	ADP
dti-1419	145	58	dietary	dietary	ADJ
dti-1419	145	59	phenylalanine	phenylalanine	NOUN
dti-1419	145	60	intake	intake	NOUN
dti-1419	145	61	(	(	PUNCT
dti-1419	145	62	from	from	ADP
dti-1419	145	63	1700.2	1700.2	NUM
dti-1419	145	64	to	to	ADP
dti-1419	145	65	2679.7	2679.7	NUM
dti-1419	145	66	mg	mg	NOUN
dti-1419	145	67	/	/	SYM
dti-1419	145	68	d	d	NOUN
dti-1419	145	69	)	)	PUNCT
dti-1419	145	70	.	.	PUNCT
dti-1419	146	1	this	this	DET
dti-1419	146	2	shift	shift	NOUN
dti-1419	146	3	may	may	AUX
dti-1419	146	4	indicate	indicate	VERB
dti-1419	146	5	a	a	DET
dti-1419	146	6	decreased	decrease	VERB
dti-1419	146	7	need	need	NOUN
dti-1419	146	8	for	for	ADP
dti-1419	146	9	medical	medical	ADJ
dti-1419	146	10	food.18	food.18	PROPN
dti-1419	146	11	efficacy	efficacy	NOUN
dti-1419	146	12	of	of	ADP
dti-1419	146	13	pegvaliase	pegvaliase	NOUN
dti-1419	146	14	without	without	ADP
dti-1419	146	15	dietary	dietary	ADJ
dti-1419	146	16	therapy	therapy	NOUN
dti-1419	146	17	was	be	AUX
dti-1419	146	18	not	not	PART
dti-1419	146	19	assessed	assess	VERB
dti-1419	146	20	in	in	ADP
dti-1419	146	21	clinical	clinical	ADJ
dti-1419	146	22	trials	trial	NOUN
dti-1419	146	23	.	.	PUNCT
dti-1419	147	1	due	due	ADP
dti-1419	147	2	to	to	ADP
dti-1419	147	3	the	the	DET
dti-1419	147	4	potential	potential	ADJ
dti-1419	147	5	shifts	shift	NOUN
dti-1419	147	6	in	in	ADP
dti-1419	147	7	dosing	dose	VERB
dti-1419	147	8	from	from	ADP
dti-1419	147	9	changing	change	VERB
dti-1419	147	10	dietary	dietary	ADJ
dti-1419	147	11	protein	protein	NOUN
dti-1419	147	12	and	and	CCONJ
dti-1419	147	13	phenylalanine	phenylalanine	NOUN
dti-1419	147	14	intake	intake	NOUN
dti-1419	147	15	,	,	PUNCT
dti-1419	147	16	continuation	continuation	NOUN
dti-1419	147	17	of	of	ADP
dti-1419	147	18	nutritional	nutritional	ADJ
dti-1419	147	19	and	and	CCONJ
dti-1419	147	20	blood	blood	NOUN
dti-1419	147	21	phenylalanine	phenylalanine	NOUN
dti-1419	147	22	monitoring	monitoring	NOUN
dti-1419	147	23	is	be	AUX
dti-1419	147	24	warranted	warrant	VERB
dti-1419	147	25	in	in	ADP
dti-1419	147	26	patients	patient	NOUN
dti-1419	147	27	treated	treat	VERB
dti-1419	147	28	with	with	ADP
dti-1419	147	29	pegvaliase.11,26	pegvaliase.11,26	NOUN
dti-1419	147	30	given	give	VERB
dti-1419	147	31	only	only	ADV
dti-1419	147	32	25	25	NUM
dti-1419	147	33	%	%	NOUN
dti-1419	147	34	to	to	PART
dti-1419	147	35	50	50	NUM
dti-1419	147	36	%	%	NOUN
dti-1419	147	37	of	of	ADP
dti-1419	147	38	patients	patient	NOUN
dti-1419	147	39	with	with	ADP
dti-1419	147	40	pku	pku	PROPN
dti-1419	147	41	respond	respond	NOUN
dti-1419	147	42	to	to	PART
dti-1419	147	43	sapropterin,3	sapropterin,3	VERB
dti-1419	147	44	the	the	DET
dti-1419	147	45	availability	availability	NOUN
dti-1419	147	46	of	of	ADP
dti-1419	147	47	additional	additional	ADJ
dti-1419	147	48	pharmacologic	pharmacologic	ADJ
dti-1419	147	49	options	option	NOUN
dti-1419	147	50	is	be	AUX
dti-1419	147	51	necessary	necessary	ADJ
dti-1419	147	52	to	to	PART
dti-1419	147	53	improve	improve	VERB
dti-1419	147	54	the	the	DET
dti-1419	147	55	quality	quality	NOUN
dti-1419	147	56	of	of	ADP
dti-1419	147	57	life	life	NOUN
dti-1419	147	58	in	in	ADP
dti-1419	147	59	patients	patient	NOUN
dti-1419	147	60	with	with	ADP
dti-1419	147	61	uncontrolled	uncontrolled	ADJ
dti-1419	147	62	pku	pku	NOUN
dti-1419	147	63	.	.	PUNCT
dti-1419	148	1	in	in	ADP
dti-1419	148	2	2015	2015	NUM
dti-1419	148	3	,	,	PUNCT
dti-1419	148	4	the	the	DET
dti-1419	148	5	national	national	PROPN
dti-1419	148	6	pku	pku	PROPN
dti-1419	148	7	alliance	alliance	PROPN
dti-1419	148	8	conducted	conduct	VERB
dti-1419	148	9	a	a	DET
dti-1419	148	10	survey	survey	NOUN
dti-1419	148	11	of	of	ADP
dti-1419	148	12	adults	adult	NOUN
dti-1419	148	13	and	and	CCONJ
dti-1419	148	14	children	child	NOUN
dti-1419	148	15	with	with	ADP
dti-1419	148	16	pku	pku	PROPN
dti-1419	148	17	in	in	ADP
dti-1419	148	18	the	the	DET
dti-1419	148	19	united	united	PROPN
dti-1419	148	20	states	states	PROPN
dti-1419	148	21	.	.	PUNCT
dti-1419	149	1	the	the	DET
dti-1419	149	2	survey	survey	NOUN
dti-1419	149	3	confirmed	confirm	VERB
dti-1419	149	4	that	that	SCONJ
dti-1419	149	5	dietary	dietary	ADJ
dti-1419	149	6	therapy	therapy	NOUN
dti-1419	149	7	is	be	AUX
dti-1419	149	8	the	the	DET
dti-1419	149	9	mainstay	mainstay	NOUN
dti-1419	149	10	of	of	ADP
dti-1419	149	11	clinical	clinical	ADJ
dti-1419	149	12	treatment	treatment	NOUN
dti-1419	149	13	.	.	PUNCT
dti-1419	150	1	approximately	approximately	ADV
dti-1419	150	2	6	6	NUM
dti-1419	150	3	%	%	NOUN
dti-1419	150	4	of	of	ADP
dti-1419	150	5	survey	survey	NOUN
dti-1419	150	6	respondents	respondent	NOUN
dti-1419	150	7	stated	state	VERB
dti-1419	150	8	they	they	PRON
dti-1419	150	9	were	be	AUX
dti-1419	150	10	not	not	PART
dti-1419	150	11	treating	treat	VERB
dti-1419	150	12	pku	pku	PROPN
dti-1419	150	13	with	with	ADP
dti-1419	150	14	medical	medical	ADJ
dti-1419	150	15	foods	food	NOUN
dti-1419	150	16	or	or	CCONJ
dti-1419	150	17	pharmacotherapy	pharmacotherapy	NOUN
dti-1419	150	18	.	.	PUNCT
dti-1419	151	1	most	most	ADJ
dti-1419	151	2	survey	survey	NOUN
dti-1419	151	3	respondents	respondent	NOUN
dti-1419	151	4	(	(	PUNCT
dti-1419	151	5	91	91	NUM
dti-1419	151	6	%	%	NOUN
dti-1419	151	7	)	)	PUNCT
dti-1419	151	8	stated	state	VERB
dti-1419	151	9	the	the	DET
dti-1419	151	10	importance	importance	NOUN
dti-1419	151	11	of	of	ADP
dti-1419	151	12	development	development	NOUN
dti-1419	151	13	of	of	ADP
dti-1419	151	14	new	new	ADJ
dti-1419	151	15	products	product	NOUN
dti-1419	151	16	for	for	ADP
dti-1419	151	17	pku	pku	PROPN
dti-1419	151	18	.	.	PUNCT
dti-1419	152	1	respondents	respondent	NOUN
dti-1419	152	2	generally	generally	ADV
dti-1419	152	3	preferred	prefer	VERB
dti-1419	152	4	oral	oral	ADJ
dti-1419	152	5	therapy	therapy	NOUN
dti-1419	152	6	over	over	ADP
dti-1419	152	7	injectable	injectable	ADJ
dti-1419	152	8	therapy	therapy	NOUN
dti-1419	152	9	,	,	PUNCT
dti-1419	152	10	and	and	CCONJ
dti-1419	152	11	home	home	NOUN
dti-1419	152	12	injections	injection	NOUN
dti-1419	152	13	over	over	ADP
dti-1419	152	14	injections	injection	NOUN
dti-1419	152	15	,	,	PUNCT
dti-1419	152	16	at	at	ADP
dti-1419	152	17	a	a	DET
dti-1419	152	18	medical	medical	ADJ
dti-1419	152	19	facility.27	facility.27	PROPN
dti-1419	152	20	pegvaliase	pegvaliase	NOUN
dti-1419	152	21	is	be	AUX
dti-1419	152	22	a	a	DET
dti-1419	152	23	novel	novel	ADJ
dti-1419	152	24	enzyme	enzyme	NOUN
dti-1419	152	25	substitution	substitution	NOUN
dti-1419	152	26	therapy	therapy	NOUN
dti-1419	152	27	which	which	PRON
dti-1419	152	28	can	can	AUX
dti-1419	152	29	be	be	AUX
dti-1419	152	30	used	use	VERB
dti-1419	152	31	in	in	ADP
dti-1419	152	32	patients	patient	NOUN
dti-1419	152	33	with	with	ADP
dti-1419	152	34	more	more	ADV
dti-1419	152	35	severe	severe	ADJ
dti-1419	152	36	disease	disease	NOUN
dti-1419	152	37	and	and	CCONJ
dti-1419	152	38	in	in	ADP
dti-1419	152	39	part	part	NOUN
dti-1419	152	40	meets	meet	VERB
dti-1419	152	41	the	the	DET
dti-1419	152	42	needs	need	NOUN
dti-1419	152	43	of	of	ADP
dti-1419	152	44	the	the	DET
dti-1419	152	45	pku	pku	PROPN
dti-1419	152	46	community	community	NOUN
dti-1419	152	47	.	.	PUNCT
dti-1419	153	1	the	the	DET
dti-1419	153	2	subcutaneous	subcutaneous	ADJ
dti-1419	153	3	prefilled	prefille	VERB
dti-1419	153	4	syringe	syringe	NOUN
dti-1419	153	5	can	can	AUX
dti-1419	153	6	be	be	AUX
dti-1419	153	7	self	self	NOUN
dti-1419	153	8	-	-	PUNCT
dti-1419	153	9	administered	administer	VERB
dti-1419	153	10	if	if	SCONJ
dti-1419	153	11	patients	patient	NOUN
dti-1419	153	12	demonstrate	demonstrate	VERB
dti-1419	153	13	adequate	adequate	ADJ
dti-1419	153	14	competency.11	competency.11	ADJ
dti-1419	153	15	although	although	SCONJ
dti-1419	153	16	an	an	DET
dti-1419	153	17	oral	oral	ADJ
dti-1419	153	18	pegylated	pegylate	VERB
dti-1419	153	19	pal	pal	ADJ
dti-1419	153	20	formulation	formulation	NOUN
dti-1419	153	21	has	have	AUX
dti-1419	153	22	been	be	AUX
dti-1419	153	23	investigated	investigate	VERB
dti-1419	153	24	in	in	ADP
dti-1419	153	25	animal	animal	NOUN
dti-1419	153	26	studies,28	studies,28	NOUN
dti-1419	153	27	similar	similar	ADJ
dti-1419	153	28	trials	trial	NOUN
dti-1419	153	29	have	have	AUX
dti-1419	153	30	not	not	PART
dti-1419	153	31	been	be	AUX
dti-1419	153	32	conducted	conduct	VERB
dti-1419	153	33	in	in	ADP
dti-1419	153	34	humans	human	NOUN
dti-1419	153	35	.	.	PUNCT
dti-1419	154	1	it	it	PRON
dti-1419	154	2	is	be	AUX
dti-1419	154	3	recommended	recommend	VERB
dti-1419	154	4	that	that	SCONJ
dti-1419	154	5	multidisciplinary	multidisciplinary	ADJ
dti-1419	154	6	teams	team	NOUN
dti-1419	154	7	continue	continue	VERB
dti-1419	154	8	involvement	involvement	NOUN
dti-1419	154	9	in	in	ADP
dti-1419	154	10	hydery	hydery	NOUN
dti-1419	154	11	and	and	CCONJ
dti-1419	154	12	coppenrath	coppenrath	PROPN
dti-1419	154	13	7	7	NUM
dti-1419	154	14	care	care	NOUN
dti-1419	154	15	of	of	ADP
dti-1419	154	16	patients	patient	NOUN
dti-1419	154	17	with	with	ADP
dti-1419	154	18	pku	pku	PROPN
dti-1419	154	19	,	,	PUNCT
dti-1419	154	20	including	include	VERB
dti-1419	154	21	monitoring	monitor	VERB
dti-1419	154	22	therapeutic	therapeutic	ADJ
dti-1419	154	23	response	response	NOUN
dti-1419	154	24	,	,	PUNCT
dti-1419	154	25	adverse	adverse	ADJ
dti-1419	154	26	effects	effect	NOUN
dti-1419	154	27	,	,	PUNCT
dti-1419	154	28	and	and	CCONJ
dti-1419	154	29	medication	medication	NOUN
dti-1419	154	30	adherence	adherence	NOUN
dti-1419	154	31	.	.	PUNCT
dti-1419	155	1	cost	cost	NOUN
dti-1419	155	2	as	as	ADP
dti-1419	155	3	of	of	ADP
dti-1419	155	4	june	june	PROPN
dti-1419	155	5	2018	2018	NUM
dti-1419	155	6	,	,	PUNCT
dti-1419	155	7	pegvaliase	pegvaliase	PROPN
dti-1419	155	8	has	have	AUX
dti-1419	155	9	been	be	AUX
dti-1419	155	10	launched	launch	VERB
dti-1419	155	11	.	.	PUNCT
dti-1419	156	1	for	for	ADP
dti-1419	156	2	cost	cost	NOUN
dti-1419	156	3	considerations	consideration	NOUN
dti-1419	156	4	,	,	PUNCT
dti-1419	156	5	the	the	DET
dti-1419	156	6	average	average	ADJ
dti-1419	156	7	wholesale	wholesale	ADJ
dti-1419	156	8	price	price	NOUN
dti-1419	156	9	(	(	PUNCT
dti-1419	156	10	awp	awp	PROPN
dti-1419	156	11	)	)	PUNCT
dti-1419	156	12	for	for	ADP
dti-1419	156	13	pegvaliasepqpz	pegvaliasepqpz	NOUN
dti-1419	156	14	prefilled	prefille	VERB
dti-1419	156	15	syringes	syrinx	NOUN
dti-1419	156	16	are	be	AUX
dti-1419	156	17	us$585.60	us$585.60	ADJ
dti-1419	156	18	which	which	PRON
dti-1419	156	19	includes	include	VERB
dti-1419	156	20	3	3	NUM
dti-1419	156	21	strengths	strength	NOUN
dti-1419	156	22	:	:	PUNCT
dti-1419	156	23	2.5	2.5	NUM
dti-1419	156	24	mg/0.5	mg/0.5	NOUN
dti-1419	156	25	ml	ml	NOUN
dti-1419	156	26	,	,	PUNCT
dti-1419	156	27	10	10	NUM
dti-1419	156	28	mg/0.5	mg/0.5	NOUN
dti-1419	156	29	ml	ml	NOUN
dti-1419	156	30	,	,	PUNCT
dti-1419	156	31	and	and	CCONJ
dti-1419	156	32	20	20	NUM
dti-1419	156	33	mg	mg	NUM
dti-1419	156	34	/	/	SYM
dti-1419	156	35	ml	ml	NOUN
dti-1419	156	36	,	,	PUNCT
dti-1419	156	37	whereas	whereas	SCONJ
dti-1419	156	38	the	the	DET
dti-1419	156	39	awp	awp	NOUN
dti-1419	156	40	of	of	ADP
dti-1419	156	41	sapropterin	sapropterin	NOUN
dti-1419	156	42	100	100	NUM
dti-1419	156	43	and	and	CCONJ
dti-1419	156	44	500	500	NUM
dti-1419	156	45	mg	mg	NOUN
dti-1419	156	46	tablets	tablet	NOUN
dti-1419	156	47	are	be	AUX
dti-1419	156	48	us$44.28	us$44.28	ADJ
dti-1419	156	49	and	and	CCONJ
dti-1419	156	50	us$221.40	us$221.40	NOUN
dti-1419	156	51	per	per	ADP
dti-1419	156	52	tablet	tablet	NOUN
dti-1419	156	53	,	,	PUNCT
dti-1419	156	54	respectively.29,30	respectively.29,30	NOUN
dti-1419	156	55	using	use	VERB
dti-1419	156	56	these	these	DET
dti-1419	156	57	awp	awp	NOUN
dti-1419	156	58	cost	cost	NOUN
dti-1419	156	59	figures	figure	NOUN
dti-1419	156	60	,	,	PUNCT
dti-1419	156	61	the	the	DET
dti-1419	156	62	30	30	NUM
dti-1419	156	63	-	-	PUNCT
dti-1419	156	64	day	day	NOUN
dti-1419	156	65	cost	cost	NOUN
dti-1419	156	66	for	for	ADP
dti-1419	156	67	a	a	DET
dti-1419	156	68	70	70	NUM
dti-1419	156	69	kg	kg	NOUN
dti-1419	156	70	patient	patient	NOUN
dti-1419	156	71	at	at	ADP
dti-1419	156	72	the	the	DET
dti-1419	156	73	maximum	maximum	ADJ
dti-1419	156	74	recommended	recommend	VERB
dti-1419	156	75	sapropterin	sapropterin	NOUN
dti-1419	156	76	dose	dose	NOUN
dti-1419	156	77	(	(	PUNCT
dti-1419	156	78	20	20	NUM
dti-1419	156	79	mg	mg	NUM
dti-1419	156	80	/	/	SYM
dti-1419	156	81	kg	kg	NOUN
dti-1419	156	82	once	once	ADV
dti-1419	156	83	daily	daily	ADV
dti-1419	156	84	)	)	PUNCT
dti-1419	156	85	is	be	AUX
dti-1419	156	86	us$5314	us$5314	ADJ
dti-1419	156	87	and	and	CCONJ
dti-1419	156	88	at	at	ADP
dti-1419	156	89	the	the	DET
dti-1419	156	90	maximum	maximum	ADJ
dti-1419	156	91	recommended	recommend	VERB
dti-1419	156	92	pegvaliase	pegvaliase	ADJ
dti-1419	156	93	-	-	PUNCT
dti-1419	156	94	pqpz	pqpz	ADJ
dti-1419	156	95	dose	dose	NOUN
dti-1419	156	96	(	(	PUNCT
dti-1419	156	97	40	40	NUM
dti-1419	156	98	mg	mg	NOUN
dti-1419	156	99	once	once	ADV
dti-1419	156	100	daily	daily	ADV
dti-1419	156	101	)	)	PUNCT
dti-1419	156	102	is	be	AUX
dti-1419	156	103	us$35	us$35	ADJ
dti-1419	156	104	136	136	NUM
dti-1419	156	105	.	.	PUNCT
dti-1419	157	1	biomarin	biomarin	NOUN
dti-1419	157	2	pharmaceuticals	pharmaceutical	NOUN
dti-1419	157	3	predicts	predict	VERB
dti-1419	157	4	the	the	DET
dti-1419	157	5	average	average	ADJ
dti-1419	157	6	annual	annual	ADJ
dti-1419	157	7	net	net	ADJ
dti-1419	157	8	cost	cost	NOUN
dti-1419	157	9	of	of	ADP
dti-1419	157	10	therapy	therapy	NOUN
dti-1419	157	11	for	for	ADP
dti-1419	157	12	a	a	DET
dti-1419	157	13	typical	typical	ADJ
dti-1419	157	14	patient	patient	NOUN
dti-1419	157	15	to	to	PART
dti-1419	157	16	be	be	AUX
dti-1419	157	17	approximately	approximately	ADV
dti-1419	157	18	us$192	us$192	ADJ
dti-1419	157	19	000	000	NUM
dti-1419	157	20	per	per	ADP
dti-1419	157	21	year	year	NOUN
dti-1419	157	22	based	base	VERB
dti-1419	157	23	on	on	ADP
dti-1419	157	24	an	an	DET
dti-1419	157	25	average	average	NOUN
dti-1419	157	26	of	of	ADP
dti-1419	157	27	1.5	1.5	NUM
dti-1419	157	28	units	unit	NOUN
dti-1419	157	29	per	per	ADP
dti-1419	157	30	patient	patient	NOUN
dti-1419	157	31	at	at	ADP
dti-1419	157	32	maintenance	maintenance	NOUN
dti-1419	157	33	dosing.24	dosing.24	NOUN
dti-1419	157	34	dietary	dietary	ADJ
dti-1419	157	35	treatments	treatment	NOUN
dti-1419	157	36	used	use	VERB
dti-1419	157	37	in	in	ADP
dti-1419	157	38	conjunction	conjunction	NOUN
dti-1419	157	39	with	with	ADP
dti-1419	157	40	currently	currently	ADV
dti-1419	157	41	available	available	ADJ
dti-1419	157	42	pharmacotherapy	pharmacotherapy	NOUN
dti-1419	157	43	pose	pose	VERB
dti-1419	157	44	an	an	DET
dti-1419	157	45	additional	additional	ADJ
dti-1419	157	46	cost	cost	NOUN
dti-1419	157	47	burden	burden	NOUN
dti-1419	157	48	to	to	ADP
dti-1419	157	49	patients	patient	NOUN
dti-1419	157	50	and	and	CCONJ
dti-1419	157	51	payers	payer	NOUN
dti-1419	157	52	.	.	PUNCT
dti-1419	158	1	conclusions	conclusion	NOUN
dti-1419	158	2	patient	patient	ADJ
dti-1419	158	3	characteristics	characteristic	NOUN
dti-1419	158	4	and	and	CCONJ
dti-1419	158	5	preferences	preference	NOUN
dti-1419	158	6	should	should	AUX
dti-1419	158	7	be	be	AUX
dti-1419	158	8	considered	consider	VERB
dti-1419	158	9	to	to	PART
dti-1419	158	10	help	help	VERB
dti-1419	158	11	guide	guide	VERB
dti-1419	158	12	treatment	treatment	NOUN
dti-1419	158	13	of	of	ADP
dti-1419	158	14	pku	pku	PROPN
dti-1419	158	15	.	.	PUNCT
dti-1419	159	1	pegvaliase	pegvaliase	PROPN
dti-1419	159	2	reduces	reduce	VERB
dti-1419	159	3	blood	blood	NOUN
dti-1419	159	4	phenylalanine	phenylalanine	NOUN
dti-1419	159	5	concentrations	concentration	NOUN
dti-1419	159	6	independent	independent	ADJ
dti-1419	159	7	of	of	ADP
dti-1419	159	8	pah	pah	PROPN
dti-1419	159	9	activity	activity	NOUN
dti-1419	159	10	compared	compare	VERB
dti-1419	159	11	with	with	ADP
dti-1419	159	12	previously	previously	ADV
dti-1419	159	13	available	available	ADJ
dti-1419	159	14	therapeutic	therapeutic	ADJ
dti-1419	159	15	alternatives.4	alternatives.4	PROPN
dti-1419	159	16	in	in	ADP
dti-1419	159	17	pivotal	pivotal	ADJ
dti-1419	159	18	phase	phase	NOUN
dti-1419	159	19	3	3	NUM
dti-1419	159	20	clinical	clinical	ADJ
dti-1419	159	21	studies	study	NOUN
dti-1419	159	22	,	,	PUNCT
dti-1419	159	23	treatment	treatment	NOUN
dti-1419	159	24	with	with	ADP
dti-1419	159	25	pegvaliase	pegvaliase	NOUN
dti-1419	159	26	was	be	AUX
dti-1419	159	27	associated	associate	VERB
dti-1419	159	28	with	with	ADP
dti-1419	159	29	overall	overall	ADJ
dti-1419	159	30	safety	safety	NOUN
dti-1419	159	31	and	and	CCONJ
dti-1419	159	32	statistically	statistically	ADV
dti-1419	159	33	significant	significant	ADJ
dti-1419	159	34	improvements	improvement	NOUN
dti-1419	159	35	in	in	ADP
dti-1419	159	36	blood	blood	NOUN
dti-1419	159	37	phenylalanine	phenylalanine	NOUN
dti-1419	160	1	concentrations.18,19	concentrations.18,19	NOUN
dti-1419	160	2	patients	patient	NOUN
dti-1419	160	3	also	also	ADV
dti-1419	160	4	had	have	VERB
dti-1419	160	5	sustained	sustain	VERB
dti-1419	160	6	reductions	reduction	NOUN
dti-1419	160	7	in	in	ADP
dti-1419	160	8	blood	blood	NOUN
dti-1419	160	9	phenylalanine	phenylalanine	NOUN
dti-1419	160	10	concentrations	concentration	NOUN
dti-1419	160	11	that	that	PRON
dti-1419	160	12	reached	reach	VERB
dti-1419	160	13	guideline	guideline	NOUN
dti-1419	160	14	-	-	PUNCT
dti-1419	160	15	recommended	recommend	VERB
dti-1419	160	16	levels	level	NOUN
dti-1419	160	17	.	.	PUNCT
dti-1419	161	1	however	however	ADV
dti-1419	161	2	,	,	PUNCT
dti-1419	161	3	due	due	ADP
dti-1419	161	4	to	to	ADP
dti-1419	161	5	risks	risk	NOUN
dti-1419	161	6	of	of	ADP
dti-1419	161	7	anaphylaxis	anaphylaxis	ADJ
dti-1419	161	8	,	,	PUNCT
dti-1419	161	9	pegvaliase	pegvaliase	PROPN
dti-1419	161	10	is	be	AUX
dti-1419	161	11	only	only	ADV
dti-1419	161	12	available	available	ADJ
dti-1419	161	13	through	through	ADP
dti-1419	161	14	a	a	DET
dti-1419	161	15	restricted	restricted	ADJ
dti-1419	161	16	program	program	NOUN
dti-1419	161	17	under	under	ADP
dti-1419	161	18	rems.11	rems.11	PROPN
dti-1419	161	19	the	the	DET
dti-1419	161	20	injectable	injectable	ADJ
dti-1419	161	21	route	route	NOUN
dti-1419	161	22	of	of	ADP
dti-1419	161	23	administration	administration	NOUN
dti-1419	161	24	,	,	PUNCT
dti-1419	161	25	potential	potential	ADJ
dti-1419	161	26	risks	risk	NOUN
dti-1419	161	27	,	,	PUNCT
dti-1419	161	28	and	and	CCONJ
dti-1419	161	29	factors	factor	NOUN
dti-1419	161	30	related	relate	VERB
dti-1419	161	31	to	to	ADP
dti-1419	161	32	insurance	insurance	NOUN
dti-1419	161	33	coverage	coverage	NOUN
dti-1419	161	34	may	may	AUX
dti-1419	161	35	limit	limit	VERB
dti-1419	161	36	the	the	DET
dti-1419	161	37	use	use	NOUN
dti-1419	161	38	of	of	ADP
dti-1419	161	39	pegvaliase	pegvaliase	NOUN
dti-1419	161	40	.	.	PUNCT
dti-1419	162	1	at	at	ADP
dti-1419	162	2	the	the	DET
dti-1419	162	3	present	present	ADJ
dti-1419	162	4	time	time	NOUN
dti-1419	162	5	,	,	PUNCT
dti-1419	162	6	pegvaliase	pegvaliase	PROPN
dti-1419	162	7	is	be	AUX
dti-1419	162	8	only	only	ADV
dti-1419	162	9	fda	fda	PROPN
dti-1419	162	10	-	-	PUNCT
dti-1419	162	11	approved	approve	VERB
dti-1419	162	12	for	for	ADP
dti-1419	162	13	use	use	NOUN
dti-1419	162	14	in	in	ADP
dti-1419	162	15	adults	adult	NOUN
dti-1419	162	16	who	who	PRON
dti-1419	162	17	have	have	VERB
dti-1419	162	18	uncontrolled	uncontrolled	ADJ
dti-1419	162	19	blood	blood	NOUN
dti-1419	162	20	phenylalanine	phenylalanine	NOUN
dti-1419	162	21	concentrations	concentration	NOUN
dti-1419	162	22	>	>	PUNCT
dti-1419	162	23	600	600	NUM
dti-1419	162	24	µmol	µmol	ADV
dti-1419	162	25	/	/	SYM
dti-1419	162	26	l.11	l.11	ADP
dti-1419	162	27	clinical	clinical	ADJ
dti-1419	162	28	guidelines	guideline	NOUN
dti-1419	162	29	have	have	AUX
dti-1419	162	30	been	be	AUX
dti-1419	162	31	updated	update	VERB
dti-1419	162	32	to	to	PART
dti-1419	162	33	address	address	VERB
dti-1419	162	34	the	the	DET
dti-1419	162	35	role	role	NOUN
dti-1419	162	36	of	of	ADP
dti-1419	162	37	pegvaliase	pegvaliase	NOUN
dti-1419	162	38	in	in	ADP
dti-1419	162	39	management	management	NOUN
dti-1419	162	40	of	of	ADP
dti-1419	162	41	pku.26	pku.26	NOUN
dti-1419	162	42	given	give	VERB
dti-1419	162	43	the	the	DET
dti-1419	162	44	high	high	ADJ
dti-1419	162	45	cost	cost	NOUN
dti-1419	162	46	,	,	PUNCT
dti-1419	162	47	therapy	therapy	NOUN
dti-1419	162	48	may	may	AUX
dti-1419	162	49	be	be	AUX
dti-1419	162	50	a	a	DET
dti-1419	162	51	viable	viable	ADJ
dti-1419	162	52	option	option	NOUN
dti-1419	162	53	for	for	ADP
dti-1419	162	54	patients	patient	NOUN
dti-1419	162	55	who	who	PRON
dti-1419	162	56	have	have	AUX
dti-1419	162	57	failed	fail	VERB
dti-1419	162	58	existing	exist	VERB
dti-1419	162	59	management	management	NOUN
dti-1419	162	60	strategies	strategy	NOUN
dti-1419	162	61	due	due	ADJ
dti-1419	162	62	to	to	ADP
dti-1419	162	63	inadequate	inadequate	ADJ
dti-1419	162	64	response	response	NOUN
dti-1419	162	65	or	or	CCONJ
dti-1419	162	66	desire	desire	NOUN
dti-1419	162	67	for	for	ADP
dti-1419	162	68	dietary	dietary	ADJ
dti-1419	162	69	relaxation	relaxation	NOUN
dti-1419	162	70	.	.	PUNCT
dti-1419	163	1	further	further	ADJ
dti-1419	163	2	research	research	NOUN
dti-1419	163	3	should	should	AUX
dti-1419	163	4	be	be	AUX
dti-1419	163	5	conducted	conduct	VERB
dti-1419	163	6	to	to	PART
dti-1419	163	7	evaluate	evaluate	VERB
dti-1419	163	8	the	the	DET
dti-1419	163	9	safety	safety	NOUN
dti-1419	163	10	and	and	CCONJ
dti-1419	163	11	efficacy	efficacy	NOUN
dti-1419	163	12	in	in	ADP
dti-1419	163	13	younger	young	ADJ
dti-1419	163	14	patients	patient	NOUN
dti-1419	163	15	,	,	PUNCT
dti-1419	163	16	those	those	PRON
dti-1419	163	17	with	with	ADP
dti-1419	163	18	milder	mild	ADJ
dti-1419	163	19	forms	form	NOUN
dti-1419	163	20	of	of	ADP
dti-1419	163	21	pku	pku	NOUN
dti-1419	163	22	,	,	PUNCT
dti-1419	163	23	in	in	ADP
dti-1419	163	24	combination	combination	NOUN
dti-1419	163	25	with	with	ADP
dti-1419	163	26	sapropterin	sapropterin	NOUN
dti-1419	163	27	,	,	PUNCT
dti-1419	163	28	and	and	CCONJ
dti-1419	163	29	with	with	ADP
dti-1419	163	30	limited	limited	ADJ
dti-1419	163	31	dietary	dietary	ADJ
dti-1419	163	32	therapy	therapy	NOUN
dti-1419	163	33	.	.	PUNCT
dti-1419	164	1	author	author	NOUN
dti-1419	164	2	contributions	contribution	VERB
dti-1419	164	3	th	th	X
dti-1419	164	4	and	and	CCONJ
dti-1419	164	5	vac	vac	NOUN
dti-1419	164	6	wrote	write	VERB
dti-1419	164	7	,	,	PUNCT
dti-1419	164	8	reviewed	review	VERB
dti-1419	164	9	,	,	PUNCT
dti-1419	164	10	and	and	CCONJ
dti-1419	164	11	approved	approve	VERB
dti-1419	164	12	the	the	DET
dti-1419	164	13	final	final	ADJ
dti-1419	164	14	manuscript	manuscript	NOUN
dti-1419	164	15	.	.	PUNCT
dti-1419	165	1	ethical	ethical	ADJ
dti-1419	165	2	approval	approval	NOUN
dti-1419	165	3	given	give	VERB
dti-1419	165	4	there	there	PRON
dti-1419	165	5	was	be	VERB
dti-1419	165	6	no	no	DET
dti-1419	165	7	human	human	ADJ
dti-1419	165	8	participation	participation	NOUN
dti-1419	165	9	or	or	CCONJ
dti-1419	165	10	use	use	NOUN
dti-1419	165	11	of	of	ADP
dti-1419	165	12	personal	personal	ADJ
dti-1419	165	13	data	datum	NOUN
dti-1419	165	14	involved	involve	VERB
dti-1419	165	15	in	in	ADP
dti-1419	165	16	the	the	DET
dti-1419	165	17	writing	writing	NOUN
dti-1419	165	18	of	of	ADP
dti-1419	165	19	this	this	DET
dti-1419	165	20	review	review	NOUN
dti-1419	165	21	article	article	NOUN
dti-1419	165	22	,	,	PUNCT
dti-1419	165	23	no	no	DET
dti-1419	165	24	ethical	ethical	ADJ
dti-1419	165	25	permission	permission	NOUN
dti-1419	165	26	was	be	AUX
dti-1419	165	27	applied	apply	VERB
dti-1419	165	28	for	for	ADP
dti-1419	165	29	.	.	PUNCT
dti-1419	166	1	informed	inform	VERB
dti-1419	166	2	consent	consent	NOUN
dti-1419	166	3	given	give	VERB
dti-1419	166	4	the	the	DET
dti-1419	166	5	writing	writing	NOUN
dti-1419	166	6	of	of	ADP
dti-1419	166	7	this	this	DET
dti-1419	166	8	review	review	NOUN
dti-1419	166	9	article	article	NOUN
dti-1419	166	10	was	be	AUX
dti-1419	166	11	non	non	ADJ
dti-1419	166	12	-	-	ADJ
dti-1419	166	13	human	human	ADJ
dti-1419	166	14	subject	subject	NOUN
dti-1419	166	15	research	research	NOUN
dti-1419	166	16	and	and	CCONJ
dti-1419	166	17	based	base	VERB
dti-1419	166	18	on	on	ADP
dti-1419	166	19	the	the	DET
dti-1419	166	20	availability	availability	NOUN
dti-1419	166	21	of	of	ADP
dti-1419	166	22	published	publish	VERB
dti-1419	166	23	clinical	clinical	ADJ
dti-1419	166	24	trial	trial	NOUN
dti-1419	166	25	data	datum	NOUN
dti-1419	166	26	,	,	PUNCT
dti-1419	166	27	written	write	VERB
dti-1419	166	28	/	/	SYM
dti-1419	166	29	verbal	verbal	ADJ
dti-1419	166	30	consent	consent	NOUN
dti-1419	166	31	from	from	ADP
dti-1419	166	32	patients	patient	NOUN
dti-1419	166	33	and/or	and/or	CCONJ
dti-1419	166	34	caregivers	caregiver	NOUN
dti-1419	166	35	was	be	AUX
dti-1419	166	36	not	not	PART
dti-1419	166	37	necessary	necessary	ADJ
dti-1419	166	38	.	.	PUNCT
dti-1419	167	1	orcid	orcid	NOUN
dti-1419	168	1	i	i	PRON
dti-1419	168	2	d	d	PROPN
dti-1419	168	3	tasmina	tasmina	PROPN
dti-1419	168	4	hydery	hydery	PROPN
dti-1419	168	5	https://orcid.org/0000-0002-7206-1668	https://orcid.org/0000-0002-7206-1668	PROPN
dti-1419	168	6	references	reference	NOUN
dti-1419	168	7	1	1	NUM
dti-1419	168	8	.	.	PUNCT
dti-1419	168	9	national	national	PROPN
dti-1419	168	10	institutes	institutes	PROPN
dti-1419	168	11	of	of	ADP
dti-1419	168	12	health	health	PROPN
dti-1419	168	13	consensus	consensus	PROPN
dti-1419	168	14	development	development	PROPN
dti-1419	168	15	panel	panel	NOUN
dti-1419	168	16	.	.	PUNCT
dti-1419	169	1	national	national	PROPN
dti-1419	169	2	institutes	institutes	PROPN
dti-1419	169	3	of	of	ADP
dti-1419	169	4	health	health	PROPN
dti-1419	169	5	consensus	consensus	PROPN
dti-1419	169	6	development	development	PROPN
dti-1419	169	7	conference	conference	NOUN
dti-1419	169	8	statement	statement	NOUN
dti-1419	169	9	:	:	PUNCT
dti-1419	169	10	phenylketonuria	phenylketonuria	NOUN
dti-1419	169	11	:	:	PUNCT
dti-1419	169	12	screening	screening	NOUN
dti-1419	169	13	and	and	CCONJ
dti-1419	169	14	management	management	NOUN
dti-1419	169	15	,	,	PUNCT
dti-1419	169	16	october	october	PROPN
dti-1419	169	17	16–18	16–18	NUM
dti-1419	169	18	,	,	PUNCT
dti-1419	169	19	2000	2000	NUM
dti-1419	169	20	.	.	PUNCT
dti-1419	170	1	pediatrics	pediatric	NOUN
dti-1419	170	2	.	.	PUNCT
dti-1419	171	1	2001	2001	NUM
dti-1419	171	2	;	;	PUNCT
dti-1419	171	3	108:972	108:972	NUM
dti-1419	171	4	.	.	NOUN
dti-1419	171	5	2	2	NUM
dti-1419	171	6	.	.	X
dti-1419	171	7	bodamer	bodamer	NOUN
dti-1419	171	8	oa	oa	PROPN
dti-1419	171	9	,	,	PUNCT
dti-1419	171	10	hahn	hahn	PROPN
dti-1419	171	11	s	s	PROPN
dti-1419	171	12	,	,	PUNCT
dti-1419	171	13	tepas	tepas	ADJ
dti-1419	171	14	e.	e.	PROPN
dti-1419	171	15	overview	overview	NOUN
dti-1419	171	16	of	of	ADP
dti-1419	171	17	phenylketonuria	phenylketonuria	NOUN
dti-1419	171	18	.	.	PUNCT
dti-1419	172	1	in	in	ADP
dti-1419	172	2	:	:	PUNCT
dti-1419	172	3	basow	basow	PROPN
dti-1419	172	4	,	,	PUNCT
dti-1419	172	5	ds	ds	ADJ
dti-1419	172	6	,	,	PUNCT
dti-1419	172	7	ed	ed	NOUN
dti-1419	172	8	.	.	PUNCT
dti-1419	172	9	uptodate	uptodate	ADJ
dti-1419	173	1	[	[	X
dti-1419	173	2	database	database	NOUN
dti-1419	173	3	on	on	ADP
dti-1419	173	4	the	the	DET
dti-1419	173	5	internet	internet	NOUN
dti-1419	173	6	]	]	PUNCT
dti-1419	173	7	.	.	PUNCT
dti-1419	174	1	waltham	waltham	PROPN
dti-1419	174	2	,	,	PUNCT
dti-1419	174	3	ma	ma	PROPN
dti-1419	174	4	:	:	PUNCT
dti-1419	174	5	uptodate	uptodate	ADJ
dti-1419	174	6	;	;	PUNCT
dti-1419	174	7	2018	2018	NUM
dti-1419	174	8	.	.	PUNCT
dti-1419	175	1	http://www.utdol.com/utd/index.do	http://www.utdol.com/utd/index.do	PROPN
dti-1419	175	2	.	.	PUNCT
dti-1419	175	3	accessed	access	VERB
dti-1419	175	4	june	june	PROPN
dti-1419	175	5	19	19	NUM
dti-1419	175	6	,	,	PUNCT
dti-1419	175	7	2018	2018	NUM
dti-1419	175	8	.	.	PUNCT
dti-1419	176	1	3	3	X
dti-1419	176	2	.	.	X
dti-1419	176	3	scriver	scriver	PROPN
dti-1419	176	4	cr	cr	PROPN
dti-1419	176	5	,	,	PUNCT
dti-1419	176	6	kaufman	kaufman	PROPN
dti-1419	176	7	s.	s.	PROPN
dti-1419	176	8	the	the	DET
dti-1419	176	9	hyperphenylalaninemias	hyperphenylalaninemias	PROPN
dti-1419	176	10	.	.	PUNCT
dti-1419	177	1	phenylalanine	phenylalanine	ADJ
dti-1419	177	2	hydroxylase	hydroxylase	NOUN
dti-1419	177	3	deficiency	deficiency	NOUN
dti-1419	177	4	.	.	PUNCT
dti-1419	178	1	in	in	ADP
dti-1419	178	2	:	:	PUNCT
dti-1419	178	3	scriver	scriver	NOUN
dti-1419	178	4	cr	cr	PROPN
dti-1419	178	5	,	,	PUNCT
dti-1419	178	6	beaudet	beaudet	PROPN
dti-1419	178	7	al	al	PROPN
dti-1419	178	8	,	,	PUNCT
dti-1419	178	9	sly	sly	ADJ
dti-1419	178	10	ws	ws	NOUN
dti-1419	178	11	,	,	PUNCT
dti-1419	178	12	valle	valle	PROPN
dti-1419	178	13	d	d	PROPN
dti-1419	178	14	,	,	PUNCT
dti-1419	178	15	eds	ed	NOUN
dti-1419	178	16	.	.	PUNCT
dti-1419	179	1	the	the	DET
dti-1419	179	2	metabolic	metabolic	NOUN
dti-1419	179	3	and	and	CCONJ
dti-1419	179	4	molecular	molecular	ADJ
dti-1419	179	5	bases	basis	NOUN
dti-1419	179	6	of	of	ADP
dti-1419	179	7	inherited	inherit	VERB
dti-1419	179	8	disease	disease	NOUN
dti-1419	179	9	.	.	PUNCT
dti-1419	180	1	8th	8th	ADJ
dti-1419	180	2	ed	ed	NOUN
dti-1419	180	3	.	.	PUNCT
dti-1419	181	1	new	new	PROPN
dti-1419	181	2	york	york	PROPN
dti-1419	181	3	:	:	PUNCT
dti-1419	181	4	mcgraw	mcgraw	PROPN
dti-1419	181	5	-	-	PUNCT
dti-1419	181	6	hill	hill	NOUN
dti-1419	181	7	;	;	PUNCT
dti-1419	181	8	2001:1667	2001:1667	NUM
dti-1419	181	9	.	.	NOUN
dti-1419	182	1	4	4	X
dti-1419	182	2	.	.	X
dti-1419	182	3	vockley	vockley	PROPN
dti-1419	182	4	j	j	PROPN
dti-1419	182	5	,	,	PUNCT
dti-1419	182	6	andersson	andersson	PROPN
dti-1419	182	7	hc	hc	PROPN
dti-1419	182	8	,	,	PUNCT
dti-1419	182	9	antshel	antshel	NOUN
dti-1419	182	10	km	km	PROPN
dti-1419	182	11	,	,	PUNCT
dti-1419	182	12	et	et	PROPN
dti-1419	182	13	al	al	PROPN
dti-1419	182	14	.	.	PROPN
dti-1419	182	15	phenylalanine	phenylalanine	ADJ
dti-1419	182	16	hydroxylase	hydroxylase	NOUN
dti-1419	182	17	deficiency	deficiency	NOUN
dti-1419	182	18	:	:	PUNCT
dti-1419	182	19	diagnosis	diagnosis	NOUN
dti-1419	182	20	and	and	CCONJ
dti-1419	182	21	management	management	NOUN
dti-1419	182	22	guideline	guideline	NOUN
dti-1419	182	23	.	.	PUNCT
dti-1419	183	1	genet	genet	PROPN
dti-1419	183	2	med	med	PROPN
dti-1419	183	3	.	.	PUNCT
dti-1419	184	1	2014;16:188–200	2014;16:188–200	PROPN
dti-1419	184	2	.	.	PUNCT
dti-1419	185	1	doi:10.1038	doi:10.1038	NOUN
dti-1419	185	2	/	/	SYM
dti-1419	185	3	gim.2013.157	gim.2013.157	NOUN
dti-1419	185	4	.	.	PUNCT
dti-1419	186	1	5	5	X
dti-1419	186	2	.	.	X
dti-1419	186	3	abadie	abadie	PROPN
dti-1419	186	4	v	v	ADP
dti-1419	186	5	,	,	PUNCT
dti-1419	186	6	berthelot	berthelot	PROPN
dti-1419	186	7	j	j	PROPN
dti-1419	186	8	,	,	PUNCT
dti-1419	186	9	feillet	feillet	NOUN
dti-1419	186	10	f	f	PROPN
dti-1419	186	11	,	,	PUNCT
dti-1419	186	12	et	et	PROPN
dti-1419	186	13	al	al	PROPN
dti-1419	186	14	.	.	PUNCT
dti-1419	187	1	[	[	X
dti-1419	187	2	management	management	NOUN
dti-1419	187	3	of	of	ADP
dti-1419	187	4	phenylketonuria	phenylketonuria	NOUN
dti-1419	187	5	and	and	CCONJ
dti-1419	187	6	hyperphenylalaninemia	hyperphenylalaninemia	ADV
dti-1419	187	7	:	:	PUNCT
dti-1419	187	8	the	the	DET
dti-1419	187	9	french	french	ADJ
dti-1419	187	10	guidelines	guideline	NOUN
dti-1419	187	11	]	]	PUNCT
dti-1419	187	12	.	.	PUNCT
dti-1419	188	1	arch	arch	ADJ
dti-1419	188	2	pediatr	pediatr	NOUN
dti-1419	188	3	.	.	PUNCT
dti-1419	189	1	2005;12:594	2005;12:594	NUM
dti-1419	189	2	.	.	PUNCT
dti-1419	189	3	doi:10.1016	doi:10.1016	PROPN
dti-1419	189	4	/	/	SYM
dti-1419	189	5	j.arcped.2005.02.004	j.arcped.2005.02.004	PROPN
dti-1419	189	6	.	.	PROPN
dti-1419	190	1	6	6	X
dti-1419	190	2	.	.	X
dti-1419	190	3	van	van	PROPN
dti-1419	190	4	wegberg	wegberg	PROPN
dti-1419	190	5	amj	amj	PROPN
dti-1419	190	6	,	,	PUNCT
dti-1419	190	7	macdonald	macdonald	PROPN
dti-1419	190	8	a	a	X
dti-1419	190	9	,	,	PUNCT
dti-1419	190	10	ahring	ahre	VERB
dti-1419	190	11	k	k	PROPN
dti-1419	190	12	,	,	PUNCT
dti-1419	190	13	et	et	PROPN
dti-1419	190	14	al	al	PROPN
dti-1419	190	15	.	.	PUNCT
dti-1419	191	1	the	the	DET
dti-1419	191	2	complete	complete	ADJ
dti-1419	191	3	european	european	ADJ
dti-1419	191	4	guidelines	guideline	NOUN
dti-1419	191	5	on	on	ADP
dti-1419	191	6	phenylketonuria	phenylketonuria	NOUN
dti-1419	191	7	:	:	PUNCT
dti-1419	191	8	diagnosis	diagnosis	NOUN
dti-1419	191	9	and	and	CCONJ
dti-1419	191	10	treatment	treatment	NOUN
dti-1419	191	11	.	.	PUNCT
dti-1419	192	1	orphanet	orphanet	PROPN
dti-1419	192	2	j	j	PROPN
dti-1419	192	3	rare	rare	ADJ
dti-1419	192	4	dis	dis	PROPN
dti-1419	192	5	.	.	PUNCT
dti-1419	193	1	2017;12:162	2017;12:162	X
dti-1419	193	2	.	.	PUNCT
dti-1419	194	1	doi:10.1186	doi:10.1186	PROPN
dti-1419	194	2	/	/	SYM
dti-1419	194	3	s13023	s13023	PROPN
dti-1419	194	4	-	-	PUNCT
dti-1419	194	5	017	017	NUM
dti-1419	194	6	-	-	PUNCT
dti-1419	194	7	0685	0685	NUM
dti-1419	194	8	-	-	SYM
dti-1419	194	9	2	2	NUM
dti-1419	194	10	.	.	NOUN
dti-1419	194	11	7	7	NUM
dti-1419	194	12	.	.	X
dti-1419	195	1	van	van	PROPN
dti-1419	195	2	spronsen	spronsen	PROPN
dti-1419	195	3	fj	fj	PROPN
dti-1419	195	4	,	,	PUNCT
dti-1419	195	5	burgard	burgard	PROPN
dti-1419	195	6	p.	p.	NOUN
dti-1419	196	1	the	the	DET
dti-1419	196	2	truth	truth	NOUN
dti-1419	196	3	of	of	ADP
dti-1419	196	4	treating	treat	VERB
dti-1419	196	5	patients	patient	NOUN
dti-1419	196	6	with	with	ADP
dti-1419	196	7	phenylketonuria	phenylketonuria	NOUN
dti-1419	196	8	after	after	ADP
dti-1419	196	9	childhood	childhood	NOUN
dti-1419	196	10	:	:	PUNCT
dti-1419	196	11	the	the	DET
dti-1419	196	12	need	need	NOUN
dti-1419	196	13	for	for	ADP
dti-1419	196	14	a	a	DET
dti-1419	196	15	new	new	ADJ
dti-1419	196	16	guideline	guideline	NOUN
dti-1419	196	17	.	.	PUNCT
dti-1419	197	1	j	j	PROPN
dti-1419	197	2	inherit	inherit	VERB
dti-1419	197	3	metab	metab	PROPN
dti-1419	197	4	dis	dis	PROPN
dti-1419	197	5	.	.	PUNCT
dti-1419	198	1	2008;31:673679	2008;31:673679	X
dti-1419	198	2	.	.	PUNCT
dti-1419	198	3	doi:10.1007	doi:10.1007	PROPN
dti-1419	198	4	/	/	SYM
dti-1419	198	5	s10545	s10545	PROPN
dti-1419	198	6	-	-	PUNCT
dti-1419	198	7	008	008	NUM
dti-1419	198	8	-	-	PUNCT
dti-1419	198	9	0918	0918	NUM
dti-1419	198	10	-	-	PUNCT
dti-1419	198	11	6	6	NUM
dti-1419	198	12	.	.	NOUN
dti-1419	198	13	8	8	NUM
dti-1419	198	14	.	.	PUNCT
dti-1419	198	15	biomarin	biomarin	NOUN
dti-1419	198	16	announces	announce	VERB
dti-1419	198	17	fda	fda	PROPN
dti-1419	198	18	approval	approval	NOUN
dti-1419	198	19	for	for	ADP
dti-1419	198	20	kuvan	kuvan	PROPN
dti-1419	198	21	.	.	PUNCT
dti-1419	199	1	biomarin	biomarin	NOUN
dti-1419	199	2	.	.	PUNCT
dti-1419	200	1	https://investors	https://investor	NOUN
dti-1419	200	2	.	.	PUNCT
dti-1419	201	1	biomarin.com/2007-12-13-biomarin-announces-fda-approval-for-kuvan	biomarin.com/2007-12-13-biomarin-announces-fda-approval-for-kuvan	NOUN
dti-1419	201	2	.	.	PROPN
dti-1419	202	1	accessed	access	VERB
dti-1419	202	2	september	september	PROPN
dti-1419	202	3	26	26	NUM
dti-1419	202	4	,	,	PUNCT
dti-1419	202	5	2018	2018	NUM
dti-1419	202	6	.	.	PUNCT
dti-1419	203	1	9	9	NUM
dti-1419	203	2	.	.	X
dti-1419	203	3	somaraju	somaraju	VERB
dti-1419	203	4	ur	ur	PROPN
dti-1419	203	5	,	,	PUNCT
dti-1419	203	6	merrin	merrin	PROPN
dti-1419	203	7	m.	m.	PROPN
dti-1419	203	8	sapropterin	sapropterin	PROPN
dti-1419	203	9	dihydrochloride	dihydrochloride	VERB
dti-1419	203	10	for	for	ADP
dti-1419	203	11	phenylketonuria	phenylketonuria	NOUN
dti-1419	203	12	.	.	PUNCT
dti-1419	204	1	cochrane	cochrane	PROPN
dti-1419	204	2	database	database	PROPN
dti-1419	204	3	syst	syst	PROPN
dti-1419	204	4	rev	rev	PROPN
dti-1419	204	5	.	.	PROPN
dti-1419	205	1	2015;3	2015;3	NOUN
dti-1419	205	2	:	:	PUNCT
dti-1419	205	3	cd008005	cd008005	NOUN
dti-1419	205	4	.	.	PUNCT
dti-1419	206	1	doi:10.1002/14651858	doi:10.1002/14651858	NOUN
dti-1419	206	2	.	.	PUNCT
dti-1419	207	1	cd008005.pub4	cd008005.pub4	NOUN
dti-1419	207	2	.	.	PUNCT
dti-1419	208	1	10	10	NUM
dti-1419	208	2	.	.	PUNCT
dti-1419	209	1	fda	fda	PROPN
dti-1419	209	2	approves	approve	VERB
dti-1419	209	3	a	a	DET
dti-1419	209	4	new	new	ADJ
dti-1419	209	5	treatment	treatment	NOUN
dti-1419	209	6	for	for	ADP
dti-1419	209	7	pku	pku	PROPN
dti-1419	209	8	,	,	PUNCT
dti-1419	209	9	a	a	DET
dti-1419	209	10	rare	rare	ADJ
dti-1419	209	11	and	and	CCONJ
dti-1419	209	12	serious	serious	ADJ
dti-1419	209	13	genetic	genetic	ADJ
dti-1419	209	14	disease	disease	NOUN
dti-1419	209	15	.	.	PUNCT
dti-1419	210	1	food	food	NOUN
dti-1419	210	2	and	and	CCONJ
dti-1419	210	3	drug	drug	PROPN
dti-1419	210	4	administration	administration	NOUN
dti-1419	210	5	.	.	PUNCT
dti-1419	211	1	https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm608835.htm	https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm608835.htm	PROPN
dti-1419	211	2	.	.	PUNCT
dti-1419	212	1	accessed	access	VERB
dti-1419	212	2	september	september	PROPN
dti-1419	212	3	26	26	NUM
dti-1419	212	4	,	,	PUNCT
dti-1419	212	5	2018	2018	NUM
dti-1419	212	6	.	.	PUNCT
dti-1419	213	1	11	11	NUM
dti-1419	213	2	.	.	PUNCT
dti-1419	214	1	palynziq	palynziq	ADJ
dti-1419	214	2	®	®	PROPN
dti-1419	214	3	[	[	X
dti-1419	214	4	package	package	NOUN
dti-1419	214	5	insert	insert	NOUN
dti-1419	214	6	]	]	PUNCT
dti-1419	214	7	.	.	PUNCT
dti-1419	215	1	novato	novato	PROPN
dti-1419	215	2	,	,	PUNCT
dti-1419	215	3	ca	can	AUX
dti-1419	215	4	:	:	PUNCT
dti-1419	215	5	biomarin	biomarin	PROPN
dti-1419	215	6	pharmaceutical	pharmaceutical	PROPN
dti-1419	215	7	inc	inc	PROPN
dti-1419	215	8	;	;	PUNCT
dti-1419	215	9	may	may	PROPN
dti-1419	215	10	2018	2018	NUM
dti-1419	215	11	.	.	PUNCT
dti-1419	216	1	12	12	NUM
dti-1419	216	2	.	.	PUNCT
dti-1419	217	1	palynziq	palynziq	ADJ
dti-1419	217	2	®	®	NOUN
dti-1419	217	3	(	(	PUNCT
dti-1419	217	4	pegvaliase	pegvaliase	NOUN
dti-1419	217	5	-	-	PUNCT
dti-1419	217	6	pqpz	pqpz	ADJ
dti-1419	217	7	)	)	PUNCT
dti-1419	217	8	formulary	formulary	NOUN
dti-1419	217	9	dossier	dossier	NOUN
dti-1419	217	10	.	.	PUNCT
dti-1419	218	1	biomarin	biomarin	NOUN
dti-1419	218	2	,	,	PUNCT
dti-1419	218	3	data	datum	NOUN
dti-1419	218	4	on	on	ADP
dti-1419	218	5	file	file	NOUN
dti-1419	218	6	.	.	PUNCT
dti-1419	219	1	13	13	NUM
dti-1419	219	2	.	.	PUNCT
dti-1419	220	1	bell	bell	PROPN
dti-1419	220	2	sm	sm	PROPN
dti-1419	220	3	,	,	PUNCT
dti-1419	220	4	wendt	wendt	PROPN
dti-1419	220	5	dj	dj	PROPN
dti-1419	220	6	,	,	PUNCT
dti-1419	220	7	zhang	zhang	PROPN
dti-1419	220	8	y	y	PROPN
dti-1419	220	9	,	,	PUNCT
dti-1419	220	10	et	et	PROPN
dti-1419	220	11	al	al	PROPN
dti-1419	220	12	.	.	PUNCT
dti-1419	220	13	formulation	formulation	NOUN
dti-1419	220	14	and	and	CCONJ
dti-1419	220	15	pegylation	pegylation	NOUN
dti-1419	220	16	optimization	optimization	NOUN
dti-1419	220	17	of	of	ADP
dti-1419	220	18	the	the	DET
dti-1419	220	19	therapeutic	therapeutic	ADJ
dti-1419	220	20	pegylated	pegylated	ADJ
dti-1419	220	21	phenylalanine	phenylalanine	ADJ
dti-1419	220	22	ammonia	ammonia	NOUN
dti-1419	220	23	lyase	lyase	NOUN
dti-1419	220	24	for	for	ADP
dti-1419	220	25	the	the	DET
dti-1419	220	26	treatment	treatment	NOUN
dti-1419	220	27	of	of	ADP
dti-1419	220	28	phenylketonuria	phenylketonuria	NOUN
dti-1419	220	29	.	.	PUNCT
dti-1419	221	1	plos	plos	PROPN
dti-1419	221	2	one	one	NUM
dti-1419	221	3	.	.	PUNCT
dti-1419	222	1	2017;12	2017;12	NOUN
dti-1419	222	2	:	:	PUNCT
dti-1419	222	3	e0173269	e0173269	NOUN
dti-1419	222	4	.	.	PUNCT
dti-1419	222	5	doi:10.1371	doi:10.1371	PROPN
dti-1419	222	6	/	/	SYM
dti-1419	222	7	journal	journal	NOUN
dti-1419	222	8	.	.	PUNCT
dti-1419	223	1	pone.0173269	pone.0173269	PROPN
dti-1419	223	2	.	.	PROPN
dti-1419	223	3	14	14	NUM
dti-1419	223	4	.	.	PUNCT
dti-1419	224	1	sarkissian	sarkissian	PROPN
dti-1419	224	2	cn	cn	PROPN
dti-1419	224	3	,	,	PUNCT
dti-1419	224	4	shao	shao	PROPN
dti-1419	224	5	z	z	PROPN
dti-1419	224	6	,	,	PUNCT
dti-1419	224	7	blain	blain	PROPN
dti-1419	224	8	f	f	PROPN
dti-1419	224	9	,	,	PUNCT
dti-1419	224	10	et	et	PROPN
dti-1419	224	11	al	al	PROPN
dti-1419	224	12	.	.	PUNCT
dti-1419	225	1	a	a	DET
dti-1419	225	2	different	different	ADJ
dti-1419	225	3	approach	approach	NOUN
dti-1419	225	4	to	to	ADP
dti-1419	225	5	treatment	treatment	NOUN
dti-1419	225	6	of	of	ADP
dti-1419	225	7	phenylketonuria	phenylketonuria	NOUN
dti-1419	225	8	:	:	PUNCT
dti-1419	225	9	phenylalanine	phenylalanine	ADJ
dti-1419	225	10	degradation	degradation	NOUN
dti-1419	225	11	with	with	ADP
dti-1419	225	12	recombinant	recombinant	ADJ
dti-1419	225	13	phenylalanine	phenylalanine	ADJ
dti-1419	225	14	ammonia	ammonia	NOUN
dti-1419	225	15	lyase	lyase	NOUN
dti-1419	225	16	.	.	PUNCT
dti-1419	226	1	proc	proc	PROPN
dti-1419	226	2	natl	natl	PROPN
dti-1419	226	3	acad	acad	PROPN
dti-1419	226	4	sci	sci	PROPN
dti-1419	226	5	u	u	PROPN
dti-1419	226	6	s	s	NOUN
dti-1419	226	7	a.	a.	NOUN
dti-1419	226	8	1999;96:2339–2344	1999;96:2339–2344	PROPN
dti-1419	226	9	.	.	PUNCT
dti-1419	227	1	doi:10.1073/	doi:10.1073/	PROPN
dti-1419	227	2	pnas.96.5.2339	pnas.96.5.2339	PROPN
dti-1419	227	3	.	.	PUNCT
dti-1419	228	1	15	15	NUM
dti-1419	228	2	.	.	PUNCT
dti-1419	229	1	longo	longo	PROPN
dti-1419	229	2	n	n	CCONJ
dti-1419	229	3	,	,	PUNCT
dti-1419	229	4	harding	harding	PROPN
dti-1419	229	5	co	co	PROPN
dti-1419	229	6	,	,	PUNCT
dti-1419	229	7	burton	burton	PROPN
dti-1419	229	8	bk	bk	PROPN
dti-1419	229	9	,	,	PUNCT
dti-1419	229	10	grange	grange	PROPN
dti-1419	229	11	dk	dk	PROPN
dti-1419	229	12	,	,	PUNCT
dti-1419	229	13	et	et	PROPN
dti-1419	229	14	al	al	PROPN
dti-1419	229	15	.	.	PROPN
dti-1419	229	16	single	single	PROPN
dti-1419	229	17	-	-	PUNCT
dti-1419	229	18	dose	dose	NOUN
dti-1419	229	19	,	,	PUNCT
dti-1419	229	20	subcutaneous	subcutaneous	ADJ
dti-1419	229	21	recombinant	recombinant	ADJ
dti-1419	229	22	phenylalanine	phenylalanine	NOUN
dti-1419	229	23	ammonia	ammonia	NOUN
dti-1419	229	24	lyase	lyase	NOUN
dti-1419	229	25	conjugated	conjugate	VERB
dti-1419	229	26	with	with	ADP
dti-1419	229	27	polyethylene	polyethylene	NOUN
dti-1419	229	28	glycol	glycol	NOUN
dti-1419	229	29	in	in	ADP
dti-1419	229	30	adult	adult	NOUN
dti-1419	229	31	patients	patient	NOUN
dti-1419	229	32	with	with	ADP
dti-1419	229	33	phenylketonuria	phenylketonuria	NOUN
dti-1419	229	34	:	:	PUNCT
dti-1419	229	35	an	an	DET
dti-1419	229	36	open	open	ADJ
dti-1419	229	37	-	-	PUNCT
dti-1419	229	38	label	label	NOUN
dti-1419	229	39	,	,	PUNCT
dti-1419	229	40	multicenter	multicenter	NOUN
dti-1419	229	41	,	,	PUNCT
dti-1419	229	42	phase	phase	NOUN
dti-1419	229	43	1	1	NUM
dti-1419	229	44	dose	dose	NOUN
dti-1419	229	45	-	-	PUNCT
dti-1419	229	46	escalation	escalation	NOUN
dti-1419	229	47	trial	trial	NOUN
dti-1419	229	48	.	.	PUNCT
dti-1419	230	1	lancet	lancet	NOUN
dti-1419	230	2	.	.	PUNCT
dti-1419	231	1	2014;384:37–44	2014;384:37–44	NUM
dti-1419	231	2	.	.	PUNCT
dti-1419	231	3	doi:10.1016	doi:10.1016	PROPN
dti-1419	231	4	/	/	SYM
dti-1419	231	5	s0140	s0140	PROPN
dti-1419	231	6	-6736(13)61841	-6736(13)61841	NOUN
dti-1419	231	7	.	.	PUNCT
dti-1419	232	1	16	16	NUM
dti-1419	232	2	.	.	PUNCT
dti-1419	233	1	thomas	thomas	PROPN
dti-1419	233	2	ja	ja	PROPN
dti-1419	233	3	,	,	PUNCT
dti-1419	233	4	longo	longo	PROPN
dti-1419	233	5	n	n	PRON
dti-1419	233	6	,	,	PUNCT
dti-1419	233	7	zori	zori	PROPN
dti-1419	233	8	r	r	PROPN
dti-1419	233	9	,	,	PUNCT
dti-1419	233	10	burton	burton	PROPN
dti-1419	233	11	bk	bk	PROPN
dti-1419	233	12	,	,	PUNCT
dti-1419	233	13	et	et	PROPN
dti-1419	233	14	al	al	PROPN
dti-1419	233	15	.	.	PUNCT
dti-1419	234	1	evaluation	evaluation	NOUN
dti-1419	234	2	of	of	ADP
dti-1419	234	3	multiple	multiple	ADJ
dti-1419	234	4	dosing	dosing	ADJ
dti-1419	234	5	regimens	regimen	NOUN
dti-1419	234	6	in	in	ADP
dti-1419	234	7	phase	phase	NOUN
dti-1419	234	8	2	2	NUM
dti-1419	234	9	studies	study	NOUN
dti-1419	234	10	of	of	ADP
dti-1419	234	11	“	"	PUNCT
dti-1419	234	12	ravpal	ravpal	ADJ
dti-1419	234	13	-	-	PUNCT
dti-1419	234	14	peg	peg	NOUN
dti-1419	234	15	”	"	PUNCT
dti-1419	234	16	for	for	ADP
dti-1419	234	17	control	control	NOUN
dti-1419	234	18	of	of	ADP
dti-1419	234	19	blood	blood	NOUN
dti-1419	234	20	phenylalanine	phenylalanine	NOUN
dti-1419	234	21	levels	level	NOUN
dti-1419	234	22	in	in	ADP
dti-1419	234	23	adults	adult	NOUN
dti-1419	234	24	with	with	ADP
dti-1419	234	25	phenylketonuria	phenylketonuria	NOUN
dti-1419	234	26	.	.	PUNCT
dti-1419	235	1	paper	paper	NOUN
dti-1419	235	2	presented	present	VERB
dti-1419	235	3	at	at	ADP
dti-1419	235	4	:	:	PUNCT
dti-1419	235	5	society	society	NOUN
dti-1419	235	6	for	for	ADP
dti-1419	235	7	the	the	DET
dti-1419	235	8	study	study	NOUN
dti-1419	235	9	of	of	ADP
dti-1419	235	10	inborn	inborn	ADJ
dti-1419	235	11	errors	error	NOUN
dti-1419	235	12	of	of	ADP
dti-1419	235	13	metabolism	metabolism	NOUN
dti-1419	235	14	(	(	PUNCT
dti-1419	235	15	ssiem	ssiem	ADJ
dti-1419	235	16	)	)	PUNCT
dti-1419	235	17	annual	annual	ADJ
dti-1419	235	18	symposium	symposium	NOUN
dti-1419	235	19	,	,	PUNCT
dti-1419	235	20	lyon	lyon	PROPN
dti-1419	235	21	,	,	PUNCT
dti-1419	235	22	france	france	PROPN
dti-1419	235	23	,	,	PUNCT
dti-1419	235	24	1–4	1–4	PROPN
dti-1419	235	25	september	september	PROPN
dti-1419	235	26	2015	2015	NUM
dti-1419	235	27	,	,	PUNCT
dti-1419	235	28	p-149	p-149	NOUN
dti-1419	235	29	.	.	PUNCT
dti-1419	236	1	17	17	NUM
dti-1419	236	2	.	.	PUNCT
dti-1419	237	1	zori	zori	PROPN
dti-1419	237	2	r	r	PROPN
dti-1419	237	3	,	,	PUNCT
dti-1419	237	4	thomas	thomas	PROPN
dti-1419	237	5	ja	ja	PROPN
dti-1419	237	6	,	,	PUNCT
dti-1419	237	7	shur	shur	PROPN
dti-1419	237	8	n	n	PROPN
dti-1419	237	9	,	,	PUNCT
dti-1419	237	10	et	et	PROPN
dti-1419	237	11	al	al	PROPN
dti-1419	237	12	.	.	PROPN
dti-1419	237	13	induction	induction	NOUN
dti-1419	237	14	,	,	PUNCT
dti-1419	237	15	titration	titration	NOUN
dti-1419	237	16	,	,	PUNCT
dti-1419	237	17	and	and	CCONJ
dti-1419	237	18	maintenance	maintenance	NOUN
dti-1419	237	19	dosing	dose	VERB
dti-1419	237	20	regimen	regiman	NOUN
dti-1419	237	21	in	in	ADP
dti-1419	237	22	a	a	DET
dti-1419	237	23	phase	phase	NOUN
dti-1419	237	24	2	2	NUM
dti-1419	237	25	study	study	NOUN
dti-1419	237	26	of	of	ADP
dti-1419	237	27	pegvaliase	pegvaliase	NOUN
dti-1419	237	28	for	for	ADP
dti-1419	237	29	control	control	NOUN
dti-1419	237	30	of	of	ADP
dti-1419	237	31	blood	blood	NOUN
dti-1419	237	32	phenylalanine	phenylalanine	NOUN
dti-1419	237	33	in	in	ADP
dti-1419	237	34	adults	adult	NOUN
dti-1419	237	35	with	with	ADP
dti-1419	237	36	phenylketonuria	phenylketonuria	NOUN
dti-1419	237	37	.	.	PUNCT
dti-1419	238	1	mol	mol	ADP
dti-1419	238	2	genet	genet	PROPN
dti-1419	238	3	metab	metab	PROPN
dti-1419	238	4	.	.	PUNCT
dti-1419	239	1	2018;125:217–227	2018;125:217–227	NUM
dti-1419	239	2	.	.	PUNCT
dti-1419	240	1	doi:10.1016	doi:10.1016	PROPN
dti-1419	240	2	/	/	SYM
dti-1419	240	3	j.	j.	PROPN
dti-1419	240	4	ymgme.2018.06.010	ymgme.2018.06.010	PROPN
dti-1419	240	5	.	.	PROPN
dti-1419	240	6	18	18	NUM
dti-1419	240	7	.	.	PUNCT
dti-1419	241	1	thomas	thomas	PROPN
dti-1419	241	2	j	j	PROPN
dti-1419	241	3	,	,	PUNCT
dti-1419	241	4	levy	levy	NOUN
dti-1419	241	5	h	h	NOUN
dti-1419	241	6	,	,	PUNCT
dti-1419	241	7	amato	amato	PROPN
dti-1419	241	8	s	s	PROPN
dti-1419	241	9	,	,	PUNCT
dti-1419	241	10	et	et	PROPN
dti-1419	241	11	al	al	PROPN
dti-1419	241	12	.	.	PROPN
dti-1419	241	13	pegvaliase	pegvaliase	PROPN
dti-1419	241	14	for	for	ADP
dti-1419	241	15	the	the	DET
dti-1419	241	16	treatment	treatment	NOUN
dti-1419	241	17	of	of	ADP
dti-1419	241	18	phenylketonuria	phenylketonuria	NOUN
dti-1419	241	19	:	:	PUNCT
dti-1419	241	20	results	result	NOUN
dti-1419	241	21	of	of	ADP
dti-1419	241	22	a	a	DET
dti-1419	241	23	long	long	ADJ
dti-1419	241	24	-	-	PUNCT
dti-1419	241	25	term	term	NOUN
dti-1419	241	26	phase	phase	NOUN
dti-1419	241	27	3	3	NUM
dti-1419	241	28	clinical	clinical	ADJ
dti-1419	241	29	trial	trial	NOUN
dti-1419	241	30	program	program	NOUN
dti-1419	241	31	(	(	PUNCT
dti-1419	241	32	prism	prism	NOUN
dti-1419	241	33	)	)	PUNCT
dti-1419	241	34	.	.	PUNCT
dti-1419	242	1	mol	mol	ADP
dti-1419	242	2	genet	genet	PROPN
dti-1419	242	3	metab	metab	NOUN
dti-1419	242	4	.	.	PUNCT
dti-1419	243	1	2018;124:27–38	2018;124:27–38	NUM
dti-1419	243	2	.	.	PUNCT
dti-1419	244	1	doi:10.1016	doi:10.1016	PROPN
dti-1419	244	2	/	/	SYM
dti-1419	244	3	j.ymgme.2018.03.006	j.ymgme.2018.03.006	PROPN
dti-1419	244	4	.	.	NOUN
dti-1419	245	1	19	19	NUM
dti-1419	245	2	.	.	X
dti-1419	246	1	harding	harding	PROPN
dti-1419	246	2	co	co	PROPN
dti-1419	246	3	,	,	PUNCT
dti-1419	246	4	amato	amato	PROPN
dti-1419	246	5	rs	rs	PROPN
dti-1419	246	6	,	,	PUNCT
dti-1419	246	7	stuy	stuy	PROPN
dti-1419	246	8	m	m	PROPN
dti-1419	246	9	,	,	PUNCT
dti-1419	246	10	et	et	PROPN
dti-1419	246	11	al	al	PROPN
dti-1419	246	12	.	.	PROPN
dti-1419	246	13	pegvaliase	pegvaliase	PROPN
dti-1419	246	14	for	for	ADP
dti-1419	246	15	the	the	DET
dti-1419	246	16	treatment	treatment	NOUN
dti-1419	246	17	of	of	ADP
dti-1419	246	18	phenylketonuria	phenylketonuria	NOUN
dti-1419	246	19	:	:	PUNCT
dti-1419	246	20	a	a	DET
dti-1419	246	21	pivotal	pivotal	ADJ
dti-1419	246	22	,	,	PUNCT
dti-1419	246	23	double	double	ADJ
dti-1419	246	24	-	-	PUNCT
dti-1419	246	25	blind	blind	ADJ
dti-1419	246	26	randomized	randomized	ADJ
dti-1419	246	27	discontinuation	discontinuation	NOUN
dti-1419	246	28	phase	phase	NOUN
dti-1419	246	29	3	3	NUM
dti-1419	246	30	https://orcid.org/0000-0002-7206-1668	https://orcid.org/0000-0002-7206-1668	NOUN
dti-1419	246	31	http://www.utdol.com/utd/index.do	http://www.utdol.com/utd/index.do	PROPN
dti-1419	246	32	https://investors.biomarin.com/2007-12-13-biomarin-announces-fda-approval-for-kuvan	https://investors.biomarin.com/2007-12-13-biomarin-announces-fda-approval-for-kuvan	PROPN
dti-1419	246	33	https://investors.biomarin.com/2007-12-13-biomarin-announces-fda-approval-for-kuvan	https://investors.biomarin.com/2007-12-13-biomarin-announces-fda-approval-for-kuvan	PRON
dti-1419	246	34	https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm608835.htm	https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm608835.htm	ADJ
dti-1419	246	35	https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm608835.htm	https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm608835.htm	ADJ
dti-1419	246	36	8	8	NUM
dti-1419	246	37	drug	drug	NOUN
dti-1419	246	38	target	target	NOUN
dti-1419	246	39	insights	insight	NOUN
dti-1419	246	40	clinical	clinical	ADJ
dti-1419	246	41	trial	trial	NOUN
dti-1419	246	42	.	.	PUNCT
dti-1419	247	1	mol	mol	ADP
dti-1419	247	2	genet	genet	PROPN
dti-1419	247	3	metab	metab	NOUN
dti-1419	247	4	.	.	PUNCT
dti-1419	248	1	2018;124:20	2018;124:20	NUM
dti-1419	248	2	-	-	SYM
dti-1419	248	3	26	26	NUM
dti-1419	248	4	.	.	PUNCT
dti-1419	249	1	doi:10.1016	doi:10.1016	PROPN
dti-1419	249	2	/	/	SYM
dti-1419	249	3	j.ymgme.2018	j.ymgme.2018	NOUN
dti-1419	249	4	.03.003	.03.003	NOUN
dti-1419	249	5	.	.	PROPN
dti-1419	250	1	20	20	NUM
dti-1419	250	2	.	.	PUNCT
dti-1419	251	1	van	van	PROPN
dti-1419	251	2	rijn	rijn	PROPN
dti-1419	251	3	m	m	PROPN
dti-1419	251	4	,	,	PUNCT
dti-1419	251	5	hoeksma	hoeksma	PROPN
dti-1419	251	6	m	m	PROPN
dti-1419	251	7	,	,	PUNCT
dti-1419	251	8	sauer	sauer	PROPN
dti-1419	251	9	pj	pj	PROPN
dti-1419	251	10	,	,	PUNCT
dti-1419	251	11	modderman	modderman	NOUN
dti-1419	251	12	p	p	X
dti-1419	251	13	,	,	PUNCT
dti-1419	251	14	reijngoud	reijngoud	ADJ
dti-1419	251	15	dj	dj	NOUN
dti-1419	251	16	,	,	PUNCT
dti-1419	251	17	van	van	PROPN
dti-1419	251	18	spronsen	spronsen	PROPN
dti-1419	251	19	fj	fj	PROPN
dti-1419	251	20	.	.	PUNCT
dti-1419	252	1	adult	adult	NOUN
dti-1419	252	2	patients	patient	NOUN
dti-1419	252	3	with	with	ADP
dti-1419	252	4	well	well	ADV
dti-1419	252	5	-	-	PUNCT
dti-1419	252	6	controlled	control	VERB
dti-1419	252	7	phenylketonuria	phenylketonuria	NOUN
dti-1419	252	8	tolerate	tolerate	VERB
dti-1419	252	9	incidental	incidental	ADJ
dti-1419	252	10	additional	additional	ADJ
dti-1419	252	11	intake	intake	NOUN
dti-1419	252	12	of	of	ADP
dti-1419	252	13	phenylalanine	phenylalanine	NOUN
dti-1419	252	14	.	.	PUNCT
dti-1419	253	1	ann	ann	PROPN
dti-1419	253	2	nutr	nutr	PROPN
dti-1419	253	3	metab	metab	PROPN
dti-1419	253	4	.	.	PUNCT
dti-1419	254	1	2011;58:94–100	2011;58:94–100	PROPN
dti-1419	254	2	.	.	PUNCT
dti-1419	254	3	doi:10.1159	doi:10.1159	PROPN
dti-1419	254	4	/000324924	/000324924	PROPN
dti-1419	254	5	.	.	PUNCT
dti-1419	255	1	21	21	NUM
dti-1419	255	2	.	.	PUNCT
dti-1419	256	1	kuvan	kuvan	PROPN
dti-1419	256	2	®	®	NOUN
dti-1419	256	3	[	[	X
dti-1419	256	4	package	package	NOUN
dti-1419	256	5	insert	insert	NOUN
dti-1419	256	6	]	]	PUNCT
dti-1419	256	7	.	.	PUNCT
dti-1419	257	1	novato	novato	PROPN
dti-1419	257	2	,	,	PUNCT
dti-1419	257	3	ca	can	AUX
dti-1419	257	4	:	:	PUNCT
dti-1419	257	5	biomarin	biomarin	PROPN
dti-1419	257	6	pharmaceutical	pharmaceutical	PROPN
dti-1419	257	7	inc	inc	PROPN
dti-1419	257	8	;	;	PUNCT
dti-1419	257	9	august	august	PROPN
dti-1419	257	10	2016	2016	NUM
dti-1419	257	11	.	.	PUNCT
dti-1419	258	1	22	22	NUM
dti-1419	258	2	.	.	PUNCT
dti-1419	259	1	macdonald	macdonald	PROPN
dti-1419	259	2	a	a	PROPN
dti-1419	259	3	,	,	PUNCT
dti-1419	259	4	van	van	PROPN
dti-1419	259	5	rijn	rijn	PROPN
dti-1419	259	6	m	m	PROPN
dti-1419	259	7	,	,	PUNCT
dti-1419	259	8	feillet	feillet	PROPN
dti-1419	259	9	f	f	PROPN
dti-1419	259	10	,	,	PUNCT
dti-1419	259	11	et	et	PROPN
dti-1419	259	12	al	al	PROPN
dti-1419	259	13	.	.	PROPN
dti-1419	259	14	adherence	adherence	NOUN
dti-1419	259	15	issues	issue	NOUN
dti-1419	259	16	in	in	ADP
dti-1419	259	17	inherited	inherit	VERB
dti-1419	259	18	metabolic	metabolic	NOUN
dti-1419	259	19	disorders	disorder	NOUN
dti-1419	259	20	treated	treat	VERB
dti-1419	259	21	by	by	ADP
dti-1419	259	22	low	low	ADJ
dti-1419	259	23	natural	natural	ADJ
dti-1419	259	24	protein	protein	NOUN
dti-1419	259	25	diets	diet	NOUN
dti-1419	259	26	.	.	PUNCT
dti-1419	260	1	ann	ann	PROPN
dti-1419	260	2	nutr	nutr	PROPN
dti-1419	260	3	metab	metab	PROPN
dti-1419	260	4	.	.	PUNCT
dti-1419	261	1	2012;61:289	2012;61:289	X
dti-1419	261	2	–	–	PUNCT
dti-1419	261	3	295	295	NUM
dti-1419	261	4	.	.	PUNCT
dti-1419	262	1	doi:10.1159/000342256	doi:10.1159/000342256	VERB
dti-1419	262	2	.	.	PUNCT
dti-1419	263	1	23	23	NUM
dti-1419	263	2	.	.	PUNCT
dti-1419	264	1	jurecki	jurecki	PROPN
dti-1419	264	2	er	er	INTJ
dti-1419	264	3	,	,	PUNCT
dti-1419	264	4	cederbaum	cederbaum	PROPN
dti-1419	264	5	s	s	PROPN
dti-1419	264	6	,	,	PUNCT
dti-1419	264	7	kopesky	kopesky	PROPN
dti-1419	264	8	j	j	PROPN
dti-1419	264	9	,	,	PUNCT
dti-1419	264	10	et	et	PROPN
dti-1419	264	11	al	al	PROPN
dti-1419	264	12	.	.	PROPN
dti-1419	265	1	adherence	adherence	NOUN
dti-1419	265	2	to	to	ADP
dti-1419	265	3	clinic	clinic	NOUN
dti-1419	265	4	recommendations	recommendation	NOUN
dti-1419	265	5	among	among	ADP
dti-1419	265	6	patients	patient	NOUN
dti-1419	265	7	with	with	ADP
dti-1419	265	8	phenylketonuria	phenylketonuria	NOUN
dti-1419	265	9	in	in	ADP
dti-1419	265	10	the	the	DET
dti-1419	265	11	united	united	PROPN
dti-1419	265	12	states	states	PROPN
dti-1419	265	13	.	.	PUNCT
dti-1419	266	1	mol	mol	ADP
dti-1419	266	2	genet	genet	PROPN
dti-1419	266	3	metab	metab	PROPN
dti-1419	266	4	.	.	PUNCT
dti-1419	267	1	2017;120:190–197	2017;120:190–197	NUM
dti-1419	267	2	.	.	PUNCT
dti-1419	268	1	doi:10.1016	doi:10.1016	PROPN
dti-1419	268	2	/	/	SYM
dti-1419	268	3	j.ymgme.2017.01.001	j.ymgme.2017.01.001	PROPN
dti-1419	268	4	.	.	PUNCT
dti-1419	269	1	24	24	NUM
dti-1419	269	2	.	.	PUNCT
dti-1419	269	3	biomarin	biomarin	NOUN
dti-1419	269	4	pharmaceuticals	pharmaceutical	NOUN
dti-1419	269	5	.	.	PUNCT
dti-1419	270	1	conference	conference	NOUN
dti-1419	270	2	call	call	NOUN
dti-1419	270	3	to	to	PART
dti-1419	270	4	discuss	discuss	VERB
dti-1419	270	5	approval	approval	NOUN
dti-1419	270	6	of	of	ADP
dti-1419	270	7	palynziq	palynziq	NOUN
dti-1419	270	8	.	.	PUNCT
dti-1419	271	1	investors.biomarin.com/download/palynziq+approval+presentation_052418	investors.biomarin.com/download/palynziq+approval+presentation_052418	PROPN
dti-1419	271	2	.	.	PUNCT
dti-1419	272	1	pdf	pdf	NOUN
dti-1419	272	2	.	.	PUNCT
dti-1419	273	1	accessed	access	VERB
dti-1419	273	2	september	september	PROPN
dti-1419	273	3	27	27	NUM
dti-1419	273	4	,	,	PUNCT
dti-1419	273	5	2018	2018	NUM
dti-1419	273	6	.	.	PUNCT
dti-1419	274	1	25	25	NUM
dti-1419	274	2	.	.	PUNCT
dti-1419	275	1	cunningham	cunningham	PROPN
dti-1419	275	2	a	a	PRON
dti-1419	275	3	,	,	PUNCT
dti-1419	275	4	bausell	bausell	PROPN
dti-1419	275	5	h	h	PROPN
dti-1419	275	6	,	,	PUNCT
dti-1419	275	7	brown	brown	PROPN
dti-1419	275	8	m	m	PROPN
dti-1419	275	9	,	,	PUNCT
dti-1419	275	10	et	et	PROPN
dti-1419	275	11	al	al	PROPN
dti-1419	275	12	.	.	PUNCT
dti-1419	276	1	recommendations	recommendation	NOUN
dti-1419	276	2	for	for	ADP
dti-1419	276	3	the	the	DET
dti-1419	276	4	use	use	NOUN
dti-1419	276	5	of	of	ADP
dti-1419	276	6	sapropterin	sapropterin	NOUN
dti-1419	276	7	in	in	ADP
dti-1419	276	8	phenylketonuria	phenylketonuria	NOUN
dti-1419	276	9	.	.	PUNCT
dti-1419	277	1	mol	mol	ADP
dti-1419	277	2	genet	genet	PROPN
dti-1419	277	3	metab	metab	PROPN
dti-1419	277	4	.	.	PUNCT
dti-1419	278	1	2012;106:269–276	2012;106:269–276	X
dti-1419	278	2	.	.	PUNCT
dti-1419	278	3	doi:10.1016	doi:10.1016	PROPN
dti-1419	278	4	/	/	SYM
dti-1419	278	5	j.ymgme.2012.04.004	j.ymgme.2012.04.004	PROPN
dti-1419	278	6	.	.	PUNCT
dti-1419	279	1	26	26	NUM
dti-1419	279	2	.	.	PUNCT
dti-1419	280	1	longo	longo	PROPN
dti-1419	280	2	n	n	CCONJ
dti-1419	280	3	,	,	PUNCT
dti-1419	280	4	dimmock	dimmock	NOUN
dti-1419	280	5	d	d	PROPN
dti-1419	280	6	,	,	PUNCT
dti-1419	280	7	levy	levy	NOUN
dti-1419	280	8	h	h	NOUN
dti-1419	280	9	,	,	PUNCT
dti-1419	280	10	et	et	PROPN
dti-1419	280	11	al	al	PROPN
dti-1419	280	12	.	.	PROPN
dti-1419	281	1	evidenceand	evidenceand	PROPN
dti-1419	281	2	consensus	consensus	NOUN
dti-1419	281	3	-	-	PUNCT
dti-1419	281	4	based	base	VERB
dti-1419	281	5	recommendations	recommendation	NOUN
dti-1419	281	6	for	for	ADP
dti-1419	281	7	the	the	DET
dti-1419	281	8	use	use	NOUN
dti-1419	281	9	of	of	ADP
dti-1419	281	10	pegvaliase	pegvaliase	NOUN
dti-1419	281	11	in	in	ADP
dti-1419	281	12	adults	adult	NOUN
dti-1419	281	13	with	with	ADP
dti-1419	281	14	phenylketonuria	phenylketonuria	NOUN
dti-1419	281	15	.	.	PUNCT
dti-1419	282	1	genet	genet	PROPN
dti-1419	282	2	med	med	PROPN
dti-1419	282	3	.	.	PUNCT
dti-1419	282	4	2018	2018	NUM
dti-1419	282	5	.	.	PUNCT
dti-1419	283	1	doi:10.1038	doi:10.1038	NOUN
dti-1419	283	2	/	/	SYM
dti-1419	283	3	s41436	s41436	PROPN
dti-1419	283	4	-	-	PUNCT
dti-1419	283	5	018	018	NUM
dti-1419	283	6	-	-	PUNCT
dti-1419	283	7	0403	0403	NUM
dti-1419	283	8	-	-	PUNCT
dti-1419	283	9	z.	z.	PROPN
dti-1419	283	10	27	27	NUM
dti-1419	283	11	.	.	PUNCT
dti-1419	284	1	brown	brown	PROPN
dti-1419	284	2	cs	cs	PROPN
dti-1419	284	3	,	,	PUNCT
dti-1419	284	4	lichter	lichter	PROPN
dti-1419	284	5	-	-	PUNCT
dti-1419	284	6	konecki	konecki	PROPN
dti-1419	284	7	u.	u.	PROPN
dti-1419	284	8	phenylketonuria	phenylketonuria	PROPN
dti-1419	284	9	(	(	PUNCT
dti-1419	284	10	pku	pku	PROPN
dti-1419	284	11	):	):	PUNCT
dti-1419	284	12	a	a	DET
dti-1419	284	13	problem	problem	NOUN
dti-1419	284	14	solved	solve	VERB
dti-1419	284	15	.	.	PUNCT
dti-1419	285	1	mol	mol	ADP
dti-1419	285	2	genet	genet	PROPN
dti-1419	285	3	metab	metab	PROPN
dti-1419	285	4	rep	rep	PROPN
dti-1419	285	5	.	.	PROPN
dti-1419	285	6	2016;6:8–12	2016;6:8–12	NUM
dti-1419	285	7	.	.	PUNCT
dti-1419	285	8	doi:10.1016	doi:10.1016	PROPN
dti-1419	285	9	/	/	SYM
dti-1419	285	10	j.ymgmr.2015.12.004	j.ymgmr.2015.12.004	PROPN
dti-1419	285	11	.	.	PUNCT
dti-1419	286	1	28	28	NUM
dti-1419	286	2	.	.	PUNCT
dti-1419	287	1	sarkissian	sarkissian	PROPN
dti-1419	287	2	cn	cn	PROPN
dti-1419	287	3	,	,	PUNCT
dti-1419	287	4	kang	kang	PROPN
dti-1419	287	5	ts	ts	PROPN
dti-1419	287	6	,	,	PUNCT
dti-1419	287	7	gamez	gamez	PROPN
dti-1419	287	8	a	a	PROPN
dti-1419	287	9	,	,	PUNCT
dti-1419	287	10	scriver	scriver	NOUN
dti-1419	287	11	cr	cr	PROPN
dti-1419	287	12	,	,	PUNCT
dti-1419	287	13	stevens	stevens	PROPN
dti-1419	287	14	rc	rc	PROPN
dti-1419	287	15	.	.	PROPN
dti-1419	287	16	evaluation	evaluation	NOUN
dti-1419	287	17	of	of	ADP
dti-1419	287	18	orally	orally	ADV
dti-1419	287	19	administered	administer	VERB
dti-1419	287	20	pegylated	pegylate	VERB
dti-1419	287	21	phenylalanine	phenylalanine	ADJ
dti-1419	287	22	ammonia	ammonia	NOUN
dti-1419	287	23	lyase	lyase	NOUN
dti-1419	287	24	in	in	ADP
dti-1419	287	25	mice	mouse	NOUN
dti-1419	287	26	for	for	ADP
dti-1419	287	27	the	the	DET
dti-1419	287	28	treatment	treatment	NOUN
dti-1419	287	29	of	of	ADP
dti-1419	287	30	phenylketonuria	phenylketonuria	NOUN
dti-1419	287	31	.	.	PUNCT
dti-1419	288	1	mol	mol	ADP
dti-1419	288	2	genet	genet	PROPN
dti-1419	288	3	metab	metab	PROPN
dti-1419	288	4	.	.	PUNCT
dti-1419	289	1	2011;104:249–254	2011;104:249–254	NUM
dti-1419	289	2	.	.	PUNCT
dti-1419	289	3	doi:10.1016	doi:10.1016	PROPN
dti-1419	289	4	/j.ymgme.2011.06.016	/j.ymgme.2011.06.016	PUNCT
dti-1419	289	5	.	.	PUNCT
dti-1419	290	1	29	29	NUM
dti-1419	290	2	.	.	PUNCT
dti-1419	291	1	pegvaliase	pegvaliase	NOUN
dti-1419	291	2	-	-	PUNCT
dti-1419	291	3	pqpz	pqpz	ADJ
dti-1419	291	4	.	.	PUNCT
dti-1419	292	1	in	in	ADP
dti-1419	292	2	:	:	PUNCT
dti-1419	292	3	basow	basow	PROPN
dti-1419	292	4	ds	ds	PROPN
dti-1419	292	5	,	,	PUNCT
dti-1419	292	6	ed	ed	NOUN
dti-1419	292	7	.	.	PUNCT
dti-1419	292	8	uptodate	uptodate	ADJ
dti-1419	293	1	[	[	X
dti-1419	293	2	database	database	NOUN
dti-1419	293	3	on	on	ADP
dti-1419	293	4	the	the	DET
dti-1419	293	5	internet	internet	NOUN
dti-1419	293	6	]	]	PUNCT
dti-1419	293	7	.	.	PUNCT
dti-1419	294	1	waltham	waltham	PROPN
dti-1419	294	2	,	,	PUNCT
dti-1419	294	3	ma	ma	PROPN
dti-1419	294	4	:	:	PUNCT
dti-1419	294	5	uptodate	uptodate	ADJ
dti-1419	294	6	;	;	PUNCT
dti-1419	294	7	2018	2018	NUM
dti-1419	294	8	.	.	PUNCT
dti-1419	295	1	http://www.utdol.com/utd/index.do	http://www.utdol.com/utd/index.do	PROPN
dti-1419	295	2	.	.	PUNCT
dti-1419	295	3	accessed	access	VERB
dti-1419	295	4	september	september	PROPN
dti-1419	295	5	26	26	NUM
dti-1419	295	6	,	,	PUNCT
dti-1419	295	7	2018	2018	NUM
dti-1419	295	8	.	.	PUNCT
dti-1419	296	1	30	30	NUM
dti-1419	296	2	.	.	PUNCT
dti-1419	296	3	sapropterin	sapropterin	NOUN
dti-1419	296	4	.	.	PUNCT
dti-1419	297	1	in	in	ADP
dti-1419	297	2	:	:	PUNCT
dti-1419	297	3	basow	basow	PROPN
dti-1419	297	4	ds	ds	PROPN
dti-1419	297	5	,	,	PUNCT
dti-1419	297	6	ed	ed	NOUN
dti-1419	297	7	.	.	PUNCT
dti-1419	297	8	uptodate	uptodate	ADJ
dti-1419	298	1	[	[	X
dti-1419	298	2	database	database	NOUN
dti-1419	298	3	on	on	ADP
dti-1419	298	4	the	the	DET
dti-1419	298	5	internet	internet	NOUN
dti-1419	298	6	]	]	PUNCT
dti-1419	298	7	.	.	PUNCT
dti-1419	299	1	waltham	waltham	PROPN
dti-1419	299	2	,	,	PUNCT
dti-1419	299	3	ma	ma	PROPN
dti-1419	299	4	:	:	PUNCT
dti-1419	299	5	uptodate	uptodate	ADJ
dti-1419	299	6	;	;	PUNCT
dti-1419	299	7	2018	2018	NUM
dti-1419	299	8	.	.	PUNCT
dti-1419	300	1	http://www.utdol.com/utd/index.do	http://www.utdol.com/utd/index.do	PROPN
dti-1419	300	2	.	.	PUNCT
dti-1419	300	3	accessed	access	VERB
dti-1419	300	4	september	september	PROPN
dti-1419	300	5	26	26	NUM
dti-1419	300	6	,	,	PUNCT
dti-1419	300	7	2018	2018	NUM
dti-1419	300	8	.	.	PUNCT
dti-1419	301	1	http://www.utdol.com/utd/index.do	http://www.utdol.com/utd/index.do	PROPN
dti-1419	301	2	http://www.utdol.com/utd/index.do	http://www.utdol.com/utd/index.do	PROPN